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ABSTRACT 
 
Background: Tuberculosis and human immunodeficiency virus (TB/HIV) co-infection 
are important global public health problems. Tuberculosis (TB)  is the most common 
opportunistic infection and the leading cause of death in HIV-infected patients. Co-
infection with TB and HIV is a situation that is becoming rampant worldwide and 
Malaysia is no exception. However, there are no substantial data concerning the co-
infection of both diseases in this country.  
 
Objectives: To determine the risk factors for defaulters of  TB treatment and predictors of 
death among TB/HIV co-infected patients in Malaysia.  
 
Methods: Medical records at the time of TB diagnosis and subsequent follow-up of all 
newly registered TB patients with HIV co-infection seen at TB clinics in the Institute of 
Respiratory Medicine and three public hospitals in the Klang Valley between January 
2010 and September 2010 were reviewed. These medical records were reviewed again 
twelve months after their initial diagnosis to determine TB treatment outcomes and 
survival. Kaplan Meier and Cox proportional hazard regression analysis were performed 
using SPSS.  
 
Results: Of 227 patients analysed, the majority of patients were males (88.1%) and 
single/divorced (67.0%). A total of 48.5% were Malays. The mean age of the patients was 
39.1 (standard deviation 8.6). The most common mode of HIV transmission was through 
injecting drug use (55.9%). Among 227 patients, successful outcomes were achieved in 117 
patients (53.4%) with 18.7% of patients ‘cured’ and another 34.7% ‘completed treatment’. 
The unsuccessful outcomes were those who ‘defaulted treatment’ (25.6%, n=56), ‘died’ 
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(21.0%, n=46); and another 8 (3.4%) who were still on treatment. There were no cases of 
treatment failure. After adjusting for other predictors in  multiple Cox regression analysis, 
the significant predictors of default from TB treatment in HIV-infected patients were: (i) not 
on antiretroviral therapy (AHR 3.75; 95%CI 2.19-6.42), (ii) low serum albumin level (AHR 
2.89; 95%CI 1.22-6.84), (iii) presence of lymphadenopathy (AHR 2.03; 95%CI 1.18-3.49) 
and (iv) alcohol intake (AHR 1.93; 95%CI 1.10-3.38). At the end of the study, seven (7) 
patients who were originally classified as defaulters were later reclassified as having died, 
making the total number of deaths during TB treatment 53 (23.3%),  with 40% of deaths 
occurring within two months of TB diagnosis. Survival at 2, 6 and 12 months after initiating 
TB treatment were 90.7%, 82.8% and 78.8% respectively. After adjusting for other factors, 
death in TB/HIV co-infected patients were associated with being Malay (AHR 4.48; 95%CI 
1.73-11.64), CD4 T-lymphocytes count < 200 cells/µl (AHR 3.89; 95% CI 1.20-12.63), 
three or more opportunistic infections (AHR 3.61; 95% CI 1.04-12.55), not receiving 
antiretroviral therapy (AHR 3.21; 95% CI 1.76-5.85) and increase per 103 total white blood 
cell count per microliter (AHR 1.12; 95% CI 1.05-1.20).  
 
Conclusion: TB/HIV co-infected patients had a high case fatality rate during TB 
treatment. Initiation of antiretroviral therapy in these patients can improve survival by 
restoring immune function and preventing opportunistic infections. 
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ABSTRAK 
Latar belakang: Koinfeksi jangkitan Tuberkulosis dan virus HIV (TB/HIV) adalah 
masalah kesihatan awam global yang penting. Tuberkulosis (TB) adalah jangkitan 
oportunis yang paling kerap dan merupakan penyebab utama kematian di kalangan 
pesakit yang dijangkiti HIV. Koinfeksi TB dan HIV semakin berleluasa di seluruh dunia 
dan tidak terkecuali di Malaysia. Walau bagaimanapun, tiada data yang jelas berkaitan 
dengan koinfeksi kedua-dua penyakit ini di negara ini. 
 
Objektif: Untuk menentukan faktor-faktor risiko pesakit yang engkar rawatan TB dan 
meramalkan faktor kematian di kalangan pesakit koinfeksi TB / HIV di Malaysia. 
 
Metodologi: Rekod perubatan pesakit-pesakit koinfeksi TB/HIV yang baru didaftarkan  
di antara bulan Januari 2010 sehingga September 2010 di Institut Perubatan Respiratori 
dan tiga buah hospital kerajaan di Lembah Klang telah disemak. Rekod-rekod perubatan 
ini diperiksa semula dua belas bulan selepas tarikh diagnosis awal bagi menentukan 
hasil rawatan TB dan status kemandirian. Anggaran Kaplan Meire dan analisis regresi 
berbilang Cox telah dijalankan menggunakan perisian SPSS. 
 
Keputusan: Daripada 227 pesakit dianalisis, majoriti pesakit adalah lelaki (88.1%) dan 
tidak berkahwin/bercerai (67.0%). Sebanyak 48.5% adalah berketurunan Melayu. Min 
umur di kalangan pesakit adalah 39.1 (sisihan piawai 8.6). Punca jangkitan HIV yang 
paling biasa adalah melalui penggunaan dadah suntikan (55.9%). Daripada 227 pesakit, 
rawatan TB berjaya ditamatkan oleh 117 pesakit (53.4 %) dengan 18.7% daripada 
pesakit tersebut ‘sembuh’; manakala 34.7% yang lain ‘sempurna rawatan’. Pesakit yang 
tidak berjaya menamatkan rawatan adalah mereka yang ‘gagal rawatan’ (25.6%, n=56), 
‘mati’ (21.0%, n=46) dan 8 yang lain (3.4%) masih di dalam rawatan. Tiada kes 
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kegagalan rawatan direkodkan. Selepas pelarasan bagi peramal lain dilakukan dalam 
analisis regresi berbilang Cox, peramal kepada engkar rawatan TB di kalangan pesakit 
yang dijangkiti HIV adalah: (i) tidak menerima rawatan antiretroviral (AHR 3.75 ; 95% 
CI 2,19-6,42 ), (ii) tahap serum albumin yang rendah (AHR 2.89 ; 95% CI 1,22-6,84), 
(iii) mempunyai limfadenopati (AHR 2.03 ; 95% CI 1,18-3,49) dan (iv) pengambilan 
alkohol (AHR 1.93 ; 95% CI 1,10-3,38). Pada akhir kajian ini, tujuh (7) pesakit yang 
asalnya dikategorikan sebagai engkar rawatan kemudiannya dikategorikan semula 
sebagai telah meninggal dunia, memberikan jumlah kematian sepanjang rawatan TB 
menjadi 53 orang (23.3%), dengan 40% daripada kematian tersebut berlaku dalam 
tempoh dua bulan selepas didiagnosa penyakit TB. Kebarangkalian jangka hayat pada 2, 
6 dan 12 bulan selepas memulakan rawatan TB, masing-masing adalah 90.7%, 82.8% 
dan 78.8%. Selepas pelarasan bagi faktor-faktor lain, kematian bagi koinfeksi TB/HIV 
dikaitkan dengan berketurunan Melayu (AHR 4.48; 95% CI 1,73-11,64), kiraan CD4 T-
limfosit <200 sel/μl (AHR 3.89; 95% CI 1.20 -12,63), mempunyai tiga atau lebih 
jangkitan oportunis (AHR 3.61; 95% CI 1,04-12,55), tidak menerima rawatan 
antiretroviral (AHR 3.21; 95% CI 1,76-5,85) dan peningkatan jumlah sel darah putih 
per 103 setiap mikroliter (AHR 1.12 ; 95% CI 1,05-1,20). 
 
Kesimpulan: Koinfeksi TB/HIV mempunyai kadar kematian yang tinggi semasa 
rawatan TB. Permulaan rawatan antiretroviral kepada pesakit-pesakit ini boleh 
meningkatkan jangka hayat dengan memulihkan fungsi imun dan mencegah jangkitan 
oportunis.  
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CHAPTER 1: INTRODUCTION 
About this chapter 
This chapter provides the background for this thesis, which describes the tuberculosis 
(TB), Human Immunodeficiency Virus (HIV) and TB/HIV situation locally and 
globally. Section 1.1 begins with a presentation of the epidemiology of TB and 
HIV/acquired immune deficiency syndrome (AIDS) in Malaysia and globally. 
Important socio-demographic and health indicators of Malaysia, the organisation of the 
health system and the national TB and HIV/AIDS control programmes and the local 
strategies adopted to control TB and HIV infections are presented.  
The problem statement, rationale of the research, objectives and research hypothesis are 
discussed in Section 1.2 to Section1.5. 
Finally, the structure of this thesis is discussed in Section 1.6.  
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1.1 Epidemiology of TB, HIV and TB/HIV co-infection 
1.1.1 Global Situation of TB 
The World Health Organization declared tuberculosis (TB) as a global health 
emergency in 1993. Despite the downward trend in the absolute number of TB cases 
since 2006 and the fall in the incidence rates since 2001, the burden of TB disease 
remains a global health challenge (WHO). TB is among the top three diseases 
worldwide, along with HIV and Malaria. Globally, there were an estimated 8.7 million 
incident cases of TB in 2011 of which 13% were co-infected with HIV. About 82% of 
global TB infections are concentrated in 22 high burden countries. The highest ranking 
five are India, China, South Africa, Indonesia, and Pakistan.  
The African region had the highest proportion of TB cases coinfected with HIV. In this 
region,  about 39% of TB cases were estimated to be coinfected with HIV which 
accounted for 79% of TB/HIV cases worldwide, followed by South East Asia with 13%. 
Deaths among TB patients who were HIV-negative were almost one million and an 
additional 0.43 million deaths were reported among TB patients who were HIV-
positive.  
TB is more common among men than women, and affects mostly adults in the 
economically productive age groups. Approximately two-thirds of cases were estimated 
to occur among people aged 15–59 years (WHO, 2011a). As part of WHO’s global TB 
control strategy, in 1994 the organization launched the ‘Directly Observed Therapy, 
Short Course’ or better known as DOTS. This strategy includes five key components 
including a government commitment to support TB treatment, passive detection of 
active tuberculosis cases by the use of sputum microscopy, direct observation of short 
course therapy for TB treatment, ensuring a regular supply of medicines, and a 
monitoring system for program supervision and evaluation (WHO, 2006). 
Introduction 
_______________________________________________________________ 
3 
 
1.1.2 TB Situation in the Western Pacific Region 
The World Health Organization (WHO) reported in 2011 that there were 22 High TB 
Burden Countries in the world which account for 81 percent of the TB burden. Four 
countries from the Western Pacific Region, namely Cambodia, China, the Philippines 
and Vietnam were included in this group.  WHO also stated that based on the 2004 data, 
there were an estimated four million prevalent cases of TB or 236 per 100,000 
population in the Western Pacific Region out of the total population of 174 million.  
Nearly two million were new cases.  It was estimated that more than 300,000 deaths 
from tuberculosis occurred in the region in 2004.  
WHO acknowledged in its report that there were three main reasons which contributed 
to the rise in TB cases all over the world in recent years, namely HIV; insufficient 
application of disease control measures; and economic decline.  The threat posed by 
TB-HIV co-infection and Multidrug Resistant Tuberculosis (MDR-TB) is an area of 
concern that may reverse the gains in TB control.  In the Western Pacific region, TB 
associated with HIV infection is a growing threat, particularly in certain areas of China, 
among specific high risk groups in Malaysia and in Papua New Guinea and Vietnam 
(WHO, 2011b). 
1.1.3 TB Situation in Malaysia 
Malaysia is located in the South-East Asian region, which comprises the peninsular area 
known as West Malaysia and part of Borneo Island known as East Malaysia. There are 
thirteen states and three Federal Territories in Malaysia with an area of about 329,758 
km square. Malaysia has a population of 29.2 million, with about 65.5% aged between 
15-64 years, and approximately 72% living in urban areas (“Malaysia Demographic 
Profiles,” 2013). Although demographic changes with rapid industrial and 
socioeconomic development are likely to shift disease patterns towards an increasing 
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importance of non-communicable disorders, nevertheless communicable diseases are 
still of tremendous importance. 
In the early 1940s and 1950s, TB was the number one cause of death in Malaysia. Anti-
tuberculosis drugs became available in Malaysia only in the late 1950s. During that era, 
TB had been already a major cause of morbidity and mortality. Realizing the 
seriousness of this public health problem, the Malaysian government launched its 
National TB Control Program (NTCP) in 1961 with the main aim to control and reduce 
the prevalence of TB. From  1961 until 1994, the National TB control programme was 
coordinated technically and administratively by the National TB Centre (NTBC) located 
in  Kuala Lumpur.  
In 1995, the National TB Control was integrated into the general communicable disease 
control programme and placed under the Disease Control Division, Ministry of Health. 
Each state and Federal Territory has its own State TB Control Program which is headed 
by the Health Director and the Chest Physician as the technical advisor. The state TB 
team consists of a TB epidemiologist, TB treatment manager and laboratory manager. 
The NTBC was re-designated as the country’s tertiary National Chest Institute. 
Malaysia had implemented directly observed treatment, short course (DOTS) strategy in 
the national TB control program in the late 90s. DOTS is the most effective treatment 
strategy recommended by the WHO for controlling TB and has been one of the most 
rapidly expanding and successful health interventions since the 1990s. DOTS was 
developed based on collective best practices, findings of clinical trials and program 
operations of TB control over the past two decades. The success of the strategy has been 
proven in both rich and poor countries. 
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Malaysia is categorized by the World Health Organization (WHO) as an intermediate 
TB burden country (WHO, 2011a). As in other developed and industrialized countries, 
the TB problem in Malaysia declined significantly between 1970 and 1980. Factors that 
have contributed to the reduction in TB incidence include improvements in 
socioeconomic status, better ventilation of homes and work sites and an improved 
health system. However, from early 1995, the incidence of tuberculosis has slowly 
increased from an incidence rate of 58 per 100,000 in 1995 to 72 per 100,000 in 2011. 
Data from the National TB Control Programme showed that the rate of TB deaths in 
Malaysia in 2011 was 8.0% of the total notified TB cases in that year; making it the 
highest mortality rate among infectious diseases in Malaysia. Several factors were 
responsible for the increasing TB incidence in Malaysia. These included the HIV/AIDS 
infection, influx of immigrants from endemic neighbouring countries, increased rural-
urban migration and drug abuse. Thus the emergence of the  HIV epidemic reinforced 
the need to focus on the identification and cure of infectious TB patients (MOH, 2011). 
 
  
 
 
 
 
 
Figure 1.1: Notified TB Cases in Malaysia, 1987-2007 
Source: Ministry of Health.  
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Although the TB situation in Malaysia is still under control, Malaysia has a high risk of 
experiencing a re-emergence of TB because it is surrounded by neighbouring countries 
with a high TB burden. Neighbouring South East Asian countries with high prevalence 
of TB infections are Cambodia, Myanmar, Vietnamsample size 
 and Indonesia. These countries ‘export’ the biggest group of migrants to Malaysia 
(Table 1.1). According to Malaysian Ministry of Health regulations, all legally 
registered migrant workers have to be screened for TB as part of their pre-employment 
requirements. If they are found to be infected with TB, they have to be deported.  
However, migrants that enter Malaysia illegally do not appear on the radar of the 
screening program and therefore become a potential source of TB. In 2011, immigrants 
made up 10 per cent of the 20,666 TB cases in the country.  
 
Table 1.1: Case notification in South East Asian countries, 2010 
Country Number of cases 
Incidence Rate  
(per 100,000) 
Brunei Darussalam 232 57.7 
Cambodia 39 994 285.7 
Singapore 1 478 29.6 
Malaysia 18 018 64.4 
Laos 3 836 63.9 
Myanmar 127 134 264.9 
Thailand 64 512 93.5 
Philippines 163 248 175.5 
Indonesia 296 272 123.4 
Vietnam 88 033 180.0 
Source: Global Tuberculosis Control 2011 
 
In Malaysia, TB treatment is initiated at Treatment Centre 1 (Pusat Rawatan 1/ PR1) by 
doctors in Hospitals and Health Clinics. Patients are referred to the nearest health care 
facility (Treatment Center 2 / PR2) which oversees  Directly Observed Therapy (DOT). 
Follow up treatment are continued at PR2 which consist of Health Clinics and 
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Community Clinics (Klinik Desa) manned by Medical Assistants or trained nurses. 
Currently they are 229 Treatment Center 1 and 2,410 Treatment Center 2 in Malaysia 
(MOH, 2010). 
First line drugs for the treatment of TB are Isoniazid (H), rifampicin (R), pyrazinamide 
(Z), Streptomycin (S) and Ethambutol (E). TB treatment comprises two phases, namely, 
the initial or intensive phase (two months) and the continuation or maintenance phase 
(four months). For  cases with extrapulmonary TB, the duration of treatment may be 
extended depending on the patient’s clinical and radiological response (MOH, 2002).  
The National Tuberculosis Control Program's policy states that HIV screening is 
compulsory for all patients who present with signs or symptoms  suggestive of  
tuberculosis as recommended by the WHO. TB is often the first clinical indication that a 
person may have an underlying HIV infection, and TB services can be an extremely 
important entry point to HIV prevention, care and treatment. In addition, the HIV status 
of TB patients makes a difference in their TB treatment (WHO, 2010a). Detecting HIV 
infection in a TB patient is also critical for the TB patient’s household members because 
HIV-positive TB patients may have household members who are also living with HIV. 
Household contacts of an infectious TB case are given high priority for TB screening 
and treatment, especially if they are living with HIV. Those who are found to have 
active TB disease need prompt treatment. Among household contacts, people living 
with HIV and children who do not have active TB are candidates for isoniazide 
treatment as a prophylaxis to prevent the development of active TB. 
1.1.4 Global Situation of HIV/AIDS 
The HIV/AIDS epidemic has created a huge challenge in many parts of the world and 
become one of the greatest threats to human health and development since the 1980s. 
Despite enhanced global efforts to curb the HIV/AIDS epidemic, HIV remains a leading 
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cause of death worldwide and the number one cause of death in Africa. Since its 
recognition, approximately 40 million people are currently living with HIV infection, 
and an estimated  25 million have died due to acquired immunodeficiency syndrome 
(AIDS).  
According to the United Nations Joint Program on AIDS (UNAIDS), the number of 
people living with HIV had increased from 29.4 million in 2001 to 34.0 million by the 
end of 2011, resulting from continuing new infections, better survival of people living 
with HIV and general population growth. However, the number of new infections is 
lower by 20% than in 2001; which is 2.5 (95%CI: 2.2-2.8) million. The number of 
AIDS-related deaths worldwide have also declined by 24% from a peak of 2.3 million 
in 2004 (95%CI: 2.1 million-2.6 million) to about 1.7 (95%CI: 1.5-1.9) million in 2011 
(UNAIDS, 2012). 
Globally, the HIV epidemic varies considerably across geographical areas. HIV 
epidemic can be categorized as low, centralized or generalized. The region that is most 
severely affected by HIV is the Sub-Saharan Africa. About 23.5 million (69%) of 
people living with HIV (PLWH) and 94% of children with HIV live in this region. Sub-
Saharan Africa is categorized as experiencing a generalized epidemic. In a generalized 
epidemic, HIV is firmly established and transmission occurs in the general population 
with their national HIV prevalence rate that is greater than 1 percent. In addition, 
according to the UNAIDS report, women and youth aged 15-24 are disproportionately 
affected, leading to large numbers of AIDS orphans, households  headed by children 
and subsequent medical, social, economic and development challenges in the worst 
affected countries. An estimated 1.8 million of people in this region became newly 
infected with HIV  in 2011. The vast majority of new infections result from unprotected 
heterosexual intercourse, including paid sex and sexual union in long-term and 
concurrent relationships, or as a result of mother-to-child transmission.  
Introduction 
_______________________________________________________________ 
9 
 
The Caribbean,  Eastern Europe and Central Asian regions ranked second as being  
heavily affected by the HIV epidemic. The Caribbean is the region outside sub-Saharan 
Africa with the highest HIV prevalence. However, the rate of new HIV infection in this 
region has declined by 42 per cent since 2001 and the number of AIDS-related deaths 
have declined by 48 per cent. In Eastern Europe and Central Asia the new HIV infection 
started to increase in the late 2000s with an accompanying 21 percent increase in 
mortality from AIDS (UNAIDS, 2012). 
In Asia, the impact of AIDS is even greater than in Africa because this region is home 
to about fifty percent of the world’s population. Therefore, even a small increase in the 
infection rates can mean large differences in the absolute number of infected people. It 
was estimated that the total number  of PLWH in Asia was five million people with 
around half of people (2.4 million) living in India. In East Asia, an estimated 14,000 
new infections were reported in 2011; but in the South and South-East Asia, the annual 
number of new HIV infections declined during that year (UNAIDS, 2012). 
1.1.5 HIV/AIDS Situation in Malaysia 
HIV/AIDS was first reported in Malaysia in December 1986. By the end of 2011, 
Malaysia had a cumulative figure of 94,841 HIV, 17,686 AIDS and 14,986 deaths, thus 
giving reported PLHIV of 79, 855. The epidemic in this country is still concentrated 
within most-at-risk populations (MARPS) especially among IDU, sex workers and 
transgender population. The number of people newly infected that was reported by the 
Ministry of Health has shown a consistent downward trend from a peak of 6,978 in 
2002. In 2011, there were 3,479 new cases reported to the Ministry of Health, 
approximately half of what was reported in 2002 with an average of nine new cases 
each day. The notification rate of HIV also continues to experience a decrease from 28.4 
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in 2002 to 23.4 in 2005 and to 12.2 cases per 100,000 populations in 2011. The number 
of HIV/AIDS-related deaths were 805 (26.1%) (MOH, 2012a).  
 
 
 
Figure 1.2: HIV and AIDS-related deaths reported in Malaysia 1986 – 2011. 
Source: Ministry of Health. 
 
 
HIV in Malaysia is predominantly among males as they constitute 90% of cumulative 
HIV cases, of whom the majority are intravenous drug users (IDU). However, the 
number of new cases among women had increased from around 5 percent of new 
infections during the late 1990s, to around 21 percent in 2011. In the earlier phase of 
HIV pandemic in Malaysia, new infections were largely driven by IDU. This trend has 
eventually changed over time from only one sexual transmission for every nine IDU in 
1990 to two sexual transmissions for every eight IDU in 2000 and five sexual 
transmission for every five IDU in 2010. Since 2005 the Malaysian MOH has launched 
an intensive harm reduction program which includes needle and syringe exchange 
programmes (NSEP) and drug substitution therapy for drug users. This program had 
successfully reduced the number of HIV infections transmitted via needle sharing. In 
2011, sexual transmission had replaced IDU as the main driving factor in the HIV 
epidemic with a ratio of six sexual transmissions for every four IDU reported. A 
training module was also developed by the Ministry of Health to teach religious leaders 
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about HIV. This is an important step in a country where the majority of people are 
Muslim. 
 
 
Figure 1.3: Reported HIV cases attributed to IDU and sexual transmission, 
Malaysia 1986 – 2011. 
Source: Ministry of Health. 
 
 
About 26% of reported infections are amongst young people aged between 13 to 29 
years old. From 1980 to December 2011, children aged below 13 years consistently 
contributed approximately one percent of the cumulative total of HIV infections.  
Malaysia is classified by the WHO as having a concentrated HIV epidemic where the 
HIV prevalence continues to be less than 1% in the general population but concentrated 
among most-at-risk groups. The most at risk populations are injecting drug users and 
sex workers with HIV prevalence ranging from 3 percent to 20 percent.  
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Figure 1.4: No. of Screening Test and Case Detection Rate of HIV Infection, 
Malaysia, 2000-2009. 
Source: Ministry of Health. 
 
The Ministry of Health (MOH)  had targeted to achieve a reduction of new HIV cases to 
11 per 100,000 populations by 2015. However, this target was  achieved much earlier, 
that is, in 2009. With the current achievement, the MOH  has reviewed its programs, to 
further reduce the new HIV cases to 9 per 100,000 populations by 2015.  
HIV screening was started in Malaysia since 1985. Currently, all government health 
facilities (2,836 health clinics inclusive of community clinics and 143 hospitals 
inclusive of non-MOH hospitals) are providing free HIV screening facilities. Malaysia 
has implemented various HIV screening programs. Among the screening programs that 
have been implemented are mandatory HIV screening of all donated blood, blood 
products and organs; antenatal screening and routine screening of inmates in drug 
rehabilitation centres and prisons, TB and STI cases, clients of harm reduction 
programs, contacts of cases; and voluntary screening for premarital couples. Over the 
past five years, a total of  1.3 million HIV screenings was conducted. Despite 
maintaining surveillance program and intensified screening activities, the detection rate 
of HIV is decreasing. This figure is compatible with the declining HIV reported cases 
through the surveillance system. 
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Recent guideline by the WHO recommends that ART should be started for all people 
living with HIV with active TB disease irrespective of their CD4 cell count. TB 
treatment should be started first, followed by ART as soon as possible and within the 
first eight weeks of starting TB treatment. If the CD4 cell count is less than 50 
cells/mm3, ART should be started within first two weeks of TB treatment as a matter of 
emergency (WHO, 2011c). 
In patients with TB-HIV co-infection, WHO recommends that the first-line ART 
regimen contain two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-
nucleoside reverse transcriptase inhibitor (NNRTI). The preferred NRTI backbone is 
zidovudine (AZT) or tenofovir disoproxil fumarate (TDF), combined with either 
lamivudine (3TC) or emtricitabine (FTC). For the NNRTI, WHO recommends either 
efavirenz (EFV) or nevirapine (NVP). The recommended first-line ART regimens for 
TB patients are those that contain efavirenz (EFV), since interactions with anti-TB 
drugs are minimal. 
1.1.6 TB/HIV Situation in Malaysia 
TB infection among HIV patients do not show a declining trend despite reduction in 
new HIV cases notification (Figure 1.5). The number of TB-HIV co-infection reported 
nationwide has increased from 64 to 1,819 cases from 1990 to 2008.  
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Figure 1.5: TB, HIV and TB/HIV Prevalence in Malaysia, 2000-2011 
 Source: Ministry of Health. 
 
The government has conducted routine TB-HIV screening for all new inmates in 
incarcerated closed settings such as prisons and drug rehabilitation centres since 2001 as 
part of its prevention and control measures. As with other opportunistic infections, the 
risk of dying is higher if TB/HIV co-infected patients are not treated. Isoniazid 
prophylaxis therapy (IPT) was started in 2011 as an effort to reduce morbidity and 
mortality of TB/HIV co-infection (MOH, 2012b). 
In Malaysia, TB and HIV programs collaboration was strengthened at the national level 
by placing all TB and HIV programs under the Disease Control Division, Ministry of 
Health. Such joint efforts included the formation of a National Committee for TB/HIV, 
implementation of a joint TB-HIV strategic plan and the development of the National 
AIDS Registry with a TB data management component. The provision of TB and HIV 
screening and treatment services are provided by primary health care services and 
hospitals with specialist expertise. TB/HIV patients were provided with universal access 
to ARTs at no cost by government health care facilities. 
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The current structure of Disease Control Division gives an advantage in the 
management of TB/HIV in which both sectors are located under the same umbrella 
namely the Communicable Disease Section which is led by a Deputy Director of 
Disease Control. Therefore the TB and HIV program's collaboration can be 
strengthened at the national level. Both sectors will be better coordinated and will have 
the same goals and directions.  
1.2 Problem Statement 
TB is still a public health problem in Malaysia despite socioeconomic progress and 
advancement in health services. TB has physical, social and economic impacts on those 
infected, their families and the populations where they live. Although TB is preventable 
and treatable, patients can die due to delayed diagnosis and inadequate treatment.  
Despite the long and continuous efforts to battle it, TB continues to be around in this 
country. The absolute number of TB cases in Malaysia is still increasing every year. In 
2011, there were 19,337 cases of all forms of TB reported with an incidence rate of 68.4 
per 100,000 people (WHO, 2011c). If these trends are sustained, the MDG target that 
TB incidence should be falling by 2015 will not be achieved.  
The HIV epidemic is believed to contribute to this inability to reduce TB incidence in 
Malaysia. In 2008 HIV prevalence among TB patients in Malaysia was 10.4% based on 
routine screening done, which put Malaysia into Category I based on the Interim Policy 
on Collaborative TB/HIV Activities by the WHO, even though the HIV prevalence rate 
among the adult population is ≤ 1% (WHO, 2004). 
It is also of public health importance in Malaysia that the death rates for HIV-infected 
TB patients are particularly high, ranging from 30% to 35% every year with an average 
of 450 deaths per year. In 2007, 30.3% of deaths were attributed to TB-HIV co-
infection.  
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Routine HIV screening among TB patients was introduced in Malaysia since 1990. HIV 
testing is not only a collaborative activity, but it links TB-HIV co-infected patients to 
availability of HIV treatment and care, thus reducing the death rate. Expert opinion and 
operational research provide evidence that HIV testing and counselling offer a direct 
entry point for care and support of tuberculosis patients with HIV. The cost-
effectiveness of voluntary HIV counselling and testing improves significantly when the 
testing is targeted at populations with high HIV prevalence.  
 
 
 
 
 
 
Figure 1.6: TB Death and TB/HIV Death in Malaysia, 1994-2005 
Source: Ministry of Health. 
 
The World Health Organization (WHO) strongly recommended that a TB/HIV 
Collaborative Committee be formed in this country to formulate policies and guidelines 
for the TB/HIV collaboration. HIV/AIDS programs and TB programs need to have 
closer collaboration to improve diagnosis, care and prevention services for people living 
with HIV and TB. The aim of collaborative TB/HIV activities is to decrease the burden 
of diseases in the populations where HIV is fuelling the TB epidemic by expanding the 
scope of TB and HIV programs and improving the quality of service provision. 
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The present study reports on the survival of a cohort of HIV-positive tuberculosis 
patients registered in 2010 in the central region of Malaysia. In Malaysia, there is still a 
gap in knowledge in the understanding of TB/HIV co-infection, particularly those 
aspects pertaining to survival and predictors of death in TB-HIV co-infected patients. 
Most of the studies on TB/HIV survival were conducted in African countries. Some 
studies have been published recently in neighbouring countries such as Thailand and 
Vietnam (Manosuthi et al., 2006; Sanguanwongse et al., 2008; Sungkanuparph et al., 
2007; Thuy et al., 2007). There are only a few articles regarding characteristics of 
TB/HIV co-infected patients in selected states in Malaysia (Mohammad & Naing, 2004; 
Nissapatorn et al., 2005), but none has reported on the factors associated with 
differences in treatment outcomes and survival. Adding data from a country with a 
moderate TB burden and concentrated HIV epidemic is a useful step forward. 
1.3 Rationale of the study 
Based on the research problem statement, there is a strong need to do a study focusing 
on the outcomes of tuberculosis treatment and the determining factors associated with 
survival in TB-HIV co-infected patients. This study expands current knowledge of 
predictors of survival to an Asian sample. 
This issue is important because, monitoring the outcomes of treatment is one of the five 
elements of TB control emphasized in the DOTS strategy, and remains one of the core 
elements of the Stop TB Strategy. It is important to know the treatment outcomes and 
the survival of TB/HIV co-infected patients in Malaysia because such information will 
provide for a better understanding of the epidemiology of TB/HIV co-infection, the 
survival rate and the predictors of survival. Information about the risk factors associated 
with death in TB/HIV co-infected patients is crucial in developing strategies to be 
targeted at this high risk group and would allow for improvements in the clinical care of 
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these patients. Hence, appropriate activities and preventive measures can be planned to 
improve the treatment outcomes and survival.  
1.4 Study Objectives 
1.4.1 General Objective 
The overall objective of this study is to study the characteristics of TB patients who are  
HIV positive, treatment outcomes and their survival probabilities in Institute of 
Respiratory Medicine, Kuala Lumpur and at three public hospitals in Selangor.   
1.4.2 Specific Objectives 
The specific research objectives are as follows: 
1. To determine the characteristics of TB patients with HIV co-infection. 
2. To determine the treatment outcomes of TB-HIV co-infected patients. 
3. To assess the risk factors for defaulting TB treatment in HIV-infected 
patients.  
4. To determine the predictors of survival in HIV-infected TB patients during 
TB treatment. 
1.5 Research Hypothesis 
1) There is an association between the socio-demographic characteristics, clinical 
characteristics, laboratory profile, radiological and treatment factors and defaulted TB 
treatment in TB/HIV co-infected patients. 
2) There is an association between the prognostic factors (socio-demographic 
characteristics, clinical characteristics, laboratory profile, radiological and treatment 
factors) and the survival of TB/HIV co-infected patients. 
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1.6 Structure of the thesis 
This thesis is divided into 6 chapters. Chapter 1 is the introduction which provides the 
background of the research and outlines the chapters in the thesis. Chapter 2 presents 
the literature review of tuberculosis treatment outcomes and survival of TB-HIV co-
infected patients. It provides a background to the thesis by reviewing the evidence from 
published literatures. 
Chapter 3 details the work done in extracting data from the study sites which took place 
between 1st of January 2010 to 30th of September 2011. For the purpose of this study, 
four hospitals were selected. The study was carried out at their TB Clinics. 
Chapter 4 documents the  comprehensive statistical analysis and results of factors 
associated with unsuccessful tuberculosis treatment outcomes and predictors of survival 
in TB/HIV co-infected patients. Data collected from the four participating sites were 
analysed. This chapter provides basic data on patients’ characteristics. Both univariate 
and multivariate statistical techniques using logistic regression and Cox proportional 
hazard are used.   
Chapter 5 discusses on the findings of this research in comparison with other studies 
from developed and developing countries. Relevant discussions regarding the 
implications of the findings are highlighted. 
Chapter 6 is the concluding chapter and rounds up the thesis. Finally, recommendations 
for policy-makers and programme managers involved in the implementation and scale-
up of TB/HIV collaborative activities are discussed, together with suggestions for 
further research. 
The overview of the thesis is presented graphically in Figure 1.7. 
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1.7 Summary 
In this chapter, the prevalence of TB, HIV and TB/HIV co-infection is reviewed. The 
structure of the thesis is explained and contributions to this field are detailed. This thesis 
represents the first known attempt by a Malaysian researcher in determining the 
TB/HIV prognosis in Malaysia.  
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Figure 1.7: Structure of the thesis 
•Overview of the thesis
•Pathogenesis of TB and TB/HIV
•Prevalence of TB, HIV and TB/HIV 
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(Methodology)
•Descriptive statistics
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analysis/Results)
•Synthesis of results
•Comparison with other studies
Chapter 5 
(Discussion )
•Summary of the main results
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CHAPTER 2: LITERATURE REVIEW 
About this chapter 
This chapter provides a detailed review of studies of tuberculosis with HIV co-infection. 
All inclusive searches for references were conducted over a span of 2.5 years. Few 
methods were utilized including querying databases, cross-referencing of 
bibliographies, journal supplements and review material, index searches of scientific 
proceedings, backtracking references from articles, consultations with experts in this 
area and contacting authors.  
This chapter starts with describing the background of the disease. Sections 2.1 to 2.3 
give an overview of TB, HIV and the pathogenesis of Tuberculosis and Human 
Immunodeficiency Virus (TB/HIV) co-infection. Section 2.4 to Section 2.7 describes 
the diagnosis of TB in HIV co-infected patients, TB treatment and management of HIV-
infected patients, TB prevention and TB/HIV policies. Section 2.8 covers the 
characteristics of TB/HIV co-infected patients, including the socio-demographic factors, 
lifestyle factors, TB-related characteristics, HIV-related characteristics and laboratory 
profiles. Section 2.9 is a systematic review of tuberculosis treatment outcomes in HIV-
infected patients from published literature. The risk factors for TB treatment default 
from previous studies were discussed in Section 2.10. Section 2.11 describes the 
survival time of TB/HIV co-infected patients and finally Section 2.12 is a discussion on 
the predictors of TB/HIV survival reported from the literatures. Section 2.13 is the 
summary of the whole chapter. 
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2.1 Tuberculosis 
Tuberculosis bacilli was discovered by Robert Koch in 1895 and his finding on the 
etiology of tuberculosis was presented in a famous paper of the Physiological Society of 
Berlin. His description on the method of staining specimen slides, the method of 
culturing and inoculating of the bacilli into animals was a major advance in 
understanding TB bacteriology. The discovery boosted further development in finding a 
cure for TB (Sakula, 1982). 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(MTB) which is transmitted via the airborne route. While TB is completely curable, it 
has persisted for over two centuries since its discovery in 1882. The most common site 
for TB infection is the lungs (pulmonary TB) but it can also affect other parts of the 
human body due to lymphohaematogenous dissemination during primary tuberculosis 
infection (extra-pulmonary TB). It is spread via air contaminated with nuclei droplets 
when a person with active TB expel bacteria for example by speaking, coughing, 
laughing, sneezing or singing. If a healthy person inhales air containing the bacilli, it 
will be lodged in the pulmonary bronchiole or alveolar. The bacilli multiply and 
produce the primary lesions there. Some of the bacilli spread to the hilar lymph node 
and caused enlargement of hilar lymph node. The bacilli from the alveolar lesion and 
from the enlarged hilar lymph nodes will be more disseminated through the lymphatic 
system or the bloodstream, causing extrapulmonary TB such as meningitis, or joint and 
bone tuberculosis. The host will respond via cell-mediated immunity involving 
macrophage and T-lymphocytes cells. The lymphocytes will identify TB antigens and 
will release cytokines such as interferon gamma which in turn will activate the 
macrophage at the site of the lesion (Dunlap, Bass, & Fujiwara, 2000).  
However, not everyone who is exposed to TB bacilli will develop TB disease. A person 
who has a good immune system will be able to fight the infection.  In general, only 10% 
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of healthy people who are infected with MTB have a probability of developing active 
TB disease in their lifetime, which has devastating consequences if left untreated. For 
some patients, they are able to control the infection, but unable to completely remove it 
from their bodies. These cases are known as Latent TB Infection (LTBI), whereby the 
infection remains in an inactive or "latent" state. Normally, they do not realize that they 
have LTBI because people with LTBI do not show any signs or symptoms of infection. 
However, this latent infection can convert to active disease and spread it to other 
individuals. The probability of developing TB is much higher when the immune system 
of a person becomes weak; for example in people who are infected with the human 
immunodeficiency virus (HIV) or as a result of a tissue or organ transplant or other 
medical treatment designed to suppress the immune system (Hauck, Neese, Panchal, & 
El-Amin, 2009).  
2.2 Human Immunodeficiency Virus (HIV) 
Human immunodeficiency virus (HIV) is a lentivirus which contains double strands of 
ribonucleic acid (RNA) as its genetic material. It is associated with immune 
suppression diseases where patients observe symptoms of diseases much later, after 
infection due to long viral incubation. HIV causes Acquired Immune Deficiency 
Syndrome (AIDS) (Barré-Sinoussi et al., 1983). 
HIV is a sexually transmitted infection, but can also be spread through blood and 
blood products. Generally HIV appears  in high concentration in the blood, genital 
secretions and breast  milk. These are significant HIV transmission routes to other 
individuals. The low concentration of HIV  in urine, sweat, saliva and tears has lower 
chances of spreading HIV to other individuals (Lifson, 1988). Unprotected sexual 
intercourse is the main transmission source of HIV. Sexual transmission occurs when 
HIV secretion of infected individual gets in contact with genital mucous, rectal 
mucous or oral contact with another individual (Boily et al.,2009).  
Literature review 
_______________________________________________________________ 
25 
 
Primarily, HIV was a sexually transmitted disease that affected a certain risk group 
in the population. It is different from the other infectious diseases where the whole 
population is at risk. The spread of HIV can develop from a man who has sex with 
woman, man who has sex with man (MSM) and a woman who has sex with man. HIV 
infections can be transmitted through sexual relationships with multiple sexual partners, 
with men with sexually transmitted diseases (STD’s), with men who are not 
circumcised and without protection.   
HIV transmission can also occur when the blood of HIV infected individual gets contact 
with another person’s wound. Different modes of infection transmission are by 
intravenous drug users, blood transfusion, hemophiliacs and blood product recipients. 
Although the chances of accident occurrence are rare, health care workers such as 
nurses, laboratory workers and doctors are also exposed to the risk of being infected 
with HIV. Healthcare workers should take necessary precautions have to be taken to 
protect themselves from getting contact with HIV infected individual‘s blood (Lifson, 
1988).   
The virus affects the lymphocytes, which mediate immune responses and therefore an 
infected person progressively loses the capacity to protect the body from pathogens. 
AIDS occurs when the infection progresses to a stage where physical symptoms 
manifest. HIV infection damages the lymphocytes and alveolar macrophages 
responsible for mediating immunity against TB by  progressively depleting them or 
making them dysfunctional (Iseman, 2000). 
2.3 Pathogenesis of Tuberculosis and Human Immunodeficiency Virus 
(TB/HIV) co-infection. 
Human immunodeficiency virus (HIV) and tuberculosis (TB) have a complex 
relationship which fuels both epidemics resulting in the worsening of the morbidity and 
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mortality from both diseases. Tuberculosis (TB) is one of the leading causes of death 
among people infected with HIV worldwide. Among people living with HIV, TB is the 
most frequent life threatening opportunistic disease, even in those receiving anti-
retroviral therapy. There are three mechanisms relevant to the development of TB in the 
people with HIV infection: reactivation of latent TB, progression of recent infection and 
re-infection. 
Patients with HIV infection have a higher risk of developing TB compared to the 
general population. TB may accelerate the natural progression of HIV infection by 
activating HIV replication and expediting the depletion of CD4 T-lymphocytes count. 
The occurrence of TB including multi-drug resistant disease, may accelerate the 
progress of HIV infected patients to active TB after a recent infection with 
Mycobacterium tuberculosis. TB infection among HIV patients is strongly associated 
with immune status in which it rises sharply if the patient had worsening immune status. 
The risk of progression of Mycobacterium tuberculosis infection to TB disease 
increases if the patient is suffering from immune suppression. In addition, the rate of 
progression of recent or latent MTB infection to TB disease is also increased. In patients 
with advanced HIV disease, they can also have an exogenous reinfection with other 
strains of Mycobacterium tuberculosis (WHO, 2004).  
Pulmonary TB is still the major type of presenting disease in TB/HIV co-infection. 
However, the frequency of extrapulmonary TB increases with the worsening immune 
compromise because there is increased susceptibility of reactivation and dissemination 
of TB in these patients. In a study in the United States, the researchers found that the 
most common site of extrapulmonary TB was lymphatic (28%), disseminated (23%) 
and central nervous system/meningeal (22%) disease. HIV-infected patients with CD4 
count less than 100 cells/uL were more likely to have a severe form of extrapulmonary 
TB (AOR: 1.6, 95% CI: 1.0-2.4)  (Leeds et al., 2012). 
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2.4 Diagnosis of TB in HIV Co-infected Patients 
The approach to diagnose TB is the same regardless of underlying HIV status. TB 
disease can be diagnosed by medical history, physical examination, chest x-ray and 
laboratory investigation. Diagnosis is confirmed by isolating Mycobacterium 
tuberculosis from clinical samples. In extrapulmonary TB or in situations where clinical 
samples are difficult to obtain, certain procedures should be carried out in order to 
establish the diagnosis of TB. 
2.4.1 Clinical presentations 
WHO recommends that all adults and adolescents living with HIV should be screened 
for TB at the time when HIV infection is diagnosed, before the initiation of 
antiretroviral therapy and at regular intervals during follow-up (WHO, 2008a). Based on 
the guidelines of the WHO International Expert Committee in 2007, screening for TB 
should be done by the combination of symptoms rather than only chronic cough. A 
meta-analysis of 12 studies involving 8,148 participants, which evaluated the 
combinations of symptoms as screening rules for TB found that the best performing rule 
was the presence of any one of the symptoms as current cough, fever, night sweats or 
weight loss. This screening rule has an overall sensitivity of 79 percent, which increases 
to 90 percent among participants selected from clinical settings (Getahun, H. et al., 
2011). 
In the WHO Clinical Staging of HIV Infection, HIV-infected patients who are 
diagnosed with active TB are categorised as WHO clinical stage 3 (if pulmonary TB) or 
stage 4 (if extrapulmonary TB) (WHO, 2007). WHO Clinical Staging of HIV Infection 
was developed by the WHO in the 1990 and has been revised in 2007. It is based on 
clinical findings that guide the HIV/AIDS patients to make a diagnosis, to manage, to 
evaluate HIV patients and do not require a CD4 count. This staging has been used by 
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many countries to determine those patients who are eligible for antiretroviral therapy, 
particularly in settings in which CD4 testing is not available. There are four categories 
of clinical stages; stage 1, 2, 3 and 4, progressing from HIV infection till AIDS 
infection. These stages are defined by symptoms or specific clinical conditions. 
According to the WHO staging system, adolescents and adults are defined as 
individuals aged 15 years (WHO, 2007). WHO clinical staging detail is found in 
Appendix D.    
2.4.2 Laboratory investigation 
In patients with symptoms and signs suggestive of TB, sputum smear microscopy and 
sputum culture for mycobacteria should be done to rule in or to rule out TB. Sputum 
smear microscopy is the most widely used test to diagnose TB in which sputum samples 
are examined under a microscope to look for bacteria. The diagnosis of TB is based on 
the detection of acid fast bacilli (AFB) on smears and cultures from clinical specimens. 
Specimens that are smear-positive should be considered to be due to M. Tuberculosis 
until proved otherwise. WHO recommended that all patients suspected of having 
pulmonary TB should submit at least two sputum specimens for microscopic 
examination in a quality-assured laboratory. At least one early morning specimen 
should be obtained when possible, as sputum collected at this time has the highest yield.  
The diagnosis of pulmonary TB in PLWHIV is more difficult because they tend to have 
non-specific symptoms and sputum smear microscopy is often negative, particularly in 
advanced HIV infection. Hence, TB culture should be obtained in all TB suspects to 
enable early diagnosis of TB in sputum smear negative cases. 
If an initial sputum smear microscopy is negative in a person with HIV infection, a 
CXR should be examined, sputum smear microscopy repeated and sputum sent for 
bacterial culture and AFB culture. Results of sputum culture for AFB would be 
available in four to six weeks or earlier. Therefore, clinical judgement is made in the 
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interim as to whether the patient has TB and managed as appropriate. The culture results 
confirm or refute the clinical diagnosis. 
The diagnosis of extrapulmonary TB is challenging as they have a lower bacterial load 
compared to PTB and sample collection is problematic. A relatively low proportion of 
cases have positive microscopy and culture for Mycobacterium tuberculosis, even with 
rapid culture methods. In clinically suspected cases of extrapulmonary TB, any relevant 
procedures such as lumbar puncture, thoracocentesis, fine needle aspiration and biopsy, 
pleuroscopy, colonoscopy and cystoscopy are required in order to support or confirm 
the diagnosis and to get the drug susceptibility profile of the organism. Presence of 
caseating granulomas, or granulomas with Langerhan’s giant cells on histology or 
cytology of the specimen is highly suggestive of TB but they are not specific. 
2.4.3 Chest X-ray 
 In a patient who has clinical features suggestive of TB, but negative on sputum smear 
microscopy, the patient should be reassessed clinically and send for chest x-ray. If the 
chest x-ray shows a typical presentation of TB, TB treatment should be started as soon 
as possible.  
The clinical presentation of TB in an HIV-infected person may differ from that in 
persons with relatively normal cellular immunity who develop reactivation TB.  The 
classic finding in immunologically normal persons which is the cavitation at the apex of 
the lung, is less common. Chest x-ray changes in TB/HIV patients reflect the degree of 
immune-suppression. Patients may present with infiltrates in any lung zone, often 
associated with mediastinal and/or hilar lymphadenopathy. In the early phase of HIV 
disease, TB/HIV patients usually present with typical chest radiographic findings, such 
as cavitation and upper lobe infiltrates; because the immune system is still relatively 
intact (CD4 > 500 cells/uL). In patients with advanced HIV disease that are severely 
immune-suppressed, the appearance is often atypical with intrathoracic adenopathy and 
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lower lobe involvement. However, HIV infected patients with pulmonary TB may have 
a normal chest radiograph.  
In HIV-infected patients, it might be difficult to distinguish pulmonary TB from other 
HIV-related pulmonary infection such as pneumocystic carinii which is the most 
common pulmonary pathogen in AIDS patients. The poor specificity of the chest X-ray 
in TB/HIV cases emphasized the need of sputum analysis for acid-fast bacilli as an 
essential diagnostic tool for TB. The other indications of chest x-ray include suspected 
complications of PTB; for example pleural effusion, pneumothorax, pericardial effusion 
and severe or on-going haemoptysis.  
2.4.4 The tuberculin skin test (TST) 
Tuberculin skin test (TST) or Mantoux test is the standard method of screening to 
identify individuals who may have been infected by the tuberculosis bacteria. TST is a 
useful method of diagnosing TB infection, however, it is not as helpful in the diagnosis 
of active TB disease. Tuberculin is a mixture of antigens obtained from the culture of 
M. Tuberculosis. Antigens are foreign particles or proteins that stimulate the immune 
system to produce antibodies. The TST is performed by injecting 0.1 ml of tuberculin 
purified protein derivative (PPD) into the inner surface of the forearm (intradermally); 
about halfway between the wrist and the elbow where a small bubble will form as the 
tuberculin is injected. The injection should produce a pale elevation of the skin (a 
wheal) 6 to 10 mm in diameter. The injection site should be examined between 48 and 
72 hours after administration by a trained person for evidence of swelling. People who 
have been exposed to tuberculosis will develop an immune reaction, causing a slight 
swelling at the injection site. In any person, including persons with no known risk 
factors for TB a reaction of 15 or more millimetres induration is considered positive. 
However, this method has many limitations. It is highly dependent on the operator for 
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correct administration and interpretation of the test. TST is also associated with false-
positive results stemming from cross-reactivity with non-tuberculous mycobacteria.  
2.4.5 New diagnostic tests for TB 
Over the past few years, development of T-cell based interferon-gamma release assays 
(IGRAs) becomes an alternative to TST in diagnosing latent TB infection. In HIV-
infected individuals, a positive TST is defined as an induration of at least 5 mm in 
response to intradermal placement of PPD. IGRAs are more recently developed assays 
that use highly M. Tuberculosis-specific antigens which are not present in most non-
tuberculous mycobacteria or in the bacillus Calmette-Guérin vaccine. It detects in vitro 
interferon-gamma release by peripheral blood monocytes in response to MTb-specific 
peptides (Mazurek et al., 2010). 
One important new advance in the diagnosis of TB is the use of molecular techniques to 
speed up the diagnostic process as well as to improve its accuracy. Molecular 
techniques are increasingly used in laboratories around the world. They include 
polymerase chain reaction to detect mycobacterial DNA in patient’s specimens; nucleic 
acid probes to identify mycobacteria in culture; restriction fragment length 
polymorphism analysis to compare different strains of TB for epidemiological studies 
and genetic-based susceptibility testing to identify drug resistant strains of mycobacteria 
(Senol, 2013). 
2.5 TB treatment and management of HIV-infected patients 
HIV-infected patients with active pulmonary TB or extrapulmonary TB require prompt 
initiation of TB treatment. Treatment should be initiated as soon as TB is suspected 
because delays in the diagnosis of TB will be associated with poor outcomes. 
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2.5.1 Standard TB treatment 
TB treatment is classified as first-line or second line drug treatments. First-line drugs 
are the drugs of choice administered to patients after their diagnosis of TB. These drugs 
are generally more effective, less toxic, cheaper and easier to administer than the second 
line agents. The most common first-line drugs are isoniazid (INH), rifampicin, 
streptomycin, ethambutol, and pyrazinamide. The primary purpose of TB treatment is to 
eliminate the infection in the body, prevent resistant strains and control transmission of 
the disease. If TB remains untreated, 50% of the cases with active TB disease would die 
within two years.  
TB treatment offered to HIV-infected adults are essentially the same as for  HIV-
uninfected patients. TB treatment requires a minimum of six month regimen consisting 
daily treatment of isoniazid, rifampicin, pyrazinamide and ethambuthol for two months 
of intensive phase; followed by four month daily treatments of isoniazid and rifampicin 
in the maintenance phase. If the cultures are still positive after two months of therapy, 
the continuation phase should be prolonged to seven months with a total of nine months 
treatment. For patients with extrapulmonary TB, a six to nine month regimen consisting 
of two months of isoniazid, rifampicin, pyrazinamide and ethambutol followed by four 
to seven months of isoniazid and rifampicin is recommended. For CNS disease 
(tuberculoma or meningitis) and bone or joint TB, nine to twelve months of anti-TB 
treatment is recommended. 
The WHO had promoted Directly Observed Treatment short course (DOTS) as a 
treatment strategy for the global control of TB mainly to ensure adherence and 
minimize the development of resistant strains. It requires drugs intake to be directly 
observed by a healthcare worker or a community health worker for at least the first two 
months of therapy.  
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2.5.2 Drug Resistant TB 
The main challenge in treating HIV-associated TB patients is the rising cost of drugs 
and the risk of developing drug resistance. The most common cause of drug resistance 
is treatment interruption which results from the decision taken by a person to stop the 
drugs once he/she feels better before completion of  the six‐months drug course. Drug‐
resistant strains of TB can also be transmitted to others.  
The cost of treatment increases dramatically as the second or third line therapies are 
much more expensive and requires a longer treatment period. Drug resistant TB is a 
form of TB in which the bacteria have become resistant to the first-line TB medicines. 
Resistance to TB drugs occurs when these drugs are misused or mismanaged. 
Multi‐drug resistant (MDR‐TB) and extensively drug resistant (XDR‐TB) are much 
more complicated to treat and contribute to increase mortality. Multidrug-resistant 
(MDR) TB is the TB bacteria which are resistant to the two most common TB 
medications, isoniazid and rifampin. The most dangerous form is Extensively Drug-
Resistant (XDR) TB where the bacteria is resistant to many common TB medicines 
such as, isoniazid, rifampin, fluoroquinolone, and at least one of three injectable 
medicines (capreomycin, kanamycin and amikacin). 
All patients should also be assessed regarding risk factors for drug-resistant TB 
including previous TB treatment (especially if it was incomplete), close contact with a 
person who has multidrug-resistant TB, history of living in a country where drug-
resistant TB is common, and previous residence in an institution such as prison, drug 
rehabilitation centers or homeless shelter which has documented transmission of a drug-
resistant strain of TB. HIV seropositive patients should be asked about antiretroviral 
therapy use. Their CD4 lymphocyte count and viral load should be measured to assist 
the treatment of the underlying HIV infection. In patients with active TB, the viral load 
will be increased; but it will decrease with appropriate therapy. 
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2.5.3 Co-trimoxazole (CTX) Prophylaxis in TB/HIV co-infection 
Co-trimoxazole (CTX) also known as Sulfamethoxazole-Trimethoprim (SMX-TMP)  is 
a broad spectrum antimicrobial agent that targets a variety of aerobic Gram-positive and 
Gram-negative organisms and protozoa. Co-trimoxazole prophylaxis should be given to 
patients with TB/HIV co-infection to prevent opportunistic infections. Provision of 
CTX as primary or secondary prophylaxis for prevention of Pneumocystis jiroveci 
pneumonia (PCP) (formerly Pneumocystis carinni pneumonia) and toxoplasmosis has 
been the part of standard care in the management of HIV-infected individuals in 
developed countries since the early 1990s. CTX is safe, well tolerated, widely available 
and inexpensive. 
Nunn et al. (2008) conducted a randomized controlled trial in Zambia that showed CTX 
prophylaxis in TB/HIV co-infected adults was associated with a 21% reduction in all-
cause mortality (AHR: 0.79; 95% CI 0.63 to 0.99) (Nunn et al., 2008). A meta analysis 
conducted by Suthar A B et al., that examined the effect of cotrimoxazole on mortality 
and morbidity in individuals aged 13 years or more, confirmed that CTX significantly 
increased survival in HIV-infected adults on ART (Suthar, Granich, Mermin, & Van 
Rie, 2012). 
2.5.4 Issues in the management of TB and HIV co-infection 
Co-infection with HIV may complicate the diagnosis and worsen the course of TB. 
There are a few issues that need to be addressed in the management of these two 
diseases (TB and HIV) in a co-infected patient. Issues that are related to the 
management of TB/HIV co-infected patients include: drug-drug interactions; immune 
reconstitution inflammatory syndrome (IRIS); overlapping drug toxicities; pill burden 
and drug adherence and coordinating care between TB and AIDS control programmes. 
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i) Drug-drug interactions 
The timing of initiation of antiretroviral therapy in patients with TB/HIV co-infection is 
challenging as potential drug interactions can occur between HAART and anti-TB. 
Rifampicin, an important drug for TB treatment reduces the blood level of antiretroviral 
drug groups, non-nucleoside reverse transcriptase (NNRTI) and protease inhibitors (PI) 
by stimulating the activity of the cytochrome P450 liver enzyme system, which 
metabolizes the PIs and NNRTIs. On the other hand PIs and NNRTIs can also alter 
blood levels of rifampicin by enhancing or inhibiting this same enzyme system. These 
potential drug-drug interactions may result in ineffective treatment of TB, ineffective of 
ART drugs or an increased risk of drug toxicity.  
ii) Immune Reconstitution Inflammatory Syndrome (IRIS)  
Immune reconstitution syndrome (IRIS) is an adverse consequence of the restoration of 
pathogen-specific immune responses during the initial months of HAART and anti-TB. 
IRIS usually occurs within three months of TB treatment, typically between two to 
twelve weeks after the initiation of HAART. The major manifestation are fever (40%) 
followed by lymphadenitis (38%). 
A prospective observational cohort study conducted in Mozambique (Letang et al., 
2011) found that predictors of IRIS were pre-ART CD4 count < 50 cells/ml (AHR 2.3, 
95% CI 1.19–4.44) and body mass index (BMI) < 18.5 (AHR 2.15, 95% CI 1.07–4.3). 
Another study found that hemoglobin < 100 g/l (OR=2.2, 95% CI 1.1-4.6) and baseline 
CD4 count < 50 cells/ml (OR=4.1; 95% CI 1.8-9.5) are predictors of IRIS. A 4-week 
course of prednisolone (1.5mg/kg/day) for two weeks, followed by 0.75 mg/kg/day for 
two weeks is recommended to improve symptoms. IRIS may cause clinical 
deterioration, but does not primarily contribute to mortality.  HAART and anti-TB 
should not be stopped while managing IRIS. 
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iii) Overlapping toxicities of antiretroviral therapy and TB drugs  
Anti-TB and ART drugs have similar side effect profiles therefore overlapping drug 
toxicities such as skin rash, hepatotoxicity and peripheral neuropathy can be difficult to 
differentiate. Furthermore, there is a potential of added toxicity when given together. 
When the side effects occur during concomitant treatment of TB and HIV, it makes 
difficult to differentiate the causative drug. The overlapping or additive toxicities due to 
antiretroviral drugs and first line anti-TB drugs are summarised in the Table 2.1. 
 
Table 2.1: Overlapping or additive toxicities due to antiretroviral drugs and first 
line anti-TB drugs 
Toxicity ART Drugs AntiTB Drugs 
Peripheral neuropathy Stavudine and didanosine Isoniazid and etambutol 
   
Gastrointestinal intolerance All All 
   
Hepatotoxicity Nevirapine, efavirenz, all 
NRTIs and Pis 
Isoniazid, rifampicin, 
rifabutin and pyrazinamide 
   
Central nervous system 
toxicity 
Efavirenz Isoniazid 
   
Bone marrow suppression Zidovudine Rifabutin, rifampicin 
   
Skin rash Abacavir, nevirapine and 
efavirenz 
Isoniazid, rifampicin and 
pyrazinamide 
   
Ocular effects Didanosine Ethambutol and rifabutin 
Source: (Kwara, Flanigan, & Carter, 2005) 
 
 
iv) Pill burden and drug adherence 
Concomitant treatment of both TB and HIV entails the use of multiple drugs especially 
during the intensive phase of TB therapy. On the top of that, usually patients are also on 
micronutrient supplements and prophylaxis for opportunistic infections. These put 
patients on a higher strain to adhere to their medications. To reduce pill burden, it is 
recommended to use a fixed - dose combination of anti-TB drugs if possible. Necessary 
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support and encouragement to adhere to treatment should be given to all TB/HIV co-
infected patients.  
v) Coordinating care between TB and AIDS control programmes 
Co-infection with TB and HIV not only affects the individual patient, but it may also 
have an impact on TB control in a population. Better coordination and communication 
between the TB and AIDS control programs is required in the management of the 
patient co-infected with TB and HIV. Screening of all HIV-infected persons for TB and 
vice-versa should be in place to ensure the best care of TB/HIV co-infected patients.  
2.6 TB Prevention 
2.6.1 Prevention of TB in people living with HIV 
To reduce the occurrence of HIV-associated TB, preventive therapy with isoniazid is 
recommended for asymptomatic patients infected with M. Tuberculosis. Although 
isoniazid is commonly used for treating TB, it is also effective as preventive therapy. 
IPT has been recommended since 1998 by WHO and the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) as part of a comprehensive HIV and AIDS care 
strategy. Isoniazid treatment is generally safe, well tolerated and  cost effective. 
A systematic review reported that isoniazid reduces the risk of clinical TB in HIV-
infected people by 32% (Akolo & Adetifa, 2010). Concerning drug resistant TB, a 
recent systematic review reported that IPT has not been convincingly associated with 
the emergence of isoniazid resistance (Balcells, Thomas, Godfrey-Faussett, & Grant, 
2006).  
There is a strong scientific evidence base to show that ART, by lowering a person’s 
viral load and restoring the immune system, significantly reduces the impact of HIV and 
TB. A retrospective study in Brazil demonstrated that risk of TB in HIV-infected 
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patients was reduced by 52% with antiretroviral therapy alone, 68% with IPT alone, and 
80% with both (Golub et al, 2007).  
2.7 TB/HIV Policies 
2.7.1 Global TB control 
TB control aims to block transmission of the disease, to reduce morbidity and mortality 
and to prevent the development of drug resistance TB. The essential strategies to control 
TB include preventing the infection, stopping the progression from latent to active TB; 
and treating the active disease. Prior to the development of anti-TB drugs, TB control 
focused mainly on prevention (Daniel, 2006). The discovery of anti-TB drugs in the 
1940s provided a significant  change to TB control strategy and from the 1950s, truly 
effective public health measures became possible with treatment to cure being the goal 
of TB control globally. Following the development of improved anti-TB drugs in the 
1970s, TB treatment was initially consisted of a standard 18 months regimen was 
reduced to 6 months with a combination of anti-TB drugs. TB control became effective 
in most developed and industrialised countries as a result of improved living conditions 
and the availability of anti-TB drugs.  Subsequently, TB was neglected from the world 
public health agenda and effective control became the responsibility of each country 
(Daniel, 2006).  
The emergence of HIV/AIDS pandemic in the 1980s led to the return of TB cases 
globally. The WHO declared TB as a global emergency in 1993 and later developed the 
directly observed therapy, short-course (DOTS) strategy in 1994 (WHO, 2002). This 
strategy was aimed to guide nations towards effective TB control after acknowledging 
that TB had been a neglected and a poorly managed disease that was associated with 
HIV. The DOTS strategy remains the core intervention for TB control recommended by 
WHO globally. The strategy was subsequently adopted by most of the WHO member 
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states with major expansion in India and China, but its scale-up was constrained by 
weak political commitment (Atun, Weil, Eang, & Mwakyusa, 2010).  
In November 1998, the Stop TB Initiative was launched at the World TB Conference in 
Bangkok, Thailand after realising that TB was a public health concern with political, 
social and economic dimensions. This initiative is a coalition of stakeholders in the 
global fights against TB. It comprised of all of the key partners and countries with 
heavy TB burdens that called for the development of a global action plan for TB control 
and addressing HIV-associated TB as well as drug-resistant TB. To accelerate social 
and political action to stop the spread of TB around the world, The Stop TB Partnership 
was eventually established in 2000. The partnership’s goal is to eliminate TB as a public 
health problem and ultimately secure the world free of TB. Later in 2001, the “Stop TB 
Partnership” launched the Global Plan to Stop TB 2001–2005 (WHO, 2005). Building 
on the success of the first plan,the “Stop TB Partnership” launched the second plan for 
2006–2015. Its targets are in line with the Millennium Development Goals (MDGs) 
which aim to reduce TB prevalence and deaths to 50% by 2015 as compared to the 1990 
levels (WHO Stop TB Partnership, 2006). In addition to expanding and enhancing 
DOTS coverage, the second plan also covers the DOTS-Plus approach which addresses 
MDR-TB and provides strategies and policies for the countries to implement and 
monitor TB/HIV collaborative activities through the TB/HIV Working Group (WHO 
Stop TB Partnership, 2006). 
In The Global Plan to Stop TB of 2006-2015, new strategies and approaches were 
introduced to address the complexities of the TB problem. The challenge of TB-HIV 
was addressed with TB/HIV collaboration which is a joint activity between TB and 
HIV/AIDS control programs in reducing the burden of TB in people living with 
HIV/AIDS and vice-versa (WHO, 2006). 
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2.7.2 Global HIV control 
HIV was first reported in the United States in 1981, and the virus was later isolated in 
1983 (Barré-Sinoussi et al., 1983). By 1985, more than 17, 000 cases of AIDS from 71 
countries had been reported to WHO (Merson, O’Malley, Serwadda, & Apisuk, 2008). 
During the early stages of the pandemic, emphasis was rather placed on warning the 
public about the “danger” of the infection due to the initial lack of knowledge about the 
modes of transmission and difficulty in diagnosis (Mann, 1998). When the modes of 
spread and diagnosis were identified, specific risk-reduction programs were designed to 
change individual behavior. The focus was mainly on information, education and 
communication (IEC) about HIV/AIDS and providing counselling and testing; and 
distribution of condoms (Mann, 1998). Later on in the epidemic, it was recognized that 
socioeconomic, political and cultural factors, including gender inequality, poverty and 
marginalisation of specific groups of the population were associated with HIV/AIDS 
(Mann, 1998; Merson et al., 2008). Despite this increasing knowledge about the 
infection, there was a lack of  response from nations to address the infection. 
Nonetheless, its rapid spread and the global threat it posed prompted the WHO to 
launch the Global Programme on AIDS (GPA) in 1987 which was tasked with 
supporting and strengthening national AIDS programmes, and providing global 
leadership (M.Mann & Kay, 1991). During that same year, the World Health Assembly 
declared HIV a “worldwide emergency” that required urgent and globally directed 
action. The human rights framework was later championed by the GPA to analyse and 
address individual and societal factors, including discrimination and other human rights 
violations directed towards PLWHA, and also to protect at risk and vulnerable 
populations to HIV (Mann, 1998). The Joint United Nations Program on HIV/AIDS 
(UNAIDS) was then established in 1996 to replace GPA. This new body was given the 
mandate to lead an expanded and coordinated multi-sectoral global response. In 1996, 
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ART became available as the standard of care (UNAIDS, 2012), though its access was 
initially limited mainly to developed nations.  
The increasing global threat of HIV/AIDS generated more coordinated and enhanced 
approaches within the global community. In Africa, the situation was referred to as a 
“state of emergency” and led to the Abuja Declaration in 2001 (Organisation of African 
Unity, 2001), where African Union member states committed themselves to allocate at 
least 15% of the health sector budget to tackle HIV/AIDS, TB and other related 
infectious diseases. In the same year, the UN set up a General Assembly Special Session 
on HIV/AIDS (UNGASS) where political leaders adopted a declaration of commitment, 
setting up targets for affected countries and funding levels for donor governments. The 
Global Fund to fight AIDS, TB and Malaria (Global Fund) was subsequently 
established in 2002 as a public/private partnership which sources funds and provides 
money to support countries in preventing and treating HIV/AIDS, TB and Malaria. The 
United States government also announced the President’s Emergency Plan for AIDS 
Relief (PEPFAR) in 2003 which since then has provided funds for prevention, 
community outreach and prevention of mother-to-child transmission (PMTCT) of HIV 
activities and increased access to ART in 15 countries (Merson et al., 2008). The fight 
against HIV/AIDS has continued to receive global support, since it is regarded as part of 
the commitments to achieve global health goals as highlighted in the MDGs.  
Since WHO launched the “3 by 5” initiative in 2003 to scale-up ART to PLWHA, the 
number of PLWHA on ART has increased steadily (WHO, 2003a). The “3 by 5” 
initiative was a global target to provide three million people living with HIV/AIDS in 
developing countries with life-prolonging antiretroviral treatment (ART) by the end of 
2005. This increased coverage prompted the commitment to scale-up universal access to 
HIV prevention, treatment,care and support services by 2010 (WHO, 2010a). At the end 
of 2009, an estimated 5.2 million people were on ART in low and middle-income 
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countries which represented a 30% increase as compared to the previous year. In sub-
Saharan Africa, almost 37% of all eligible patients were on treatment in the region. 
However, there were regional variations with some countries like Botswana, Namibia 
and Rwanda achieves 80% coverage (UNAIDS, 2012). The incidence of new HIV 
infections has declined globally, with much of this decline partly attributed to 
behavioural change including increased condom use, delayed sexual debut and 
reduction in multiple partnerships (UNAIDS, 2012). Since it is estimated that only 22% 
of all AIDS spending in 106 low and middle-income countries is on prevention, much 
effort is still needed in scaling-up HIV prevention strategies.  
2.7.3 Development of policies on TB/HIV 
During the early stages of the HIV epidemic in 1980s, researchers had demonstrated the 
association between TB and HIV/AIDS and the devastating impact of the co-epidemic. 
However, despites the alarming increase in the incidence of TB cases, especially in high 
HIV-prevalent countries particularly in sub-Saharan Africa,  the coordinated responses 
between TB and HIV programmes globally to curb the associated morbidity and 
mortality were slow and minimal (Getahun, Gunneberg, Granich, & Nunn, 2010). The 
first international meeting to  discuss modalities for controlling both epidemics was 
organized by the WHO in 1989. It was concluded that countries with poor TB-control 
programmes; which include mostly countries with increasing HIV prevalence should 
prioritise improve TB treatment and cure through DOTS.  
In response to this, in 1997 ProTEST Initiative (promotion of voluntary testing) was 
launched by the WHO at  sub-district level in three sub-Saharan Africa countries 
(Malawi, South Africa and Zambia) as the first step towards exploring TB and HIV 
collaborative service delivery (Lienhardt et al., 2012). The objective of the project was 
to promote testing for HIV using voluntary counselling and testing (VCT) as an entry 
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point to access a range of interventions aimed at decreasing the burden of HIV-related 
TB. The projects demonstrated that TB and HIV programmes could collaborate 
effectively in service delivery from sub-district to national levels. The lessons learned 
from this project prompted calls from participants at the “Global DOTS Expansion 
Meeting” in Cairo, Egypt in 2000 for the creation of the Global TB/HIV Working 
Group (WHO, 2001). The Working Group, coordinated by WHO was eventually 
established in 2001 under the auspices of the Global Stop TB Partnership with the goal 
to reduce the burden of TB in high HIV-prevalent populations. Guidelines for 
implementing collaborative TB and HIV programme activities was developed in 2003 
(WHO, 2003b). The recommended activities to be carried out under the TB and HIV 
programs at worldwide, national and local levels have operated separately with separate 
management and funding streams and with little coordination for many years. The 
implication of this policy is that patients with HIV and TB have to access different 
services for screening, testing, care, treatment and adherence support. The Interim 
Policy on Collaborative TB/HIV Activities was published by the WHO which was 
intended to assist policy-makers to understand what should be done to decrease the joint 
burden of tuberculosis and HIV in populations affected by both diseases (WHO Stop 
TB Partnership, 2004). The term collaboration and integration have been used 
interchangeably in relation to implement joint TB and HIV control activities. However, 
collaboration implies that TB and HIV programmes work together on a set of activities 
in order to achieve certain goals or objectives. For countries in which the HIV 
prevalence is more than 5%, WHO had recommended collaborative TB/HIV activities 
as showed in Table 2.2 below: 
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Table 2.2. Recommended collaborative TB/HIV activities* 
 
 
A. Establish the mechanism for collaboration between tuberculosis and 
HIV/AIDS programmes  
1. Set coordinating bodies for TB/HIV effectives activities at all levels  
2. Conduct surveillance of HIV prevalence among Tuberculosis patients  
3. Carry out joint TB/HIV planning  
4. Monitor and evaluate collaboration TB/HIV activities  
 
B. Decrease the burden of tuberculosis in people living with HIV/AIDS  
1. Establish intensified tuberculosis case-finding  
2. Introduce isoniazid preventive therapy  
3. Ensure tuberculosis infection control in health and congregate settings  
 
C. Decrease the burden of HIV in tuberculosis patients  
1. Provide HIV testing and counselling  
2. Introduce HIV prevention methods  
3. Introduce co-trimoxazole prevention therapy  
4. Ensure HIV/AIDS care and support  
5. Introduce antiretroviral 
 
Source: (WHO Stop TB Partnership, 2004) 
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The Three I's for TB/HIV 
In view of the alarming increasing rate of TB among people living with HIV, WHO 
strongly recommends the implementation of the Three I's in addition to initiating earlier 
antiretroviral therapy (ART) to be part of a TB prevention package which includes: 1. 
Intensified TB case finding; 2. Isoniazid preventive therapy and 3. Infection control for 
TB (WHO, 2008b).  WHO emphasizes that they should be the core components of HIV 
services with AIDS programmes and service providers taking the primary responsibility 
for the ‘Three I's for TB/HIV’. The World Health Organization (WHO) reported that 
900,000 lives had already been saved over six years by protecting people living with 
HIV from TB. In 2010 some 2.3 million people living with HIV were screened for TB 
and 2.2 million TB patients were tested for HIV. 
In Malaysia, TB and HIV programs collaboration was strengthened at the national level 
by placing all TB and HIV programs under the Disease Control Division, Ministry of 
Health. Such joint efforts included the formation of a National Committee for TB/HIV, 
implementation of a joint TB-HIV strategic plan and the development of the National 
AIDS Registry with a TB data management component. The provision of TB and HIV 
screening and treatment services are provided by primary health care services and 
hospitals with specialist expertise. TB-HIV patients were provided with universal access 
to ARTs at no cost by government health care facilities. 
The current structure of Disease Control Division gives an advantage in the 
management of TB/HIV in which both sectors are located under the same umbrella 
namely the Communicable Disease Section which is led by a Deputy Director of 
Disease Control. Therefore the TB and HIV program's collaboration can be 
strengthened at the national level. Both sectors will be better coordinated and will have 
same directions.  
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2.8 Characteristics of TB/HIV Co-infected Patients 
TB and HIV co-infection has been characterized as a 'dual epidemic' in view of their 
serious implications for public health. Results of previous studies have shown that many 
factors were associated with TB / HIV co-infection. To understand more about the 
disease, its characteristics are divided into socio-demographic factors, lifestyle factors, 
TB-related characteristics, HIV-related characteristics and laboratory profile. Published 
epidemiological studies in TB and HIV co-infection were reviewed to determine the 
characteristics of TB/HIV co-infection.The following search form terminology in full 
and implied Boolean keywords were entered into electronic databases such as PubMed 
Central, Science Direct, ProQuest, Medical Database@EBSCHOHost, Wiley 
InterScience: tuberculosis, HIV, characteristics, clinical manifestations.  
2.8.1 Socio-demographic Factors 
a)  Age 
Age is the most frequently studied variable in determining the characteristics of TB/HIV 
co-infected patients. Most of the studies found that TB/HIV co-infection was 
significantly more common among young to middle aged adults (Korzeniewska-Kosela 
et al., 1992; Mohammad & Naing, 2004; Van Der Werf, Sebhatu, Weldegergis, 
Tesfazion, & Borgdorff, 2007; Weis, Foresman, Cook, & Matty, 1999). However, one 
study found that TB patients with HIV infection were more likely to have age less than 
35 years (Cain et al., 2007) and another study found that it is more frequent in advanced 
age (Carvalho, Monteiro, Pires Neto, Grangeiro, & Frota, 2008). The survey done in 
Delhi during September 1997 to August 1998 period found an increase in age 
distribution of HIV seroprevalence in TB patients with rising age (Jain, Aggarwal, 
Rajpal, & Baveja, 2000). The prevalence was 0.51% in 15-24 years group, 1.55% in 25-
34 years group and 1.66% in the 35 years and more group. 
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b) Gender   
In most of the studies, including those performed in both developed and developing 
countries, the highest prevalence of TB/HIV co-infection is among males (Alpert, 
Munsiff, Gourevitch, Greenberg, & Klein, 1997; de Castro Toledo, Greco, & Antunes, 
2000; Kung et al., 2009; Mohammad & Naing, 2004; Weis et al., 1999).  In Eritrea, the 
proportion of female and male TB patients infected with HIV was comparable (Van Der 
Werf et al., 2007). 
c) Ethnic 
The risk of TB/HIV co-infection may differ by ethnic group, however the mechanism is 
still uncertain. It may be due to differences in socioeconomic, cultural, physiological or 
behavioural factor. There is a variation in ethnic contribution to TB/HIV co-infection in 
the United States. A study done in the Fort Worth, Tex (Weis et al., 1999) showed that 
TB/HIV co-infection was significantly more common among Black (p=0.018) as 
compared to White, Hispanic or Asian. However, a study that was conducted in New 
York found that HIV-infected patients were more likely to be Hispanic (Alpert et al., 
1997). 
d) Educational level 
Studies show that having a lower educational level is an indirect risk factor for the 
development of TB/HIV co-infection. The patients from this group may be illiterate and 
it could be a barrier in the health education. A study done in Delhi (Jain et al., 2000) 
examined the association of educational level and TB/HIV co-infection and they found 
that the risk of TB/HIV co-infection among illiterate and those educated only up to 
primary level were significantly more as compared to those with middle or higher 
education (p=0.020). This finding is supported by another study in Brazil (Carvalho et 
al., 2008) who found that HIV-infected patients with a lower educational level (less than 
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eight years of schooling) had almost two times higher risk of developing TB (p<0.0001, 
relative risk = 2.36) (Carvalho et al., 2008) compared to HIV-negative patients. 
e) Employment status  
Patients from low socioeconomic level are prone to get TB compared to the higher 
socioeconomic level(WHO, 2004). In Brazil, employment was found to be significantly 
associated with lower risk of death in TB patients (OR:0.32, 95%CI: 0.11-0.94)  
(Pelaquin, e Silva, & Riberio, 2007).  
f) Marital status 
Several studies had reported a higher proportion of single patients among TB/HIV co-
infected patients (Carvalho et al., 2008; de Castro Toledo et al., 2000; Mohammad & 
Naing, 2004; Putong et al., 2002). 
2.8.2 Lifestyle Factor 
a) Smoking 
Most of the studies do not include smoking as an independent risk factor for TB/HIV 
co-infection. A study done in Kathmandu, Nepal in 2008 found that HIV-infected 
patients who were smoking had an odd of seven times higher risk of developing TB as 
compared to non-smokers (Govinda Prasad, P, S, & BP, 2008). In resource-poor 
countries, there are now three interacting epidemics: smoking, TB and HIV. In addition 
to the interactions between smoking and TB and the known interaction between TB and 
HIV, smoking may also be associated with HIV infection. Thus, the interaction between 
smoking and TB–HIV co-infection deserves further study. 
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b) Alcohol consumption 
The data from the United States U.S. National TB Surveillance System for the 
period1993-2005 reported that the groups of TB patients at greater risk for HIV 
infection included alcohol abusers (15%). A study done among armed forces who were 
admitted to a referral chest clinic in India for TB/HIV co-infection found that 80% 
(48/60) of TB/HIV co-infected patients give a history of alcohol consumption and 
alcohol is a contributory factor of visiting commercial sex workers. In a study in 
Thailand, alcohol use was reported in 70% from 769 patients (Mankatittham et al., 
2009). However, patients in New York were less likely to have a history of alcohol use 
(Alpert et al., 1997).  
c) HIV risk  
An association between TB and HIV is particularly striking among groups with a high 
prevalence of both tuberculosis and HIV infections, e.g., intravenous-drug users (IDU). 
However, HIV-related TB is not restricted to IDUs only. It has also been reported in 
other mode of HIV transmission, including homosexuals, bisexual men, sexual contacts 
of bisexual men and in person with transfusion-associated AIDS.  
In  a  study in Switzerland (Fenner et al., 2012), among HIV-infected TB patients the 
most likely sources of HIV infection were heterosexual transmission (57.3%), followed 
by injecting drug users (12.6%) and men having sex with men (9.7%). Where as in 
British,  Columbia, Canada; homosexual men had the highest risk of TB/HIV co-
infection which constitute 75% of all 40 cases (Korzeniewska-Kosela et al., 1992). 
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2.8.3 TB-related characteristics 
a) Types of TB  
Most of  previous studies reported that HIV-infected patients were two to three times 
more likely to have extra-pulmonary disease (Alpert et al., 1997; Cain et al., 2007; 
Kung et al., 2009). However, a study in Kota Bharu, Malaysia reported that the highest 
number of patients (78.5%) had pulmonary TB while an additional four patients (2.7%) 
had both pulmonary and extra-pulmonary TB (Mohammad & Naing, 2004). Similarly, 
in a study that was conducted in 769 HIV-infected TB patients in Thailand, most of the 
patients were diagnosed with Pulmonary TB (60%) and another 40% had 
extrapulmonary TB. Among the patients with extrapulmonary TB, 75% had extra-
pulmonary TB only and the rest (35%) had both extra-pulmonary and pulmonary TB 
(Mankatittham et al., 2009). 
b) Chest x-ray at TB diagnosis  
Generally, chest x-ray changes in TB/HIV co-infected patients show the degree of 
immune-compromise. In mild immune-compromise patients, the chest x-ray appearance 
is often classical with cavitation and upper lobe infiltrates whereas in severe immune-
compromise, the appearance is often atypical (WHO, 2004). From an observational 
study in Rwanda (Batungwanayo et al., 2000), HIV-positive patients were found to be 
significantly less likely to develop cavitary lesion than HIV-negative TB patients 
(p=0.002).  Mohammad & Naing (2004) identified that the majority of the cases 
(55.0%) were found to have either typical or atypical pulmonary lesions in their study in 
Kota Bharu (Mohammad & Naing, 2004).  
c) Bacillus Calmette-Guerin (BCG) 
BCG is the only vaccine available today for protection against tuberculosis. BCG was 
first used as a vaccine to protect humans against tuberculosis in 1921. Conventionally, 
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the site of BCG vaccination is the left shoulder  of a person. After ten to twelve weeks 
of vaccination, a tiny scar is formed at the injection site. The scar serves as a guide if 
one wants to know whether a person has been BCG vaccinated or not. Several studies 
examined BCG scars in their research. In Kota Bharu, BCG scars were present in 89% 
of HIV-infected TB patients in the study (Mohammad & Naing, 2004). In a study done 
in Malawi , 73.1% were found to have a BCG scar from a total of 491 patients that were 
examined for BCG scars in 1999 and 2000. Where as Mankatittham et al found that 
514 (67%) TB/HIV co-infected patients had a BCG scar in Thailand (Mankatittham et 
al., 2009). 
d) Tuberculin skin test 
In populations with a high prevalence of TB, tuberculin skin test (TST) does not give 
accurate results in the diagnosis of TB. A positive tuberculin skin test does not by itself 
distinguish M. tuberculosis infection from TB disease. A person who was exposed to 
environmental mycobacteria also may have a false positive test result. On the other 
hand, in certain circumstances, TST may produce negative results even when the patient 
has TB such as in HIV patients. Twenty-five cases (16.8%) of TB/HIV in Kota Bharu 
had a documented history that TST were done with a median of 6.0 mm, ranging from 0 
to 25 mm (Mohammad & Naing, 2004). 
e) Symptoms at TB diagnosis 
Fever, cough and weight loss were the most consistent TB symptoms at presentation 
reported by HIV-infected patients (Batungwanayo et al., 2000; Korzeniewska-Kosela et 
al., 1992; Mankatittham et al., 2009). Apart from that, Batungwanayo et al also found 
that diarrhoea, oral candidiasis, active or past history of candidiasis were significantly 
more common in HIV-positive than HIV negative patients in Rwanda (Batungwanayo 
et al., 2000). 
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f) Lymph node enlargement 
Lymphadenopathy was common in both HIV positive and HIV-negative patients but 
significantly more often seen in HIV-positive cases (p < 0.001) (Nauclér et al., 1996). 
Similar finding was found in a study in Rwanda (Batungwanayo et al., 2000). 
2.8.4 HIV-related characteristics 
a) Antiretroviral Therapy (ART) 
The fact that antiretroviral therapy improves the quality of life and greatly improves 
survival for people living with HIV/AIDS is well established. The availability of 
antiretroviral therapy can serve as an incentive for people to be tested for HIV and can 
prolong the life expectancy of HIV patients. In South Africa, a study on the impact of 
antiretroviral therapy among TB patients with HIV infection showed that it can reduce 
the incidence of tuberculosis in HIV-positive person by more than 80% (Badri, Wilson, 
& Wood, 2002). Antiretroviral therapy is more beneficial if initiated at an early stage of 
the disease and it requires a high rate of compliance. In the developed countries, 
transient worsening of tuberculosis symptoms and signs were seen in up to 30% of the 
patients after the initiation of antiretroviral in HIV-infected tuberculosis patients. The 
directly observed treatment programs (DOT) for tuberculosis could be used as a model 
for antiretroviral therapy in some situations to ensure patient’s compliance.  
b) Regime of antiretroviral therapy 
WHO had updated the guidelines for antiretroviral therapy for HIV infection in adults 
and adolescent in 2010. If in previous guideline, ART is indicated in TB/HIV co-
infected patients with CD4 ≤ 350 cells/mm3, but based on the current guidelines ART 
should be started as soon as possible irrespective of CD4 cell count, preferably within 
eight weeks after the initiation of TB treatment. First line therapy should consist of an 
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NNRTI and two NRTIs. The recommended first line ART in these patients is the 
combination of Zidovudine (AZT), Lamivudine (3TC) and Efavirenz (EFV).  
c) CD4 cell counts 
A case-control study in Switzerland (1996) found that immune suppression, as indicated 
by low CD4+ cell count, was an independent risk factor for tuberculosis in HIV positive 
patients (OR 7.8; 95% CI 7.3–8.3 for patients with CD4+ <50 cells/mm3 as compared to 
those with CD4+ >500 cells/mm3) (Sudre, Hirschel, Toscani, Ledergerber, & Rieder, 
1996). In a study conducted in Brazil, it was found that CD4+ cell counts of less than 
200 cells/μL were observed in 71.9% of the TB/HIV co-infected patients with the mean 
of 169 cells/µL(Carvalho et al., 2008). In HIV-infected patients receiving HAART, the 
study by Lawn et al (2005) showed that  the risk of TB was independently associated 
with CD4 cell count < 100 cells/ml (adjusted risk ratio [ARR]: 2.38; 95%CI: 1.01–
5.60)(Lawn, Badri, & Wood, 2005). 
c) Opportunistic infections/ AIDS-defining illnesses 
AIDS-defining illness is a clinical marker of immunodeficiency, which has a good 
correlation with high risk of opportunistic infections, included tuberculosis (Ackah et 
al., 1995; P. P. Nunn, Elliott, & McAdam, 1994; Shafer et al., 1996). Opportunistic 
infections (OIs) that are considered as AIDS-defining conditions by the CDC are as 
follows: 
 Bacterial infections, multiple or recurrent (only for children less than 13 
years old) 
 Candidiasis of bronchi, trachea, or lungs  
 Candidiasis, esophageal  
 Cervical cancer, invasive (only among people 13 years old or older) 
 Coccidioidomycosis, disseminated or extrapulmonary  
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 Cryptococcosis, extrapulmonary  
 Cryptosporidiosis, chronic intestinal (for longer than 1 month)  
 Cytomegalovirus disease (other than liver, spleen, or nodes), beginning when 
older than one month  
 Cytomegalovirus retinitis (with loss of vision)  
 Encephalopathy, HIV-related  
 Herpes simplex: chronic ulcers (lasting longer than 1 month); or bronchitis, 
pneumonitis, or esophagitis (beginning when older than one month) 
 Histoplasmosis, disseminated or extrapulmonary  
 Isosporiasis, chronic intestinal (for longer than 1 month)  
 Kaposi sarcoma  
 Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia 
complex (only for children less than 13 years old)  
 Lymphoma, Burkitt (or equivalent term)  
 Lymphoma, immunoblastic (or equivalent term) 
 Lymphoma, primary, of brain  
 Mycobacterium avium complex or M. kansasii, disseminated or 
extrapulmonary 
 Mycobacterium tuberculosis, of any site, pulmonary (only among people 13 
years old or older), disseminated, or extrapulmonary  
 Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary  
 Pneumocystis jirovecii pneumonia (PCP)  
 Pneumonia, recurrent (only among people 13 years old or older)  
 Progressive multifocal leukoencephalopathy  
 Salmonella septicemia, recurrent  
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 Toxoplasmosis of the brain, beginning when older than one month  
 Wasting syndrome due to HIV  
 
A study done in Brazil found that the presence of HIV related symptoms; or AIDS-
related complex (ARC) is the only risk factor for tuberculosis development in HIV-
infected patients (OR: 3.5; CI 95% - 1.2-10.8) after adjusting for the past history of 
pneumonia, past history of hospitalization, CD4 count and no anti-retroviral use (de 
Castro Toledo et al., 2000).  
d) RNA Viral load 
In a study that was conducted in Thailand, among 87 patients with HIV RNA viral load 
result, the median HIV RNA viral load was 308,000 copies/ml (IQR, 51,900- 759,000) 
at the time of TB diagnosis (Mankatittham et al., 2009).  
2.8.5 Laboratory profiles 
a) Haemoglobin 
No study reported  any association between low hemoglobin level or anemia and risk of 
developing TB in HIV-infected patients, but a study conducted in Zambia (Elliott et al., 
1995) found that it was associated with higher risk of dying in this group of patients. 
Another study that was done in Zambia and Malawi (Ciglenecki et al., 2007) 
demonstrated that in HIV-infected TB patients, the hemoglobin level that is 10 g/dl is 
associated with lower mortality both during (HR:0.22; 95%CI:0.1–0.4) and after 
(HR:0.25; 95%CI: 0.1–0.5) tuberculosis treatment. 
b) Albumin 
In several studies, albumin level was examined as an indices of malnutrition. Serum 
albumin level is a well known marker for HIV disease progression (Mehta, 
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Astemborski, Sterling, Thomas, & Vlahov, 2006; Shah et al., 2007). In Brazil, high 
serum albumin was  found to be associated with lower in-hospital mortality (HR:0.16; 
95%CI:0.05-0.56) in disseminated TB patients who were infected with HIV (dos 
Santos, Deutschendorf, Scheid, & Zubaran Goldani, 2011). 
c) Hepatitis viral serology 
Only one study reported viral serology assessment in TB/HIV co-infected patients 
(Kingkaew et al., 2009). From 769 HIV-infected patients in the study, 9% were HbsAg 
reactive and 31% were anti-HCV reactive.  
 
2.9 Systematic review: TB treatment outcomes in TB/HIV co-infected 
patients 
Treatment outcome results serve as an indirect measure of the quality of TB 
management and care provided by a health care system. World Health Organization 
(WHO) had recommended that tuberculosis treatment outcomes should be monitored 
using standardized categories by the epidemiological surveillance system- cure, 
treatment completed, treatment failure, died, defaulted or transferred out. In line with 
that recommendation, National TB Control Programs (NTCP) in all countries routinely 
report treatment outcomes for all TB patients to the World Health Organization (WHO), 
but there was limited information on outcomes of tuberculosis treatment in HIV-
infected patients. 
A systematic review was conducted to evaluate the TB treatment outcomes in TB/HIV 
co-infected patients based on published articles. 
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Search strategy 
A systematic search of studies dealing with TB treatment outcomes in TB/HIV co-
infected patients were conducted using three electronic databases (Pubmed, Science 
Direct and Medline via EBSCOhost). Various combinations of the terms “tuberculosis”, 
“HIV”, “AIDS”, “co-infection” and “outcome” were used to screen for potentially 
relevant studies. Additional studies were also identified using cross-referencing. 
Inclusion and exclusion criteria 
Original articles after 1993, the year that WHO launched the surveillance of TB 
treatment outcomes; were included in this review. The inclusion criteria is an article that 
estimated both successful and unsuccessful treatment outcomes in the total population 
of HIV-infected TB patients who started treatment. Studies conducted in children, case 
reports, editorials or reviews were not included. If the article dealt with specific group; 
such as extra-pulmonary TB alone or with only specific risk factor such as MDR-TB, 
then the study was also excluded.  The selection process of the studies is summarized in 
Figure 2.1. 
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Figure 2.1: Flow chart of study selection process. 
 
  
Records identified through 
database search 
(n = 59  ) 
Additional records identified 
through other sources 
(n =  5 ) 
Records after duplicates removed 
(n =  58 ) 
Records after abstract screening 
(n =  25 ) 
Full-text articles assessed 
for eligibility 
(n = 12  ) 
Studies included in 
qualitative synthesis 
(n = 11  ) 
Records excluded 
(n =  13 ) 
Full-text articles 
excluded  
(n =  1 ) 
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Definitions of outcome measures  
The TB treatment outcomes in TB/HIV co-infected patients were measured as 
percentages of successful and unsuccessful outcomes among all patients who started 
therapy. As suggested by the WHO, successful outcomes included cured patients and 
those who completed TB treatment. Some studies that used other terms for successful 
treatment, such as ‘favorable outcome’(Klautau & Kuschnaroff, 2005; S Vijay, Kumar, 
Chauhan, Rao, & Vaidyanathan, 2011) were also included in this group. For this review, 
defaulted or treatment interrupted; failed treatment and died were pooled into 
unsuccessful outcomes. Transferred out cases are classified as outcome not evaluated. 
Critical appraisal 
Critical appraisal is a useful tool in assessing the comprehensivity of the whole paper as 
well as it allows researcher to systematically review the research papers’ relevance, 
results and validity. It also identifies the strengths and difficulties of the research papers. 
The critical appraisal that was undertaken in this review is using the Glasgow Critical 
Appraisal Checklist for Cohort Studies (adapted from Jaeschke, 1994). An overall score 
was given to each study by allocating one point for each positive result on the checklist. 
All the papers had clear research questions and a well-defined representative population. 
Most studies provided estimates of the accuracy of the outcomes measured (Table  2.3). 
Table 2.3 Critical appraisal of studies on TB treatment outcomes in TB/HIV co-
infected patients. 
(Appendix F) 
Data extraction 
For all included studies, the following data was extracted from original publications: 
first author and year of publication; study site, study design, types of TB, category of 
TB diagnosis (new case or recurrent) and the proportion (%) of each category of 
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treatment outcomes (cured, completed treatment, treatment failure, treatment default, 
died and not evaluated).  
Findings 
As shown in Figure 2.1, the literature search identified 59 potentially relevant articles 
published in English. An additional five articles were identified from the cross 
referencing. After reading the full text, twelve studies satisfied the inclusion criteria for 
review and one study was excluded because almost half of the cases loss of follow up. 
Finally, eleven studies from nine different countries, addressing TB treatment outcomes 
in TB/HIV co-infected patients were included in this review. The findings from this 
review is presented in the Table 2.4 below.  
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Table 2.4: Tuberculosis treatment outcomes in TB/HIV co-infected patients for articles included in the review 
Study, year Country Study design Cases Treatment outcome (%) 
      Successful  Unsuccessful Not 
evaluated 
   Type Category Total 
(N*) 
Total Cured Completed Total Failure Default Died  
              
Broek, 1998 Tanzania Prospective All All 146 59.0 NR NR 18.0 3.0 NR 16.0 22 
Harries, 1998 Malawi Prospective All New 
cases only 
554 50.9 NR NR 40.7 0.5 6.3 33.9 8.3 
Murray, 1999 South 
Africa 
Prospective SP and 
SN 
All 190 77.4 NR NR 21.1 5.3 2.1 13.7 1.6 
Mwaungulu, 
2004 
Malawi Retrospective 
Prospective 
All All 220 61.8 NR NR 35.4 1.8 4.1 29.5 2.7 
Klautau, 2005 Brazil Prospective All All 78 78.0 NR NR 22.0 5.1 11.0 6.4 NR 
Thuy,2006 Vietnam Retrospective All All 637 71.0 59.0 12.0 28.0 1.0 1.0 26.0 1.0 
Quy, 2006 Vietnam Prospective All All 39 56.5 53.9 2.6 38.4 7.7 5.1 25.6 5.1 
Maruza, 2008 Brazil Retrospective All All 262 58.8 NR NR 41.2 0.8 11.5 29.0 NR 
Kingkaew, 
2009 
Thailand Prospective All All 769 64.0 NR NR 26.0 1.0 8.0 17.0 10.0 
Vijay, 2012 India Prospective All All 281 75.0 NR NR 24.4 0.4 15.0 9.0 NR 
Girardi, 2012 Italy Prospective All All 246 52.8 30.5 22.4 24.8 0.8 10.2 14.6 21.6 
N*= Total number of HIV-positive cases in the study; NR: not reported; SP: smear positive; SN: smear negative 
Type, All: Smear positive pulmonary TB, smear negative pulmonary TB and extrapulmonary TB 
Category, All: New and recurrent cases. 
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Eight were prospective studies, two retrospective studies and one study manipulate 
retrospective and prospective study design. All included studies were population-based 
study. The sample size of HIV-infected TB patients in the reviewed studies ranged from 
39 (Quy et al., 2006)  to 769 (Kingkaew et al., 2009).  
Success rates were ranging from 50.9% (Harries et al., 1998) to 78% (Klautau & 
Kuschnaroff, 2005). Results from two different regions in Vietnam gave a variation in 
treatment success rate; which is 56.5% (Quy et al., 2006) and 71% (Thuy et al., 2007) 
respectively. Among the unsuccessful outcomes group, patients who died attribute the 
largest proportion. The highest reported death rate in the included studies was 33.9% in 
Malawi (Harries et al., 1998). However, the mortality rate is declining to 9% as reported 
by a study in India (S Vijay et al., 2011). 
Completion of TB treatment is the most important priority of TB control programs. 
From the included studies, the study in India (S Vijay et al., 2011) reported the highest 
defaulter rate in TB/HIV co-infected patients (15%). (Van den Broek et al., 1998) did 
not report the number of HIV patients who defaulted TB treatment but analyse them as 
‘uncertain outcome’; together with patients who were transferred out. In this study, 22% 
of the cases were evaluated as uncertain outcome. 
The World Health Organization (WHO) reported that globally, a total of 14,188 people 
living with HIV/AIDS (PLWH) were registered with TB in 2004 as compared to 
123,297 in 2008 showing an increase of 88%. In HIV negative patients, the registered 
TB cases increased from 4,380,029 in 2004 to 5,457,800 in 2008 (20% increase). The 
treatment success rate in PLWH was improved from 47% in 2004 to 71% in 2008 and 
the mortality rates declined over years from 16% in 2004 to 12% in 2008.   
In this review the successful TB treatment outcomes in HIV-infected patients were 
ranged between 48.4% to 78%; which is below the 85% threshold that was suggested by 
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the WHO. Further, this review also shown that TB/HIV-infected persons have an 
alarming default rate. An urgent attention from the health care system is needed as co-
infected persons who default from TB treatment can lead to treatment failures and the 
emergence of drug-resistant TB in the community. Patient non-compliance to treatment 
can be interpreted as a failure of the health care system in dealing with the natural 
tendency of humans to stop treatment as soon as they feel better. 
Generally, the mortality rates of TB/HIV co-infected patients are higher than TB 
patients who are HIV negative. HIV co-infected TB patients respond to anti-TB drugs 
as well as HIV negative TB patients, but they may have a higher short-term mortality. 
In South Africa, the probability of death for TB with HIV-positive patients were 
greatest in two weeks following the start of treatment. It continued to increase 
throughout the treatment period in HIV-positive patients at an average of three percent 
per month (Murray, Sonnenberg, Shearer, & Godfrey-Faussett, 1999). 
To ascertain TB treatment outcomes among HIV-infected patients, appropriate 
recording and reporting in both TB and HIV clinics is important, especially information 
about deaths. It is also crucial to monitor the progress in the prevention and control of 
TB. 
2.10 Risk factors for TB treatment default 
Defaulting from treatment is one of the unfavourable outcomes for patients on DOTS 
and represents an important challenge for the TB control program. Default is defined by 
the WHO as a treatment interruption of two consecutive months or more after at least 
one month of treatment but the definition of defaulters can vary within national 
programs. Defaulting TB treatment can lead to prolonged periods of infectiousness, 
recurrent TB infections, emergence of drug-resistance, and increased morbidity and 
mortality.  
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A total of 18 studies were identified, all of which were conducted in developing 
countries and published between 2000 and 2013. Out of 18 studies, only four studies 
specifically looked at the risk factors for defaulting TB treatment among TB/HIV co-
infected patients (Amuha, Kutyabami, Kitutu, Odoi-Adome, & Kalyango, 2009; 
Elbireer, Guwatudde, Mudiope, Nabbuye-Sekandi, & Manabe, 2011; Kittikraisak et al., 
2009; M Maruza et al., 2011). Table 2.4 shows the results of the search studies carried 
on risk factors for defaulting TB treatment. Each study included different 
characteristics, therefore the factors identified are heterogeneous. Overall, available 
literature identified several factors associated with defaulting from TB treatment which 
includes socioeconomic, treatment related factors and health system factors.  
Table 2.5: Independent factors for TB treatment default.               
(Appendix G) 
Socioeconomic factors 
Socioeconomic factors were identified as predictors for TB treatment default. Gender, 
alcoholism, smoking, homelessness, illiteracy and low income are some of the 
socioeconomic factors which have been found to be associated with higher default rates.   
Alcoholism has been cited as one of the major factors contributing to default by most of 
the studies (Amuha et al., 2009; Garrido et al., 2012; Hasker et al., 2008; Jakubowiak, 
Bogorodskaya, Borisov, Danilova, & Kourbatova, 2007; Muture et al., 2011; Naidoo et 
al., 2013; Sophia Vijay, Balasangameswara, Jagannatha, Saroja, & Kumar, 2003). The 
altered behaviour under the influence of alcohol and other substances is believed to be 
the reason for such observations. When one is under the influence of alcohol, he is 
likely to forget to take the medicines, and the chances that it may subsequently lead to 
poor compliance are high. Smoking was found to be significant predictive factor of TB 
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treatment default in Thailand (Kittikraisak et al., 2009), Brazil (Magda Maruza, Arraes, 
& Ximenes, 2008) and South Africa (Naidoo et al., 2013).  
Another factor implicated with defaulting among TB patients is the distance of the 
residence of the patient from the treatment facility which was reported by studies done 
in Southern Euthopia (Shargie & Lindtjørn, 2007) and Uganda (Elbireer et al., 2011). 
The continuation phase of treatment is the most crucial time for defaulting from 
treatment and future interventions should take this into consideration. (Shargie & 
Lindtjørn, 2007). 
In Nepal, Mishra et al. (2005) examined the contribution of socio-economic status to 
non-adherence to treatment. The results of their study revealed that unemployment 
(AOR: 9.2; 95%CI: 2.8–29.8), low status occupation (AOR 4.4; 95%CI:1.5-12.5 ), low 
annual income (AOR: 5.4, 95%CI: 1.0-30.0), and cost of travel to the TB treatment 
facility (AOR: 3.0; 95%CI 1.2–7.3) are significantly associated with non-adherence to 
treatment. They concluded that low socioeconomic status and particularly lack of 
money are important risk factors for nonadherence to treatment in a poor country as 
Nepal.  
Personal factors 
The contribution of previous history of defaulting has been demonstrated in several 
studies (Chan-Yeung, Noertjojo, Leung, Chan, & Tam, 2003; Garrido et al., 2012; 
Muture et al., 2011).  Chan et al. (2003) in Hong Kong evaluated the contribution of 
side effects of treatment to defaulting and found that treatment side effects were 
associated with default (AOR 13.30, 95%CI 3.23–54.79) (Chan-Yeung et al., 2003). 
This finding was also supported by Elbireer et al. (2011) who found that side effects of 
treatment were almost six times associated with TB treatment default (Elbireer et al., 
2011). 
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In patients who were co-infected with HIV, CD4 counts lower than 200 cells/mm were 
found to be associated with TB treatment default (M Maruza et al., 2011). They also 
found that the use of HAART was a protective factor for defaulting TB treatment 
(AOR: 0.12; 95%CI: 0.05-0.33). 
Health system factors 
Factors related to the health system have also been identified as reasons for non-
completion of treatment. A study by Elbireer S (2011) looked at the health facility 
factors and their contribution for TB treatment default in TB/HIV co-infected patients. 
They found that long waiting time at the clinic (AOR 4.18; 2.18-8.02), poor drug 
availability (AOR 4.75; 2.29-9.84), conduct of staff (AOR 2.72; 1.02-7.25), lack of 
opportunity to express feeling (AOR 3.47; 1.67-7.21) and  lack of health education 
(AOR 5.31; 1.94–14.57)  were significantly associated with TB treatment default 
(Elbireer et al., 2011).  
Supervised TB treatment was one of  the protective factors for  treatment 
discontinuation. In Brazil, DOT was associated with a lower risk of TB treatment 
default (Garrido et al., 2012) . Likewise, another study in China also found that direct 
observation by village doctors had protective effect to non-adherence (Xu et al., 2009). 
This suggests that direct supervision reduces the risk of dropout. This could be 
explained by the fact that those who received anti TB treatment by the health staff 
would also receive more education about the disease, its duration and the outcome of 
care and are therefore more motivated to continue treatment for the required duration.  
In sum, defaulting from treatment is a multi-factorial issue that has organizational and 
socio-economic implications. It is important to understand predictive factors for 
treatment default so that programs can implement specific measures to target the 
population at risk which is important not only to improve the patient’s life expectancy, 
but also preventing disease transmission to the general population. Most importantly 
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inadequate treatment adherence is considered as a potential cause for the development 
of multidrug-resistant TB (MDR-TB) which is more difficult and costly to treat.    
2.11 Survival time of TB/HIV co-infected patients 
Time taken from TB diagnosis or TB treatment initiation to death in TB/HIV co-
infected patients may vary in each individual. In most studies, the median survival time 
was calculated as the period between the date of TB treatment initiation and the date of 
death. 
From the literatures, the median survival time in TB/HIV co-infected patients ranged 
from 7.3 months as documented from a study in India (S Vijay et al., 2011); to 22 
months in Zambia (Elliott et al., 1995). Four studies assessed six-month survival in 
TB/HIV co-infected patients and found that the six-month survival rates were 71% 
(Sanguanwongse et al., 2008), 76% (Elliott et al., 1995), 78% (Palmieri et al., 1999) and 
79% (P. Nunn et al., 1992) respectively. A study in Southern Euthopia that comparing 
the survival between HIV positive and HIV negative patients found that the survival 
rate at the end of the intensive phase was similar between both groups (93.7% and 
94.0%, respectively). In HIV-infected TB patients, the survival rate decreased to 85.7% 
at the end of the study period (eight months). However, HIV negative TB patients in 
this study had better survival with the survival rate of 92.2% at the end of the eight 
months  (Shaweno & Worku, 2012).  
In a study done by Whalen et al., the median survival for the entire cohort of TB/HIV 
co-infected patients were 18.1 months with 1-year survival of 64% (Whalen et al., 
1997). Manosuthi et al. reported that in TB/HIV co-infected patients who were on 
antiretroviral therapy, the survival rates at one (1), two (2) and three (3) years after TB 
diagnosis were much higher (96.1%, 94.0%, 87.7% respectively) as compared to 
patients without antiretroviral therapy (44.4%, 19.2%, 9.3% respectively) (Manosuthi, 
Chottanapand, Thongyen, Chaovavanich, & Sungkanuparph, 2006). The summary of 
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median survival time in TB/HIV co-infected patients from published articles is 
presented in Table 2.6. 
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Table 2.6: Median survival time from TB diagnosis to death in TB/HIV co-
infected patients. 
Citation Study Design N Outcome 
(P. Nunn et al., 1992) Retrospective, Kenya 281 6-month survival probability 
in TB with HIV positive was 
79% (95% CI = 69-85%) 
    
(Elliott et al., 1995) Prospective, Zambia 239 The probability of survival for 
HIV-positive patients at 2,6, 
12 and 18 months was 89%, 
76%, 66% and 55% 
respectively. 
Median survival time was 22 
months. 
 
(Whalen et al., 1997) Retrospective cohort 
study in four US 
academic medical 
centers 
112 The median survival for the 
entire cohort was 18.1 months 
with a 1-year survival of 64%.  
 
The median survival was 
shorter in TB/HIV co-infected 
patients with both pulmonary 
and extra-pulmonary disease 
(8.4 months). 
 
(Palmieri et al., 1999) Retrospective, Rome, 
Italy 
118 The median survival time was 
15.2 months. 
6-month survival was 78% 
1-year survival rate was 57%. 
    
(Chaisangcharoen, 
2005) 
Retrospective, 
Thailand 
310 The median survival time was 
10.9 months (95% CI =  8.42-
13.45) 
    
(S Vijay et al., 2011) Prospective, India 281 The median survival time 
between the date of TB 
treatment initiation and the 
date of death was 7.3 months. 
    
(Shaweno & Worku, 
2012) 
Retrospective, 
Ethiopia 
370 The survival probabilities at 2 
months was 93.7% and 85.7% 
at seven months. 
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2.12 Systematic reviews: Predictors of survival in TB/HIV Co-
infected Patients 
Many factors may potentially contribute to shorter survival of HIV-infected TB patients, 
particularly in poor resource setting. A large number of observational studies conducted 
among patients with TB-HIV co-infection reported that several factors can predict 
unfavourable outcomes. However, these factors have not been consistent across studies 
and settings. This review aims to identify the most consistent variables which are 
predictive of mortality among TB-HIV co-infected patients based on findings from 
observational studies. Understanding the prognostic factors of poor outcome in TB-HIV 
co-infection can help clinicians to identify a patient’s level of risk; thus facilitating 
clinical decision making. 
Search strategy 
A literature search was done using five major databases including PubMed, 
ScienceDirect, CINAHL, Scopus and Ovid. All prognostic studies predicting death in 
Tuberculosis and HIV co-infection were considered eligible for this review. Data for the 
present review were identified using the following terms: (Tuberculosis OR TB) AND 
(Human Immunodeficiency Virus OR HIV) AND (survival OR mortality). The titles 
and abstracts identified from the search were independently assessed by two reviewers 
against the inclusion criteria. Full text of all studies that meet the inclusion criteria were 
retrieved and read by the same two reviewers and subsequently discussed during a 
consensus meeting. Any disagreement between the two reviewers was addressed 
through consensus, otherwise the third reviewer was asked to act as an arbiter. 
Literature selection 
The titles which were related to our domain, determinants and outcome (DDO) were 
scanned to determine eligibility and relevance. Relevant titles were selected by two 
independent reviewers. The abstracts of the selected titles were read and only abstracts 
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that met the inclusion criteria; which were defined prior to the search; were selected. 
Any disagreement regarding eligibility of the abstracts was resolved by consensus. 
Included studies were articles that met these criteria: the primary aim was to investigate 
prognostic factors or risk factors for death in TB-HIV patients, studies designed as 
longitudinal cohort; either prospective or retrospective, studies conducted in adults and 
that were published in English. 
The exclusion criteria were case series or case studies, articles published as abstracts 
only, articles without detailed description of methods, where the primary objective was 
not to investigate predictors for death in TB-HIV patients, where the analysis of risk 
factors for death were very specific; for example co-trimoxazole prophylaxis 
(Mwaungulu et al., 2004), where multivariate analysis regarding the strength of 
association was not reported, studies conducted in children, editorials, reports or 
unpublished reports and studies that were done before 1996. We selected only original 
articles. Articles were also screened for duplicate publication. 
Data extraction and analysis 
Data extraction was done to collect information on the participants, characteristics of 
the study, methods and outcomes. A standardized form was used to extract data from 
full text articles. From the included articles, the following information was extracted: 
country, period of enrollment, the sample size, the characteristics of study population 
(age, sex); study design; duration of follow up; the outcome measures (total death, %) 
and prognostic variables assessed in each study; and quality of the regression model. 
Quantitative analysis was not performed due to heterogeneity in study population and 
analyses of the included studies.  
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Findings 
Studies selection 
Figure 2.2 summarizes the selection process of the studies. A total of 3695 were 
identified using search strategy in PubMed (57), ScienceDirect (124), CINAHL (34), 
Scopus (34) and Ovid (3446). Of these, 209 articles were selected after reading the 
titles. All abstracts were reviewed and 147 were excluded because they did not meet 
inclusion criteria by the reading of abstracts.  After reading the entire article, 47 articles 
were excluded because they did not meet the eligibility criteria. Finally, 15 studies 
satisfied the pre-determined criteria and were retained for this review. 
 
 
 
 
 
 
 
 
  
Literature review 
_______________________________________________________________ 
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Flow chart of study selection process 
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n=209 articles 
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n=62 articles 
 Articles that did not 
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- Not in English = 4 
- RCT = 6 
- Review/report = 5 
- Others = 32 
Articles that met the criteria & 
included in the final review, 
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Studies Characteristics and Patients  
The characteristics of the fifteen studies that assessed factors potentially associated with 
mortality in TB/HIV co-infection are summarized in Table 2.3. Year of publication 
ranged from 1996 to 2013. Six studies (dos Santos et al., 2011; Manosuthi et al., 2006; 
Sanguanwongse et al., 2008; Sileshi, Deyessa, Girma, Melese, & Suarez, 2013; 
Sungkanuparph, Eampokalap, Chottanapund, Thongyen, & Manosuthi, 2007; Varma et 
al., 2009) were from high TB burden countries and covered  3668 patients and nine 
studies (Catala et al., 2011; Dheda, Lampe, Johnson, & Lipman, 2004; Gadkowski et 
al., 2009; Girardi et al., 2001; Palmieri et al., 1999; Podlekareva et al., 2009; Shafer et 
al., 1996; Velasco et al., 2009; Whalen et al., 1997) were from intermediate or low TB 
burden countries and covered  3230 patients. There was considerable variation with 
respect to population size (54 – 1269) and follow-up duration between the studies. 
Mean or median ages of patients varied from 33 to 40 years. In most studies the 
predominant gender was male. Most studies (87.5%) were retrospective studies and 
only two were prospective.  
Statistical quality and the presentation of methods and results were acceptable for many 
studies according to the PRISMA (preferred reporting items for systematic review and 
meta-analysis) guidelines (Moher, Liberati, Tetzlaff, & Altman, 2009). All studies 
performed regression analysis, and reported the probability value or the survival curves, 
or both. Only one article did not provide the values of hazard ratios and 95% confidence 
intervals (Shafer et al., 1996). No studies clearly stated that collinearity was assessed or 
developed a risk score based on the multivariate analysis results. One study (Varma et 
al., 2009) reported that interaction effects were evaluated. 
The majority of reviewed studies measured the primary outcome as all-cause mortality; 
which is consistent with World Health Organization guideline. This guideline defined 
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TB death as any death that occurred during TB treatment, irrespective of cause. Only 
five studies discussed causes of death (Catala et al., 2011; Dheda et al., 2004; Girardi et 
al., 2001; Manosuthi et al., 2006; Sungkanuparph et al., 2007). The case fatality rates 
ranged from 4% to 84%.   
None of the studies included post-mortem findings in their reports. Only post-mortem 
studies can determine the cause of death definitively.  
From 15 studies included in this review, demographic (in 4 studies), clinical (in 14 
studies) and laboratory (in 13 studies) variables were most frequently evaluated by 
multivariable modelling (Tables 2.7). 
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Table 2.7(a): Independents predictors of death in TB/HIV co-infected patients. 
Factors Catala  
et al., 
2011 
Dos-Santos  
et al, 2011 
Gadkowski 
et al, 2009 
Girardi  
et al, 2001 
Manosuthi 
et al, 2006 
Palmieri 
et al, 1999 
Podlekareva 
et al, 2009 
Sanguanwongse 
et al, 2008 
Socio-demographic Factors 
Increasing age +  + +    + 
Non-citizen        + 
Inner-city residence +        
Injecting Drug User +        
Clinical factors         
Fever on admission  +       
Time of TB diagnosis         
Extrapulmonary TB     +    
Disseminated TB       + + 
Non-cavitary 
radiological pattern 
+        
AIDS-defining 
illnesses 
+   +  + +  
History of previous 
AIDS 
        
No appropriate anti-
TB 
     +   
TB treatment not 
containing RHZ 
      +  
No ART   + + +   + 
No Fluconazole use        + 
No CPT         
Laboratory factors         
Low serum albumin  +       
Low CD4 counts +  + +  + + + 
Anti-TB drug resistant         + + + + 
RHZ indicates Rifamycin, Isoniazid & Pyrazinamide; ART: Antiretroviral therapy;  CPT: Cotrimoxazole prophylactic therapy 
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Table 2.7(b): Independents predictors of death in TB/HIV co-infected patients. 
Factors Shafer  
et al, 1996 
Sungkanuparph  
et al, 2006 
Varma  
et al, 2009 
Velasco 
et al,2009 
Whalen et al, 
1997 
Dheda et al., 
2004 
Sileshi et al., 
2013 
Socio-demographic 
factors      
  
Increasing age        
Non-citizen        
Inner-city residence        
Injecting Drug User        
Clinical factors        
Fever on admission        
Time of TB diagnosis    +  +  
Extrapulmonary TB  +   +   
Disseminated TB        
Non-cavitary radiological 
pattern      
  
AIDS-defining illnesses     +   
History of previous AIDS      +  
No appropriate anti-TB        
TB treatment not 
containing RHZ      
  
No ART  + + +   + 
No Fluconazole use        
No CPT       + 
Laboratory factors        
Low serum albumin        
Low CD4 counts +   +  + + 
Anti TB drug resistant  +      
RHZ indicates Rifamycin, Isoniazid & Pyrazinamide; ART: Antiretroviral therapy; CPT: Cotrimoxazole prophylactic therapy 
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Deaths during anti-tuberculosis treatment 
Six studies focused on deaths occurring during anti-tuberculosis treatment. The case 
fatality rates in these studies ranged between 19% and 72%. These studies found 
disseminated TB, (Podlekareva et al., 2009; Sanguanwongse et al., 2008), resistance to 
anti-tuberculosis drugs (Manosuthi et al., 2006; Palmieri et al., 1999; Podlekareva et al., 
2009; Sanguanwongse et al., 2008), presence of acquired immune-deficiency syndrome 
(AIDS)-defining illnesses, (Palmieri et al., 1999; Podlekareva et al., 2009) and low CD4 
counts (Dheda et al., 2004; Palmieri et al., 1999; Podlekareva et al., 2009; 
Sanguanwongse et al., 2008; Sileshi et al., 2013) to be major determinants of poor 
outcome. Palmieri et al. (Palmieri et al., 1999) found that patients without appropriate 
anti-tuberculosis therapy within the first few weeks after TB diagnosis had a survival 
rate of 48% at six months. One study focused only on hospitalized patients (dos Santos 
et al., 2011) demonstrated that fever on admission and low serum albumin to be 
independent predictors of early death.  
Deaths after completion of anti-tuberculosis treatment 
Nine studies assessed deaths occurring in patients more than one year after TB 
treatment. These studies found that socio-demographic factors including increasing age 
(Catala et al., 2011; Gadkowski et al., 2009; Girardi et al., 2001; Sanguanwongse et al., 
2008), injecting drug user (Catala et al., 2011), extra-pulmonary TB (Manosuthi et al., 
2006; Sungkanuparph et al., 2007; Whalen et al., 1997) and immunological features of 
advanced immune suppression (Catala et al., 2011; Gadkowski et al., 2009; Girardi et 
al., 2001; Shafer et al., 1996; Sungkanuparph et al., 2007; Velasco et al., 2009) to be 
independent predictors of death in TB-HIV co-infected patients. 
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Predictors of death in TB-HIV co-infected patients 
Socio-demographic factors 
There were some variations in socio-demographic factors being analysed across studies 
due to the unique character of different countries. In Thailand, mortality was 
independently associated with Thai nationality as compared to non-Thai 
(Sanguanwongse et al., 2008) In Spain, residence in a socio-economically deprived 
neighborhood or categorized as inner-city residents, were more likely to die (Catala et 
al., 2011). 
Several studies described an association between increasing age and death in TB/HIV 
co-infection. Gadkowski et al.(Gadkowski et al., 2009) found that during TB treatment, 
age more than 45 (RR: 2.18, 95% CI 1.11, 4.29) was independently associated with 
increased death. These findings could be explained by the association of age with a rise 
in co-morbidity which frequently accounted for death.  
One study (Catala et al., 2011) have demonstrated that history of injection drug use 
resulted in higher risk of death in TB/HIV co-infected patients (AHR:1.4; 95%CI: 1.1–
1.8). Injection drug users are prone to have social problems including unemployment, 
incarceration and homelessness, which may affect their access to health care. They are 
also having a higher risk of non-adherence to treatment.  
Clinical characteristics 
As shown in Table 2.7 ((a) and (b)), the clinical variables found to be the most common 
independent predictor of death were types of tuberculosis (extra-pulmonary TB and 
disseminated TB), not on ART and the presence of other acquired immune-deficiency 
syndrome (AIDS) defining illnesses. Other variables found to be predictive of mortality 
were no fever on admission (one study), presumptive TB diagnosis (one study), time of 
TB diagnosis (two studies), non-cavitary radiological pattern (one study), history of 
previous AIDS (one study), no appropriate anti-TB (one study), TB treatment not 
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containing RHZ (two studies), no Fluconazole use and no cotrimoxazole prophylactic 
therapy in one study, respectively. 
Whalen and his colleague (Whalen et al., 1997) have demonstrated that HIV-infected 
patients with extra-pulmonary TB had shorter survival time. This finding may be 
explained by the fact that patients with extra-pulmonary TB have more severe 
immunodeficiency status and higher bacterial load of Mycobacterium tuberculosis. 
Manosuthi et al. (2006) had demonstrated that gastrointestinal TB is an independent 
predictor of death in TB-HIV co-infected patients (AHR: 9.22; 95%CI 1.10-78.02) in 
Thailand (Manosuthi et al., 2006). 
In the study done by Dos santos et al.(dos Santos et al., 2011),  TB-HIV co-infected 
patients who had fever at admission had better prognosis (HR 0.18, 95%CI 0.06-0.54) 
which could be due to secretion of several cytokines as a result of adaptive cell-
mediated immune response to Mycobacterium tuberculosis. 
Catala et al. (Catala et al., 2011) found that presentation with an abnormal non-cavitary 
chest x-ray pattern was associated with lower survival as compared to a cavitary chest 
x-ray pattern. Patients who develop cavitations have better survival because they have 
better immunity (Geng, Kreiswirth, Burzynski, & Schluger, 2005).  
Five studies demonstrated that patients who suffered a prior AIDS-defining illness are 
associated with increased risk of death (Catala et al., 2011; Girardi et al., 2001; Palmieri 
et al., 1999; Podlekareva et al., 2009; Whalen et al., 1997). 
Several studies demonstrated that TB/HIV co-infected patients who were not on ART 
were associated with higher risk of death. A study (Whalen et al., 1997) that was done 
before ART was widely available showed a much higher mortality rate (84%) as 
compared to 4% to 43.7% in other studies. This finding support the facts that ART can 
save patients’ live. 
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Among patients with ART, Manosuthi et al.(Manosuthi et al., 2006) found that fifty 
percent of patients who did not receive ART in this study died within 10.7 months after 
they were diagnosed with TB. They also concluded that those who started ART less 
than six months after they were diagnosed with TB had a longer survival as compared to 
the patients who delayed ART more than six months after their TB diagnosis (HR 2.65, 
95% CI 1.15-6.10). Whereas Velasco et al.(Velasco et al., 2009) proved that HIV-
associated TB patients will have better survival if HAART and TB treatment were 
started concurrently (AHR 0.37, 95% CI 0.17 – 0.66). Only one study (Palmieri et al., 
1999) analyzed the association of appropriate anti-tuberculosis therapy with survival in 
TB/HIV co-infected patients which reported that those who were not on appropriate 
anti-tuberculosis therapy had higher mortality rates (AHR 2.6, 95%CI 1.5-4.4).  
Laboratory factors 
Low CD4 lymphocytes count (≤ 200cells/mm3) (Catala et al., 2011; Dheda et al., 2004; 
Gadkowski et al., 2009; Girardi et al., 2001; Palmieri et al., 1999; Podlekareva et al., 
2009; Sanguanwongse et al., 2008; Shafer et al., 1996; Sileshi et al., 2013; Velasco et 
al., 2009) and anti-TB drugs resistant (Alpert et al., 1997; Manosuthi et al., 2006; 
Palmieri et al., 1999; Podlekareva et al., 2009; Sungkanuparph et al., 2007) have been 
reported as consistent predictors of mortality in HIV-associated tuberculosis. 
In studies where drug susceptibility testing was performed, resistance to anti-
tuberculosis drugs was independently associated with an increased risk of death 
(Manosuthi et al., 2006; Palmieri et al., 1999; Podlekareva et al., 2009; Sanguanwongse 
et al., 2008; Sungkanuparph et al., 2007). Palmieri et al (Palmieri et al., 1999) found 
that median survival of patients with multi-drug resistant tuberculosis (MDR-TB) was 
4.6 months from their TB diagnosis. Low serum albumin (hypoalbuminaemia) was 
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associated with poorer prognosis in only one study (dos Santos et al., 2011). However, 
other studies did not reproduce this finding.  
The most important finding of this review is that it confirms the degree of immuno-
suppression influences survival in TB/HIV co-infected patients both during anti-
tuberculosis treatment and even after the completion of anti-tuberculosis treatment. 
Most of the studies demonstrated that variables associated with immunodeficiency, such 
as low CD4 lymphocyte count and the presence of AIDS defining illnesses were 
important independent predictors of mortality. The fact that low CD4 lymphocyte count 
is a potent predictor of death in TB-HIV co-infected patients leads to the inevitable 
conclusion that early access to ART has huge potential to improve immune function and 
to save lives. 
Resistance to anti-tuberculosis drugs as a predictor of mortality in TB patients has been 
well described (Amnuaiphon et al., 2009; Garcia-Garcia et al., 2002; Kawai et al., 2006; 
Lefebvre & Falzon, 2008; Low et al., 2009; Mathew et al., 2006; Quy et al., 2006). 
HIV/AIDS was also associated with the current emergence of drug resistant 
tuberculosis, thus drug susceptibility testing in TB patients co-infected with HIV is 
important. In view of the high mortality among patients with HIV and drug-resistant TB 
co-infection, empiric second-line TB therapy should be considered for previously 
treated and hospitalized patients particularly in settings with a high-burden of 
MDR/XDR-TB; while awaiting confirmatory drug susceptibility testing results 
(Andrews et al., 2010). 
HIV-associated morbidity and mortality has significantly reduced with the use of ART. 
It has also improved the survival of TB-HIV co-infected patients during and after 
completion of TB treatment. The World Health Organization (WHO) currently 
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recommends that ART should be given to all HIV-infected TB patients regardless of 
CD4 cell count (WHO, 2011c).  
Documented benefits of ART in HIV-infected TB patients and appropriate anti-
tuberculosis drugs and HAART combinations have been recommended by the Centre 
for Disease Control and Prevention (CDC). Unfortunately, still it is not widely used in 
many countries (Sanguanwongse et al., 2008). Patients were not prescribed with ART or 
delayed initiation of ART during TB treatment possibly  due to physicians’ concerns 
about the number of pills to be taken, overlapping drug toxicities, drug-drug interactions 
between rifamycins and antiretroviral drugs and the possible immune reconstitution 
syndrome (McIlleron, Meintjes, Burman, & Maartens, 2007). The findings that deaths 
were less common among HIV-infected TB patients receiving ART should convince 
physicians that the benefits of ART outweigh the risks of toxicity when these drugs are 
used in combination. 
Collaborations between TB and HIV services and interventions to improve HIV-related 
health care utilization is needed to increase survival and reduce AIDS-related and non-
AIDS-related death among TB-HIV co-infected patients (Catala et al., 2011; Gadkowski 
et al., 2009).These interventions include improving access to health services, expansion 
of laboratory services to ensure early detection of TB and drug-resistant TB, adherence 
to ART and anti-tuberculosis treatment and improvements in clinical management, such 
as early and continuous ART during TB treatment. Preventive measures such as 
prevention of HIV transmission, harm reduction programme among injecting drug 
users, as well as early hepatitis B and hepatitis C treatment in co-infected patients are 
also necessary (WHO, 2004). 
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This review has several important limitations. First, all studies included in this review 
were observational studies which are affected by selection bias. Secondly, there was 
substantial variability in settings, patients’ characteristics, variables and outcome 
assessed, which resulted in considerable heterogeneity. The wide range of reported 
mortality rates across the study, which vary from 4% to 84% in part could have resulted 
from the heterogeneity of the included patients. Third, most studies were conducted at 
single centres, which affect the generalisability of the results. In addition two studies 
(dos Santos et al., 2011; Shafer et al., 1996) had a limited sample size (less than 100 
subjects). The search strategy was restricted to articles that were available in the used 
electronic databases and full reports that were published in English. Relevant studies 
might be missed and resulted in language or publication bias. 
This systematic review proposes some important prognostic factors for the prediction of 
mortality in TB-HIV co-infected patients. Low CD4 lymphocyte count (≤ 
200cells/mm3), drug-resistant tuberculosis and not on ART is the most consistent 
predictors of mortality in HIV-associated TB patients. Early initiation of ART prior to 
the development of clinical markers of survival will help to maximize clinical outcome. 
Identification of predictors of death in TB-HIV co-infected patients may allow closer 
clinical monitoring of high-risk individuals. 
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2.13 Summary 
In this chapter, an overview about TB and HIV infection, including the pathogenesis, 
epidemiology, characteristics, treatment and survival were reviewed from many 
evidences of research that have been done in various places in the world. TB among 
HIV patients is unique in that while it is contagious, both diseases can be treated with 
standard drugs and potentially preventable. HIV seropositive patients with TB will 
develop AIDS faster and die earlier than HIV-infected patients without TB. The early 
diagnosis and prompt management of TB among HIV patients may ensure longer life 
and reduced morbidity.  
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CHAPTER 3: METHODOLOGY 
About this chapter 
This chapter provides details of work done related to collection and processing of data. 
Section 3.1 and 3.2 introduces the topic of study design and the study area where the 
data collection was conducted. Section 3.3 to 3.7 explains the methodology used in this 
study, which includes study duration, study population, sample size calculation, 
sampling procedure and study variables and the definitions of outcome measures. 
Section 3.8 introduces the conceptual framework of this study. Section 3.9 to 3.11 
provides a detailed account of the data extraction process and ethic clearance. Section 
3.12 and 3.13 explains the data management and data analysis process. 
3.1 Study Design 
The design of this study is a prospective observational, multi-centre study. In the 
hierarchy of epidemiological studies, Randomized Controlled Trial (RCT) is the best 
study design because randomization can reduce biases to facilitate isolation of the true 
treatment effect. However, for a prognostic research question, the highest evidence 
come from a systematic review then followed by a cohort study. A prospective cohort 
study is the best design to determine risk factors. 
This is a prognostic study which assesses several variables to determine the predictors 
of an outcome. Prognostic studies begin with observation at a specified point in time the 
course of a disease and follow-up patients for an adequate period of time and measure 
all relevant outcomes (Fletcher and Fletcher, 2005). 
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3.2 Study Area/ Site 
This study was conducted at four public hospitals in the Klang Valley including the 
Institute of Respiratory Medicine, Kuala Lumpur and three hospitals in Selangor namely 
Kajang Hospital, Hospital Tuanku Ampuan Rahimah, Klang and Sungai Buloh 
Hospital.  
The Klang Valley is an area in Malaysia that consists of Kuala Lumpur and 
neighbouring cities and towns in the state of Selangor. In the year 2006, the population 
in this area was estimated to be 6.0 million. Being the most urbanized area with major 
industrial and commercial activities in Malaysia, the Klang Valley became a focus for a 
large number of migrants from other states within Malaysia and foreign immigrants 
especially from Indonesia, India and Nepal. 
In 2008,  the proportion of TB/HIV among all TB cases in Klang Valley was 24.4%; 
ranked the second highest TB/HIV in Malaysia after Kelantan (31.3%). 
 
 
Figure 3.1:  Map shows the location of Klang Valley 
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The Institute of Respiratory Medicine is the main TB treatment centre in Kuala Lumpur. 
Kajang Hospital, Hospital Tuanku Ampuan Rahimah, Klang and Sungai Buloh Hospital 
were selected as study sites because they are specialist hospitals that have both TB 
Clinic and HIV Clinic. They are the only public hospitals that offer HIV treatment and 
care in the state of Selangor. 
 
Figure 3.2: Map of four participating hospitals in Klang Valley. 
 
3.2.1 Institute of Respiratory Medicine, Kuala Lumpur 
Institute of Respiratory Medicine or better known as IPR was established in 1958 as a 
small clinic called Klinik Jalan Pahang. New structures were built in 1960 to house the 
country’s National Tuberculosis Program and Tuberculosis Hospital. The new 
establishment was then named National Tuberculosis Centre (NTBC). It served as the 
nerve centre for TB control activity and its laboratory served as the National Reference 
Laboratory for Tuberculosis. With the decline of tuberculosis, in 1996 the MOH 
upgraded the NTBC and expanded  its services to cater for other respiratory diseases 
too. Since then the NTBC was renamed as the Institute of Respiratory Medicine (IPR) 
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and now functions as a hospital providing specialized care in all areas of respiratory 
medicine including tuberculosis. The bed strength of this hospital is 104 with four high 
dependency beds and four newly built negative pressure isolation rooms. The patients at 
this health facility are managed by Chest Physicians and medical officers.  
The Institute of Respiratory Medicine (IPR) was chosen for this study because it is the 
main hospital for TB management in Kuala Lumpur. Based on the National TB Control 
Programme (NTCP), IPR has been categorized as a TB Treatment Centre (1) where new 
cases are diagnosed and TB treatment initiated for patients after physical examination 
and investigation. TB patients who do not need specialist care and management will be 
transferred to the TB Treatment Centre (2) for continuation of their TB treatment and 
follow-up. This clinic receives walk-in patients, referrals from the Out-patient 
Department, Hospital Kuala Lumpur and from Community Health Clinics. There are 
also referrals from private hospitals and general practitioners. The majority of TB 
notifications received by the Health Department of Kuala Lumpur Federal Territory are 
from the Institute of Respiratory Medicine.  The TB Clinic in IPR is scheduled weekly 
every Monday and Thursday. TB cases found to be HIV positive are referred to the 
Infectious Disease Unit of Hospital Sungai Buloh.  
3.2.2 Kajang Hopital 
Kajang Hospital is a district hospital located in the district of Hulu Langat in Selangor, 
Malaysia about 30 km Southeast of Kuala Lumpur. According to historical records, 
Kajang Hospital was initially founded in 1889 with the founding of the town. It is 
located on 16 acres of land and since 2010 has been able to accommodate 306 
inpatients. 
The TB Clinic in Kajang Hospital is scheduled for every Wednesday. HIV positive TB 
patients will be referred to the HIV Clinic for HIV management and care including 
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initiation of antiretroviral therapy. Both these clinics are managed by the Medical 
Department personnel. 
The Medical Department of Hospital Kajang has been established since the 1980’s. 
However, the medical specialist service was only made available in the 1990’s. 
Currently Hospital Kajang has five in-house medical specialists and a visiting 
consultant from Hospital Sungai Buloh who provides his services one day a week at the 
HIV clinic. 
3.2.3 Hospital Tuanku Ampuan Rahimah, Klang (HTAR) 
The Tengku Ampuan Rahimah Hospital (HTAR) in Klang is a government tertiary 
hospital with 28 wards and 893 beds. The HTAR which is located in South Klang in the 
Klang district has about twenty clinical disciplines and functions as the main referral 
hospital for many peripheral district hospitals, including Sabak Bernam, Petaling, Kuala 
Langat, Kuala Selangor and Sepang.  
The TB Clinic in HTAR is also known as the Chest Clinic. The TB Clinic  is conducted 
every Tuesday. TB patients who are HIV positive will be referred to the HIV Clinic, 
which is located adjoining to the Chest Clinic. Methadone replacement therapy is also 
offered to intravenous drug users at this clinic. 
3.2.4 Hospital Sungai Buloh 
Hospital Sungai Buloh is a hospital with 646 inpatient beds. It is located in the district 
of Gombak, Selangor, about 25 km away from Kuala Lumpur. It is located on a 130-
acre (0.53 km2) site and provides a variety of secondary and tertiary medical services. It 
was initially built to reduce patient overcrowding at the Kuala Lumpur General 
Hospital. 
The catchment areas of this hospital include the districts of Gombak, Petaling, Hulu 
Selangor and Kuala Selangor.  The population in these three districts form 40% of the 
population of the state of Selangor, which totals approximately 2.18 million residents. 
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Sungai Buloh Hospital is the National Referral Centre for Infectious Diseases. The TB 
clinic in Hospital Sungai Buloh is located at the National Leprosy Centre, opposite the 
main hospital building. The TB Clinic of Hospital Sungai Buloh is scheduled for every 
Friday. This TB clinic is managed by medical officers and supervised by an Infectious 
Disease Specialist. Even though the Sungai Buloh Hospital is equipped with the 
Electronic Hospital Information System (EHIS), records at the TB Clinic still use the 
conventional method of reporting. TB patients are treated and managed based on the 
MOH Guidelines for Tuberculosis treatment. After successful completion of TB 
treatment, patients will be referred to the infectious disease clinic for continuation of 
their follow-up.  
3.3 Study Duration 
The recruitment phase of the subjects was between 1st January 2010 and 30th September 
2010 (9 months). Additional follow up period was from 1st October 2010 until 30th 
September 2011 (12 months).  This duration was chosen in line with WHO guidelines 
which recommended that all National TB Control Programs evaluate patients’  
treatment outcome 12 months after initiating TB treatment.  
Data collection was carried out in two phases. The first phase was between 1st January 
2010 and 30th September 2010 where data on socio-demographic background, lifestyle 
factors, clinical characteristics, pharmacological information and laboratory profiles 
were collected. The second phase of data collection was between 1st October 2010 and 
30th September 2011 where the TB treatment outcome data were collected and efforts 
were made to complete missing data.  
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3.4 Study Population 
The study population consisted of all patients who had registered for TB treatment as a 
result of clinical suspicion or laboratory confirmation and were tested positive for HIV 
in Institute of Respiratory Medicine, Kuala Lumpur and at three public hospitals in 
Selangor (Kajang Hospital, Klang Hospital and Sungai Buloh Hospital)from January 
2010 until September 2010 (nine months).  
3.4.1 Definition 
Cases were newly diagnosed TB patients who were HIV positive and who registered at 
the Institute of Respiratory Medicine, Kuala Lumpur and at three public hospitals in 
Selangor (Kajang Hospital, Klang Hospital and Sungai Buloh Hospital) during the study 
period. World Health Organization defines a newly diagnosed TB patient as a patient in 
whom tuberculosis had been  diagnosed by a clinician or was bacteriologically 
confirmed, had never received treatment for tuberculosis or who had taken anti-
tuberculosis drugs for less than 30 days (WHO, 2010b). 
3.4.2 Inclusion criteria 
The inclusion criteria were: 
1. TB patients aged 15 years and above who tested positive for HIV. 
2. Sputum-smear positive or sputum-smear negative and/or having extra-
pulmonary tuberculosis. 
3.4.3 Exclusion criteria 
The exclusion criteria were: 
1. Pregnant mothers 
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2. Patients who were transferred out to other centres during tuberculosis 
treatment. 
3. Patients who had their TB diagnosis changed to other diagnosis after starting 
anti- tuberculosis treatment. 
3.5 Sample Size Estimation 
The estimation of sample size was calculated according to the objectives of the study.  
For the descriptive objectives, the sample size was calculated by using the formula for 
cross sectional study to estimate how many TB patients who are HIV positive required 
for the study. The formula is as below: 
n = Z 1-α/2 
2  p(1-p) 
      ----------------- 
                 d2 
 
n = sample size 
Z 1-α/2 =  Standard normal variate (at 5% type 1 error (p<0.05) it is 1.96) 
p = expected proportion in population 
d = absolute error of precision. 
Based on literature review, the proportion of HIV cases among TB patients in Malaysia 
in 2008 was 10.4% ( ). In this study, used values are Z 1-α/2 = 1.96, p = 0.10 and d = 
0.05. 
Therefore, 
n =  (1.96)2 x 0.10 (1-0.10) 
        --------------------------- 
                       (0.05)2 
 
n = 139 
Assuming 30% of missing data, the number of the sample size should be at least 181.  
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3.5.1 Sample size calculation for risk factors of TB treatment default in HIV-
infected patients 
The calculation of sample size was done using Power and Sample Size Calculation (PS) 
software version 2.1.31 (Dupont and Plummer, 1997). The estimation of sample size 
was based on the alpha level of 0.05, with desired statistical power of 80% 
Table 3.1: Sample size calculation for risk factors of TB treatment default 
 
 
 
 
 
 
3.5.2 Sample size calculation for predictors of survival in HIV-infected TB 
patients during TB treatment. 
The significance level  was set at 0.05 and the power of the study was set at (1- ) of 
80%. The median survival time of those without the prognostic factor(m1) and the ratio 
of those without prognostic factor to those with prognostic factor (m) were obtained 
from the literature. Patients were recruited during accrual period of length A. After 
recruitment ended, there was an additional follow-up of length F. Patients remained in 
the study from the time they were recruited until the end of the study. Therefore, the 
first patient in was followed for time A + F; and last patient in was followed for F. 
 
Significance level () 0.05 
Power (1- )  0.8 
P0 (the probability of the outcome for a control 
patient.) 
0.08 (Kittikraisak, 
2009) 
P1 ( the probability of the outcome in an experimental 
subject.) 
0.20 
m  (the ratio of control to case patients.) 
 
1:2 
n  276 
Total sample size (+30% lost to follow-up) 276 + (276 x 30%) 
= 359 
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Table 3.2: Sample size calculation for predictors of survival in HIV-infected TB 
patients 
 
 
 
 
 
 
 
 
Overall, the calculated sample size ranged from 181 to 359. 
 
3.6 Sampling Procedure 
All eligible patients seen between January and September 2010 at Institute of 
Respiratory Medicine and three public hospitals in Selangor (Kajang Hospital, Klang 
Hospital and Sungai Buloh Hospital), who were registered for TB treatment and were 
also documented to have concomitant HIV infection were included in the study. 
According to the National TB Control Program, for TB management and care, health 
centres are designated as, TB Treatment Centre (1) and TB Treatment Centre (2). TB 
Treatment Centres (1) are health centres which are manned by Family Medicine 
Specialists or Medical Officers trained in TB management and have laboratory and x-
ray facilities for the diagnosis of TB. These health centres function as centres for TB 
diagnosis and initiation of treatment. TB Treatment Centres (2) do not have these 
Significance level () 0.05 
Power (1- )  0.8 
R (The hazard ratio both pulmonary and extra-
pulmonary TB compared to pulmonary TB only) 
4.0 
(Whalen, 1996) 
m1 (Median survival time of  pulmonary TB only)  30.4 months 
(Whalen, 1996) 
m (Ratio of  both pulmonary and extra-pulmonary TB 
to pulmonary TB only)  
      Both pulmonary and extra-pulmonary TB = 54 
      Pulmonary TB only = 36 
1.5 : 1 
A (The accrual time during which patients were 
recruited)  
9 months 
F (Additional follow-up after end of recruitment) 12 months 
n (Sample size determined by the PS Software) 49 
n + n(m) 49 + (49 x 1.5) 
= 122.5 
Total sample size (+30% lost to follow-up) 123 + (123x 30%) 
= 159.9 
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facilities, and they can only function as Directly Observed Treatment (DOT) centres for 
continuation of TB treatment. Every patient diagnosed with  TB will be offered routine 
HIV testing. Patients confirmed to have TB and who are HIV positive will be referred to 
the nearest public hospital for further management and care. 
The National TB Control Program requires that patients who were diagnosed with TB 
and who had started treatment should be registered at their treatment centre. Since there 
were only 267 TB/HIV co-infected cases registered in the four centres between 1st 
January 2010 and 30th September 2010, all the identified patients were included in the 
study due to the limited number of patients available to meet the calculated sample size. 
 
3.7 Operational definitions  
3.7.1 Independent variables (Patients’ characteristics) 
The selected independent variables were based on the literature review. Independent 
study variables were grouped into socio-demographic, lifestyle, TB-related 
characteristics, HIV-related characteristics and laboratory profile. 
a) Socio-demographic: 
1. Age.    
Age was categorised into three groups: ≤ 34, 35-54 and more than 55 years old.                                  
2. Gender. 
Male or female. 
3. Ethnicity 
Ethnicity was grouped into four: Malay, Chinese, Indian and Others. 
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4. Marital status. 
Marital status was grouped into single, married and divorced. 
5. Nationality.  
Nationality was categorized into Malaysian and non-Malaysian. Non- Malaysians 
comprised a small number of patients originating from Indonesia, Myanmar, Thailand  
and Nepal. 
6. Employment status 
Occupation status was classified as ‘employed’ and ‘unemployed’. Housewives, 
students, pensioner or patients who were not working were included in the unemployed 
group.  
b) Lifestyle: 
1. Smoking status. 
Smokers were defined as people who smoked, regardless of the number of sticks, 
duration and type of cigarette. Nonsmokers were those who had never smoked in their 
lifetime. 
2. Alcohol consumption 
Ever take alcohol were defined as people who took alcohol, regardless of the number of 
glasses and duration. Never take alcohol were those who had never drunk in their 
lifetime. 
3. Mode of HIV transmission 
Mode of HIV transmission was grouped into intravenous drug user (IDU), heterosexual, 
homosexual and others. The Centre for Disease Control and Prevention (CDC) 
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suggested that cases of HIV infection and AIDS are counted only once in a hierarchy of 
exposure categories. Persons with more than one reported mode of exposure to HIV are 
classified in the exposure category listed first in the hierarchy. For example, injecting 
drug use is accepted as the highest risk activity even though there may also be risk of 
HIV infection through sexual activity. 
4. Body weight 
Body weight recorded at the time of TB diagnosis (in kilogram (kg)). 
c) TB-related characteristics: 
1. Types of TB  
Type of TB was categorized into three groups: 
i) Pulmonary TB – TB disease involving the lung parenchyma 
ii) Extrapulmonary TB - TB disease in the organs through lympho-haematogenous 
spread. For example: miliary TB, TB meningitis, TB lymphadenitis, TB of the pleura, 
genitourinary TB, TB of the bones. 
iii) Both Pulmonary TB and extra-pulmonary TB- Patients suffering from both 
Pulmonary TB and Extra-pulmonary TB at the same time. 
2.  Status of TB diagnosis 
Status of TB diagnosis was categorized into two groups: 
i) New TB Case – Patient who was newly diagnosed with TB and had not 
received any previous TB treatment; or TB patients who have taken TB 
treatment, but less than four weeks; or patient who claims to have taken TB 
treatment but has no evidence of registration. 
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ii) Ever had TB before – Whether patients had relapsed TB, treatment after 
interruption or treatment after failure. 
 Relapsed TB cases - TB cases that have been cured or completed TB 
treatment but became active again with positive sputum or based on 
bacteriological examination, histological or clinical-radiological (re-
diagnosed as TB and treated as a new episode). 
 Treatment after interruption – TB cases that were re-started TB 
treatment after previous treatment had stopped. 
 Treatment after failure- TB cases that were re-started TB treatment 
after previous treatment had failed. 
3. TB case detection 
Active or passive case detection. 
4. Presence of BCG scar 
Bacillus Calmette–Guérin (BCG) scar was grouped into three categories: 
i) Presence – Scar measuring more than 2 mm including keloid scars that arise 
above the surface of the skin. 
ii) No scar – No scar at all or a small ‘pinpoint’ scar measuring less than 2 mm. 
iii) Not recorded – if both of the above columns in TBIS-10A1 form were left 
blank. 
5. Chest x-ray at TB diagnosis. 
Chest x-ray at TB diagnosis was grouped into: 
i) No lesion 
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ii) Minimal lesion – Slight lesions without demonstrable cavitation confined to 
a small part of one or both lungs. The total extent of the lesions should not 
exceed the volume of lung on one side which lies above the second 
chondrosternal junction and the spine of the fourth or the body of the fifth 
thoracic vertebra. 
iii) Moderately advanced lesion – One or both lungs may be involved, but the 
total extent of the lesions should not exceed the following limits: 
a. Disseminated lesions of slight to moderate density not exceeding the 
total volume of one lung or the equivalent in both lungs. 
b. Dense and confluent lesions not exceeding one third the volume of one 
lung.  
c. Total diameter of cavitation, if present, not more than 4cm. 
iv) Far advanced lesion – Lesions are more extensive than moderately advanced.  
6. Tuberculin skin testing (TST) 
The TST result values for each patient were coded as negative, positive or missing. 
7. TB treatment 
TB treatment is divided into two phases which is the Intensive Phase and the 
Maintenance Phase. 
i) Intensive phase or initial phase is defined as standard TB treatment on a 
daily basis during the first two months of initiating  TB treatment. For 
certain cases, the intensive phase may extend up to three months. 
The treatment regimen can be 2SHRZ or 2EHRZ or 2HRZ  
ii) Maintenance Phase or continuation phase is usually for the next four 
months but can be more than four months in certain cases. 
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The treatment regimen for maintenance phase can be 4S2H2R2 or 4R2H2 or 
4H3R3 or 4HR or 4S3H3R3 
(E= Ethambuthol, S = Streptomycin, H = Isoniazid, R = Rifampicin, Z = 
Pyrazinamide) 
 
8. Co-morbidities/past medical histories 
Co-morbidities and past medical histories that were assessed in the form TBIS 10A1 
include diabetes mellitus, congenital heart disease, liver disease, chronic renal failure, 
malabsorption syndrome, steroid therapy, history of gastrectomy and cancer. 
d) HIV-related characteristics 
1. Date of HIV diagnosis   
The date when the patient was first diagnosed as HIV positive based on the laboratory 
results. 
2. Timing of HIV diagnosis in relation to TB diagnosis. 
Timing of HIV diagnosis was classified as pre-TB diagnosis or post-TB diagnosis. It 
was later classified as HIV diagnosis before the year 2010 or after 2010. 
3. Status of anti-retroviral therapy 
Status of anti-retroviral therapy was grouped into ‘Yes’ for patients who were initiated 
ART or ‘No’ for those who were not on ART. 
4. Timing of anti-retroviral therapy 
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Timing of anti-retroviral therapy was grouped into three categories: not on anti-
retroviral therapy, anti-retroviral therapy started before TB diagnosis and anti-retroviral 
therapy started during TB treatment. 
5. Regime of Anti-retroviral Therapy (ART) 
Following the guidelines by the Malaysian Ministry of Health (MOH), the regime of 
anti-retroviral therapy in TB/HIV co-infection is categorized into: 
i. No ART 
ii. 2NRTIs + NNRTI 
iii. 2NRTIs + PI 
 (NRTI = Nucleoside Reverse Transcriptase Inhibitor, NNRTI = Non-Nucleoside 
Reverse Transcriptase Inhibitor, PI= Protease Inhibitor) 
Table 3.2: Selection of antiretroviral therapy 
Group Drug 
Nucleoside Reverse Transcriptase 
Inhibitor (NRTI) 
 Lamivudine (3TC) 
 Stavudine (d4T) 
Non-Nucleoside Reverse 
Transcriptase Inhibitor (NNRTI) 
 Efavirenz (EFV) 
 Nevirapine 
Protease Inhibitor (PI)  Ritonavir 
 Indinavir 
 
6. Opportunistic infections 
Infections caused by a microorganism that does not normally in humans, such as 
Pneumocystic Carinii Pneumonia (PCP), candidiasis; and other infections occurs in 
AIDS patients. 
7. Number of opportunistic infections (OI) 
How many OIs occur in AIDS patients. Categorized into ‘No OI’, ‘One OI’, ‘two OIs’ 
and ‘three or more OIs’ 
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8. Baseline CD4+ T-lymphocytes count 
Categorised into ‘< 200 cells/µl’, ‘≥ 200 cells/µl’ and ‘not available’. 
e) Laboratory profile 
Baseline laboratory results that were collected for each patient are as follows: 
 Haemoglobin (g/dL) 
 Total white blood cell count (103/µl) 
 Platelet (103/µl) 
 Urea (mmol/L) 
 Natrium (mmol/L) 
 Potassium (mmol/L) 
 Creatinine (mmol/L) 
 Total protein (g/L) 
 Serum albumin (g/L) 
 Total bilirubin (µmol/L) 
 Alkaline Phosphatase (ALP) (U/L) 
 Alanine Transaminase (AST) (U/L) 
 CD4 T-lymphocytes count (cells/µl) 
 HIV RNA viral load (copies/ml) 
 HbsAg – reactive, non-reactive 
 Anti-HCV– reactive, non-reactive 
 Toxoplasma IgG – reactive, non-reactive 
 Rapid Plasma Reagen (RPR) – reactive, non-reactive 
3.7.2 Dependent variable (Outcomes).  
a) Tuberculosis Treatment Outcomes 
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TB treatment outcomes were classified according to WHO recommendations - cure, 
treatment completed, treatment failure, died, defaulted or transferred out; and ‘still on 
treatment’. The outcomes were assessed twelve (12) months after the TB diagnosis was 
made. 
 Cured: Former smear-positive patient who was smear-negative in the last month 
of treatment, and on at least one previous occasion. 
 Completed treatment: A patient who has completed treatment but who does 
not meet the criteria to be classified as a cure or a failure. 
 Treatment success: A patient who is cured and who has completed treatment. 
 Treatment Failure: A smear-positive patient who has remained smear-positive 
at five months or later during treatment. 
 Defaulted/Treatment Interrupted: A patient who has interrupted treatment for 
two consecutive months or failure of the patient to attend the clinic after the date 
that the patient was due for follow-up. 
 Died: A patient who dies for any reason during the course of treatment 
 Still on treatment: The patient is still on treatment at the end of the study 
period and did not meet any other outcome during treatment. This category 
includes patients whose treatment were prolonged because of side effects or 
complications or whose initial regimen had been planned for more than twelve 
months. 
b) Survival time 
Survival time at  2 months (end of intensive phase of TB treatment), 6 months, 9 months 
and 12 months after starting TB treatment. 
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c) Survival probabilities  
Survival probabilities or survival function is the probability that the individual survives 
from the date of diagnosis until 30th September 2011. The 2, 6, 9 and 12-month survival 
rate refers to the percentage of patients who were still alive at least 2, 6, 9 and 12 
months respectively after the TB treatment was initiated. Hazard is the probability that 
patients under observation experience the event (death). 
The event in this study was death regardless of the cause. The outcome was survival 
time, which refers to the time in months from the date of TB diagnosis until the patients 
died due to TB or other related causes or until when data were censored. 
Patients were considered as censored if (1) they had not experienced the event (death) at 
the end of the study period (30th September 2011); (2) they were still alive at the end of 
the study period; (3) lost to follow up during the study period. For patients who were 
still alive when discharged, then subsequently lost to follow up, the date of their last 
follow up visits written in the medical records was the date of censoring.  
3.8 Conceptual framework 
Figure 3.3  shows the conceptual framework of risk factors for TB treatment default in 
TB/HIV co-infected patients. The conceptual framework shows that treatment behavior 
is influenced or shaped by personal, socioeconomic and treatment related factors. These 
factors are interrelated, and may affect behavior positively or negatively. The resulting 
behavior is determined by the ultimate balance of the negative and positive effects of 
these factors in an individual. 
Figure 3.4 displays the conceptual framework of predictors of survival in TB/HIV co-
infected patients. Survival among TB/HIV co-infected patients are affected by several 
factors that influence the risk of death identified as prognostic factors. In this study, 
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patients who were diagnosed with TB associated with HIV were followed up until they 
died or were censored at the end of the study period. The patients’ survival times were 
calculated from the date their TB treatment were initiated. 
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Figure 3.3: Conceptual framework of risk factors for TB treatment default in 
TB/HIV co-infected patients. 
Treatment behaviour 
Compliance Defaulted 
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Figure 3.4: Conceptual framework of predictors of survival in 
TB/HIV co-infected patients. 
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3.9 Methods of Data Collection 
3.9.1 Patient’s recruitment 
All TB patients who were tested positive for HIV, registered between January 2010 and 
September 2010 in Institute of Respiratory Medicine and three public hospitals in 
Selangor (Kajang Hospital, Klang Hospital and Sungai Buloh Hospital) were included 
in the study. In Malaysia, all TB patients were screened for HIV routinely, based on the 
guidelines by the Ministry of Health. HIV Enzyme-linked immunosorbent assay 
(ELISA) test results for these patients were traced and those who had positive results 
were included in the study. 
The list of patients diagnosed with TB and HIV positive was obtained from the TB 
registration book (TBIS 101B) which was kept at each TB clinic. The patient’s 
registration number or National Registration Identity Card (NRIC) number was used to 
retrieve their medical records. For non-citizens, their passport numbers or hospital 
registration numbers were used. Patients’ medical records and TBIS documents were 
reviewed to obtain all the dependent and independent variables including information 
on socio-demographic data, lifestyle factors, clinical characteristics, pharmacological 
information and laboratory profiles.  
3.9.2 Follow-up and exclusion 
Data on further follow-up were reviewed and the required information was retrieved in 
the data collection form. Patients who were transferred out to other treatment centres or 
had their initial TB diagnosis changed to other diagnosis by the attending physician 
were excluded from the study. Then, patients’ survival status and their survival times 
were determined. For this purpose, patients were followed up until 30thSeptember 2011. 
The date and cause of death of patients who died during hospitalization were extracted 
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from medical records. Survival status for those who were discharged alive and on 
regular appointment were also determined from their medical records. There were also 
patients who either defaulted treatment or follow-up appointment or were lost to follow-
up. For these patients, their survival status was obtained by contacting the patients or 
relatives through the phone number or address as recorded in their medical records. For 
confirmation, the survival status was also obtained through the Department of National 
Registry. Further matching with the Electoral Register of 2011 was done to confirm 
their mortality status. 
Date of initial diagnosis was defined as the first time individuals were diagnosed with 
TB diagnosis and specific treatment was initiated. Treatment outcomes were assessed at 
the end of TB treatment according to WHO guidelines. Survival time was defined as 
time in months from the date of initial diagnosis to death, or in the case of individuals 
who did not die, the last follow up recorded by the health centres. The ascertainment of 
mortality data was done by reviewing hospital records and data was matched with the 
National Registration Department using the identity card number.Information gathered 
from the medical records and TBIS documents were used to complete a standard data 
collection form. To ensure confidentiality, each case was assigned a study identification 
number that was included on all records as personal identifiers. 
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Figure 3.5: Flow chart of data collection process. 
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3.10 Study Instruments 
Socio-demographic data, clinical and laboratory information and treatment outcome 
information were extracted from the patient’s medical record and TBIS documents 
(TBIS 10A1, TBIS 10A2and TBIS10-I); HIV clinic records and in-patient records. All 
this information was documented in a standard data collection form. 
3.10.1 National Tuberculosis Information System (TBIS) documents. 
The National TB Information System is a system of reporting TB cases in Malaysia 
which was implemented in 2003. Through this system, TB data are collected and 
reported uniformly by all TB clinics or treatment centres across the country using 
standardized forms. In this system, all TB cases are notified to the District Health 
Office, which also functions as  the data centre for the collection, supervision, 
monitoring and reporting of all TB activities of a district. 
These data were used for the purpose of monitoring TB cases not only in the treatment 
centres, but also at the district, state, and at the national level. This allows for 
comparison of data made at the national and at the international level through the annual 
reports to the World Health Organization (WHO).  
TBIS documents prepared for three major activities of TB control programs, include: 1) 
patient and contact management, 2) laboratory services and 3) BCG vaccination. Each 
one has three different formats which include accessories (for daily operational use), TB 
registers and TB reports. For the purpose of data collection for this study, document 
TBIS that were used are TBIS 101B (TB patients registration book), TBIS 10A1 (Initial 
information on TB treatment) and TBIS 10A2 (Information on follow-up treatment) and 
TBIS 10I (TB patient's treatment card). 
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TBIS 101B (TB registration book) 
This book is available and maintained in all Treatment Centers (1). This register 
contains all cases treated at the concerned treatment centre. Among the important 
information contained in this register are patient information and records of specific 
events during the treatment; particularly the transfer of patients to other treatment 
centres. It also documents patient’s records of missing treatment and treatment outcome. 
TBIS 10A1 
This form contains TB patients’ data and is designed for the purpose of registration  of 
TB patients and input to the national TBIS database, Ministry of Health Malaysia. It 
contains basic information on individual TB patients including aspects of socio-
demographic, clinical, laboratory test results and the initiation of TB treatment. 
TBIS 10A2 
This form is records the progress of patients during follow-up and their treatment 
outcomes. 
TBIS 10I 
The TBIS 10-I or TB treatment card records all information pertaining to the treatment 
of each patient, sputum status monitoring, DOT and treatment outcomes. The TB 
treatment card is coloured either orange or white. The Orange coloured card is designed 
for cases that are TB positive (sputum smear positive) and white coloured card for TB 
negative (sputum smear negative) cases. This treatment card is filled in the TB 
Treatment Centre (1) immediately after a TB diagnosis is made. For patients who are 
transferred out to other treatment centres, the 10-I TBIS copy will be sent by post to the 
new treatment centre. Data contained in this card include: 
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i. Name of treatment centre that started TB treatment and continued 
treatment 
ii. Category of TB cases, status of TB diagnosis and serial sputum status. 
iii. Regime of TB treatment received, the date of TB treatment regime 
changed and the reasons for changing treatment regime. 
iv. TB treatment outcomes 
Medical Records 
Other medical records were reviewed to obtain information that could not be retrieved 
from the above TBIS documents. The records included medical records in TB clinics, 
medical records in HIV clinics, medical records during admission, which were filed in a 
record office, laboratory results and death certificate. 
As Hospital Sungai Buloh utilizes Information and Communication Technology (ICT) 
applications in its clinics, patient information in the Electronic Hospital Information 
System (e-HIS) was also reviewed to  retrieve the missing data. 
3.10.2 Data Collection Form 
The data collection form was developed based on TBIS documents, particularly TBIS-
10A1 and information for literature review. The data collection forms have three parts.  
Part A collected details about each patient’s socio-demographic characteristics, mainly 
their age, gender, ethnicity, marital status and employment status. It also included 
patient’s lifestyle practices, including their smoking status and alcohol consumption. 
Part B documented the clinical information of each patient, which included details about 
the date of TB diagnosis, type of TB, status of TB diagnosis, TB treatment received 
(intensive and maintenance phase), date of HIV diagnosis, chest x-ray changes, 
lymphadenopathy, co-morbidities, antiretroviral therapy, opportunistic infection; and 
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clinical signs and symptoms at the time of TB diagnosis. Section E in Part B recorded 
their laboratory results which included a full blood count, Renal Profile, Liver Function 
Test, CD4+ T-lymphocytes count, Hepatitis B serology (HbsAg), Hepatitis C serology 
(AntiHCV), Toxoplasma serology (Toxo IgG) and Rapid Plasma Reagin for the 
screening of syphilis. Part C recorded TB patient’s treatment outcome after they 
completed treatment.  
3.11 Ethical Consideration and Confidentiality 
The main ethical issue was patients’ privacy since their medical records were retrieved 
to obtain information. Instead of using the patient’s name in the data collection sheet, 
the researcher used a confidential code to represent each patient. Ethical clearance was 
obtained from the Medical Ethics Committee of University of Malaya on 24 March 
2010 (MEC Ref No. 776.11) and from Ministry of Health Research and Ethics 
Committee (MREC) with the reference number NMRR-10-1201-6599. The requirement 
to obtain informed written consent from each individual was waived by the institutional 
review board as the study was limited to review of existing medical records. 
3.12 Data Management 
The data were entered into the personal computer using a Statistical Package for Social 
Sciences (SPSS) Version 16.0 at the end of the day after the data collection or if time 
did not permit, it was entered no more than a week from data collection day. Entry was 
double checked immediately against the raw data to exclude typing errors. The double 
data entry method was done to check the consistency of data whereby data were entered 
by two persons and saved in two different files. Data were compared using Epi Info to 
check for dissimilar records in the two different files. Where the data did not match, it 
was checked with the original data set. Duplicate entries were identified and eliminated. 
Data was also checked for outliers by running the ‘frequencies’ of all variables. After 
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that, data transformation was performed using SPSS for Windows (version 22.0) by 
creating new variables using the Transform, Recode or Compute commands; when 
necessary. The data cleaning such as validation, editing and tracing the missing data 
was carried out before commencing the data analysis. For the purpose of safekeeping, 
all files were backed up regularly.  
3.13 Data analysis and interpretation of results 
SPSS for Windows (version 16.0) was used for data entry and all statistical analyses. 
The data analysis was divided into descriptive and inferential analysis. 
3.13.1 Descriptive analysis  
In the descriptive analysis, the frequency distribution, measures of central tendencies 
and measures of distribution were produced. Continuous data were checked for 
normality by testing for the presence of skewness and kurtosis. The skewness value 
gives information about the symmetry of the distribution. Kurtosis gives information 
about the ‘peakedness’ of the distribution. Positive skewness values mean clustering of 
scores on the left at the low values or known as positive skew. Negative skewness 
values mean scores are clustered at the right-hand side of the graph. Positive kurtosis 
values mean that the distribution is slightly peaked or clustered in the center; with long 
thin tails. Kurtosis values below 0 indicate a distribution that is relatively flat (too many 
cases in the extremes). Kolmogorov-Smirnov statistic results were also reviewed to 
assess for normality. A non-significant result (‘Sig.’ value of more than 0.05) indicates 
normality. 
 
Data exploration was done mainly to acquire the descriptive statistics that describe all 
the variables and to examine the distribution of the data graphically. Following data 
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exploration the tables were constructed. The continuous variable with normal 
distribution was summarized using mean and standard deviation and the skewed 
distribution was summarized using the median and interquartile range (IQR). Certain 
continuous variables such as age, hemoglobin level, albumin level and CD4 T-
lymphocytes count were transformed into categorical variables for further analysis.  
All the categorical variables were summarized using counts and percentages (%). After 
examining the data, some categories of certain variables were collapsed due to small 
numbers of the sample.  For continuous variables, the Student t test was performed for 
normally distributed variables and Mann-Whitney U test for non-normally distribution. 
For categorical variables, the Pearson chi square test or Fisher’s exact test was used 
depending on the expected values in the cells. Simple logistic regression was used for 
categorical data with more than two categories. 
Some of the independent variables were re-categorized when it was deemed necessary. 
For variables which had more than two categories, dummy variables were created 
before further bivariate analyses were done. An example of the dummy table is shown 
in table 3.2. 
 
Table 3.3: Dummy variable for the independent groups which have more 
than two categories 
Variables Reference   Dummy variable 
Ethnicity Others  
Malay 
Chinese 
Indian 
Others 
 
 
Ethnic(1) 
1 
0 
0 
0 
Ethnic(2) 
0 
1 
0 
0 
Ethnic(3) 
0 
0 
1 
0 
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Student t test 
There are three types of t-test, namely one sample t-test, paired t-test and independent t-
test. In this study, independent t-test was used for data analysis. The independent t test is 
a statistical test used to compare the means of two groups. It is performed when there is 
one nominal variable and one measurement variable with the following assumptions: 
i) Normal distribution in each group (if the sample size is 30 or more in each group, the 
need for normality is reduced) 
ii) Equality of variances (if the sample sizes are equal, this assumption may be ignored) 
iii) Independence of observations 
The equation for independent t-test is as follows: 
𝒕 =  
?̅?1 − ?̅?2
√(
𝟏
𝒏1
+
𝟏
𝒏2
)
𝒔
 
Where, 
√(1/𝑛1  + 1/𝑛2)
𝑠
  is the estimated standard error of the difference between the means. 
‘t’ is considered to be statistically significant if it’s calculated value is sufficiently 
different from 0. 
3.13.2 Inferential analysis 
Inferential analysis was performed to examine the relationship between each independent 
variable with the outcome. In this study, survival analysis was conducted to determine the 
association of all independent variables with the following dependent variables, namely,  
(i) defaulted TB treatment (defaulters and non-defaulters) and (ii) survival of TB/HIV 
co-infected patients (mortality status : alive/dead). 
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Survival Analysis 
Survival analysis was developed to estimate the survival of a cohort over time. It can be 
applied to any outcomes that are dichotomous and occur only once during follow-up. 
The time to event or survival time can be measured in days, weeks or years. In survival 
analysis, subjects are usually followed over a specified time period and the focus is on 
the time at which the event of interest occurs. Observations are called censored when 
the information about their survival time is incomplete.  
Kaplan Meier analysis 
Kaplan Meier is a non-parametric method that is widely used to estimate and 
graphically plot survival probabilities as a function of time. It can be used to obtain 
univariate descriptive statistics for survival data, including the median survival time; 
and compare the survival experience for two or more groups of subjects. The log-rank 
test was used to estimate the probability of survival and compare the survival curves 
between the various categories. Survival probabilities across the groups were plotted for 
each variable using Kaplan-Meier Product Limit estimates of survivorship function 
method.  
The survival probability at any particular time is calculated by the formula given below 
(Kleinbaum & Klein, 1996):  
 
   S (t) =  π      ni - di  
                                    ti < t       ni 
 
Where; 
S(t) = proportion of individuals surviving until time t.  
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 ni = the number of survivors just prior to time ti or the number of survivors less the 
number of losses/censored cases  
di = the number of deaths at time ti 
Cox proportional hazards regression 
Univariable Cox proportional hazards analysis was conducted for all independent 
variables to get the independent effects of each variable and to have a preliminary idea 
of which variable(s) that might be of prognostic importance. The Cox proportional 
hazards model assumes that the time to event and the covariates are related through the 
following equation: 
 
hi (t) = [h0(t)] x [exp(β1Xi1 + β2Xi2 + ..............+ βpXip) 
 
Where  
hi (t) represents the hazard, or the risk of suffering the event of interest, of patient i at 
time t,  
h0(t) is the baseline hazard at time t  
p is the number of covariates 
Multiple Cox Regression 
Multivariable Cox hazard regression was applied to identify the independent prognostic 
variables of TB/HIV co-infection. A combination of variables will produce a more 
accurate prognosis than any of these variables examined one at a time. The log rank p-
value less than 0.25 was set as cut off value to choose predictors for entry into multiple 
Cox proportional hazards regression analysis. The cut off value of p less than 0.25 was 
 Methodology 
 
 
 
121 
chosen in order not to miss significant predictors which may have been confounded 
during univariate analysis. This is similar to the Hosmer-Lemeshow approach in logistic 
regression.  
Predictors with p-value less than 0.25 from the univariate analysis were then fitted 
jointly into a Cox regression model. In the presence of multiple variables, some 
variables may not be significant anymore. Each variable starting from the least 
statistically significant was dropped individually from the model and the -2 log 
likelihood (-2LL) from the nested models were compared with and without that 
variable. If the value of the difference in -2LL was not increased significantly, the 
variable was dropped. Once a variable was discarded, the effect of omitting each of the 
remaining covariates in turn was examined. Here, “preliminary main effect model” was 
obtained.  
Interaction 
To refine the model, all possible two-ways interactions of independent variables in the 
preliminary main effect model were checked. The inclusion of the interactions was to 
improve inferences and to obtain a more realistic model. Interactions among the 
covariates were examined by creating a new covariate as a product of the original 
covariates. For example, the interaction of X1 and X2 can be defined as X1X2 and 
represented as X3. There will be a new term β3X1X2 in the hazard function.  
1) If X1=0, one additional unit of X2 has a hazard ratio of exp(β2) 
2) If X1=1, one additional unit of X2 has hazard ratio of exp(β2+ β3) 
Positive β3 enables X2 to have more effect in group 1 of X1than in group 0. If β3 is 
negative the effect of X2 could be less in group 1 than in group 0. A similar explanation 
can be achieved by exchanging the positions of X1 and X2. 
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Then, the independent variables were fitted into linear regression model and Variation 
Inflation Factor (VIF) was obtained to assess the multicolinearity (MC). The VIF value 
of more than 10 was considered to indicate a problem of multicollinearity, which 
required remedial action.  
Model Fitness 
Model fitness was done by testing the assumption of proportional hazards and 
diagnostics statistics using two ways (Rosner B., 2006): 
1. Graphical approach using  Log-Minus-Log plot  
Hazard regression models for survival involved the proportional hazards assumptions, 
where the variables were independent with respect to time, hazards were proportional 
and their hazards ratios should be constant across time, that is, the proportionality of 
hazards from one case to another should not vary over time. The assumption was 
verified graphically by inspection of the cumulative hazards curves (log minus log 
plots) and hazard plots in all categorical independent variables in the preliminary final 
model. The almost parallel curves indicate that the hazards of dying were proportional 
over time. Thus, the assumption of the proportional hazards model would be fulfilled 
and the Cox regression model would be valid.  
2. Goodness-of-fit (GOF)  
The implementation of the test is by correlating the partial residuals and the survival 
time rank. This is a more confirmatory test because it provides a test statistic and p-
value for assessing the proportional hazard assumption for a given predictor of interest. 
Thus, a more objective decision can be done using a statistical test. This is done by 
performing a Cox regression model and saving the partial residuals for each predictor. 
The time variable is ranked from 1 for the subject who has the earliest event, to the 
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largest value and then correlated with the residuals. The tests will suggest that the 
proportional hazard assumption is violated if the p-value is less than 0.05. 
The results from the final model were summarized with regression coefficient, adjusted 
hazard ratio (AHR), which described the risk of death, its 95% confidence interval (CI) 
and its corresponding p-value. The significant level was set at 0.05, two-tailed. An HR 
is a ratio of the risks for different subgroups of a co-variate. For example, for a binary 
co-variate such as gender where males are coded as 1 and female 0, a hazard ratio of 
2.00 would imply that the risk of dying among male is 2.00 times higher than among 
female. 
3.14 Summary 
This chapter details the study design and work done in extracting the data from four 
study centres, namely Institute of Respiratory Medicine, Kajang Hospital, HTAR Klang 
and Sungai Buloh Hospital. The data collection process took longer than expected due 
to various logistic issues. Data cleaning, transformation and data analysis were also 
performed. 
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CHAPTER 4: RESULTS 
About this chapter 
The results of this report will be presented following the sequence of the specific 
objectives as in Chapter 3. This chapter is divided into five sub-sections which describe 
the following information in detail: Section 4.1 is the descriptive analysis which 
describes the socio-demographic, lifestyle, TB-related characteristic, HIV-related 
characteristics and laboratory profiles of TB/HIV co-infected patients in this study. 
Section 4.2 presents the results on TB treatment outcomes in TB/HIV co-infected 
patients. The factors associated with default from TB treatment in TB/HIV co-infected 
patients are also described in detail. Section 4.3 describes the mortality rate and the 
causes of death in TB/HIV co-infected patients in this study, the survival curves and 
finally the predictors of death in TB/HIV co-infected patients. Section 4.5 is the 
summary of this chapter. 
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Figure 4.1 Flowchart of data analysis. 
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4.1 Descriptive Analysis 
A total of 2262 tuberculosis patients were registered between 1st January 2010 and 30th 
September 2010 in Hospital Sungai Buloh, Hospital Kajang, Hospital Tuanku Ampuan 
Rahimah, Klang; and Institute of Respiratory Medicine, Kuala Lumpur. Among these 
patients, 267 patients were co-infected with HIV, 32 patients (12.0%) were transferred 
out to other treatment centres and 8 patients (3.0%) had their diagnosis changed because 
they were later found to have a different diagnosis and were thus excluded. Finally, 227 
patients were eligible for analyses according to the inclusion criteria. The mean follow-
up duration was 14.3 months (SD 6.3) months and the median was 15.9 (IQR 5.8) 
months.  
 
Table 4.1: No of TB Cases and TB with HIV positive registered in four centres 
between 1st January 2010 and 30th September 2010. 
Location Total TB Cases 
(n) 
TB with HIV-positive 
           (n, %) 
Hosp. Sungai Buloh 381  193(50.7) 
Hosp. Kajang 208 17 (8.2) 
HTAR Klang 371 19 (5.1) 
Inst. Respiratory Medicine 1302 38 (2.9) 
TOTAL 2262 267 (11.8) 
 
 
The characteristics of patients included in the analyses and those who were excluded 
(transferred out and changed diagnosis) by age, gender and ethnicity in the control 
group is illustrated  in table 4.2. There was no statistically significant difference in the 
age group, gender and ethnic distribution between  the two groups.  
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Table 4.2: Characteristics of patients included in analyses compared to 
transferred out and changed diagnosis. 
Variables  Included  
(n = 227) 
No (%) 
Excluded  
(n = 40) 
No (%) 
p 
value 
     
1. Age group, year < 34 73 (32.2) 13 (32.5%) 0.279 
 35-54 141 (62.1) 22 (55.0%)  
 ≥ 55 13 (5.7) 5 (12.5%)  
     
2. Gender Male 200 (88.1) 35 (87.5%) 0.921 
 Female 27 (11.9) 5 (12.5%)  
     
3. Race Malay 110 (48.5) 20 (50.0%) 0.517 
 Chinese 37 (16.3) 8 (20.0%)  
 Indian 37 (16.3) 3 (7.5%)  
 Others 43 (18.9) 9 (22.5%)  
     
 
4.1.1 Socio-Demographic Distribution 
Table 4.3 displays the distribution of socio-demographic characteristics of TB/HIV co-
infected patients.  The mean age of TB/HIV co-infected patients were 39.1(SD 8.6) 
years old and ranged from 16 to 62 years old. The peak age group was patients from 35 
to 54 years old (62.1%). Male to female ratio was 7:1.  The TB/HIV co-infected patients 
were predominantly Malays (48.5%) followed by Chinese (16.3%), Indians (16.3%) and 
Others (18.9%). Other race includes indigenous ethnic groups born in Sabah and 
Sarawak; those who were born from interracial marriages and also non-citizens. A total 
of 182 (81.5%) Malaysians formed the majority of  TB/HIV co-infected patients while 
there were only 42 (18.5%) non-Malaysians patients who originated from Myanmar, 
Indonesia, Nepal and Thailand. More than half the patients were unemployed (57.3%). 
The majority of TB/HIV co-infected patients were single or divorced (67.0%). 
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Table 4.3: Distribution of socio-demographic characteristics of 227 TB/HIV 
patients. 
Variables                           N (%) 
Age group, years < 34 73 (32.2) 
 35-54 141 (62.1) 
 ≥ 55 13 (5.7) 
   
Age (mean (SD)) 39.1 + 8.6 years 
   
Gender Male 200 (88.1) 
 Female 27 (11.9) 
   
Race Malay 110 (48.5) 
 Chinese 37 (16.3) 
 Indian 37 (16.3) 
 Others 43 (18.9) 
   
Nationality Malaysian 185 (81.5) 
 Non- Malaysian 42 (18.5) 
   
Employment status Employed 97 (42.7) 
 Unemployed 130 (57.3) 
   
Marital status Single/divorced 152 (67.0) 
 Married 75 (33.0) 
   
Religion Islam 121 (53.3) 
 Buddhist 38 (16.7) 
 Hindu 30 (13.2) 
 Others 38 (16.8) 
   
Incarceration* Yes 21 (18.5) 
 No 206 (81.5) 
   
*Incarceration: Prisoners/Drug Rehabilitation Centre  inmates at the time of TB diagnosis. 
 
4.1.2 Lifestyle Factors 
Lifestyle factors referred to the smoking status, alcohol consumption mode of HIV 
transmission and body weight. The lifestyle characteristic of TB/HIV co-infected 
patients are highlighted in Table 4.4. 
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The majority of the respondents in this study were smokers (74%) and non-consumers 
of alcohol (76.2%). Mode of HIV transmission was mainly through injecting drugs 
(55.9%) followed by heterosexual (35.7%) homosexual (3.5%) and others (4.8%, n=11). 
The median body weight of these patients was 49.7 (SD 9.0) kg. 
 
Table 4.4: Distribution of lifestyle factors of 227 TB/HIV patients. 
Variables 
 
 N (%) 
Smoking status Smoker 168 (74.0) 
 Non-smoker 59 (26.0) 
   
Alcohol intake No 173 (76.2) 
 Yes 54 (23.8) 
   
Mode of HIV transmission Intravenous drug users 127 (55.9) 
 Heterosexual 81 (35.7) 
 Homosexual 8 (3.5) 
 Othersa 11 (4.8) 
   
Body weight (Mean (SD))    49.7 (±9.0)kg 
   
a Others: Blood transfusion (n=1) and Unknown (n=10). 
 
4.1.3 TB-related Characteristics  
TB related characteristics referred to the type of TB, status of TB diagnosis, TB 
treatment, status of BCG immunization and other co-morbidities. The TB-related 
characteristics are illustrated in Table 4.5. Pulmonary TB occurred in 48.9% of patients, 
followed by extra-pulmonary TB (28.2%) and 22.9% had both pulmonary and extra-
pulmonary TB. The majority of patients (70.9%) were newly diagnosed TB cases 
whereas another 29.1% had previous history of TB. Among 227 patients, only 62.6% of 
cases had at least one specimen collected at any time before or during treatment which 
was positive for acid-fast bacilli and/or culture-positive for Mycobacterium tuberculosis 
(MTB) in the sputum, or other type of samples (blood, pleural fluid, cerebro-spinal fluid 
etc.). 
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Among all patients, 85.9% were on anti-tuberculosis regimes that contained rifampicin, 
as recommended by the WHO. The median time of the intensive phase was 61 days or 
2.0 months. Patients who developed adverse drug reactions to rifampicin, were 
prescribed another  drug regimen such as isoniazide (H) and pyrazinamide (Z) (3.5%) 
and others (10.6%). Maintenance phase was continued for 71.9% of patients with 137 
(60.4%) on isoniazid (H) and rifampicin (R) regime. Another 28.8% were not on 
maintenance therapy mainly because they defaulted follow-up. In patients who were on 
maintenance therapy, the median time of maintenance phase was 149 days (5.0 months).  
All TB types were included in this study. Smear positive pulmonary TB was reported in 
40.5% of patients, in which 29.5% of total cases had smear positive TB only. Another 
11.0% had smear positive and extra-pulmonary TB. Smear negative PTB only was 
diagnosed in 18.9%, smear negative PTB and extrapulmonary TB in 12.3% and 28.2% 
had extrapulmonary TB only. 
Among those with extrapulmonary TB, 32.2% had disseminated or miliary TB, 10.1% 
had TB lymphadenitis, 5.3% had TB meningitis, 1.3% had intra-abdominal TB and 
pleural TB respectively and another 3.5% were at other sites.  
Co-morbidities that were assessed included diabetes mellitus, congenital heart disease, 
malabsorption syndrome, malignancies, chronic liver disease and history of 
gastrectomy. The frequencies of other co-morbidities were low in these patients. 
Overall, only 41 (18.1%) cases had co-morbidities. Diabetes mellitus was present in 
only 2.6% (n=6) of cases. 
Case detection was classified as ‘Passive’, if the patient came to hospital for TB 
investigation by himself (self-referral) and ‘Active’ if household and other close 
contacts of infectious case subjects were identiﬁed and tested for TB infection or via 
screening of high risk individuals. Among 227 patients, 11 (4.9%) were diagnosed as 
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having TB through active case finding while 10 patients (4.4%) were detected through 
screening of inmates in prisons and drug rehabilitation centres. One patient was 
identified by contact tracing of a TB case. 
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Table 4.5: Distribution of TB-related characteristics in 227 TB/HIV co-infected 
patients 
Variables 
 
 N (%) 
Types of TB Pulmonary TB 111 (48.9) 
 Extra-pulmonary TB  64 (28.2) 
 Both 52 (22.9) 
   
Status of TB diagnosis Newly diagnosed TB 161 (70.9) 
 Ever had TB before 66 (29.1) 
   
Case detection Passive 216 (95.2) 
 Active  11 (4.9) 
   
Intensive phase regime HRZa 195 (85.9) 
 HZ 8 (3.5) 
 Others 24 (10.6) 
   
Maintenance phase No maintenance therapy 64 (28.2) 
 HR 137 (60.4) 
 Others 26 (11.4) 
   
Changed in treatmentb Yes 37 (16.4) 
 No 190 (83.7) 
   
Median time of intensive phase 
(days) 
61.0 (IQR 52 -78) 
   
Median time of maintenance 
phase (days) 
149.0 (IQR 111-210) 
   
BCG scar Scar present 197 (86.8) 
 No scar/ NR 30 (13.2) 
   
Co-morbiditiesc Yes 41 (18.1) 
 No 186 (81.9) 
   
Diabetes Mellitus Yes 6 (2.6) 
 No 221 (97.4) 
   
   
aHRZ: Isoniazid, Ryfampycin & Pyrazinamide; HZ: Isoniazid & Pyrazinamide only; HR: Isoniazid &Ryfampycin 
bChange in diagnosis: change from the initial TB regime (HRZ) to another due to side effects of treatment or adverse reaction. 
cCo-morbidities: Include diabetes mellitus, congenital heart disease, malabsorption syndrome, malignancies, chronic liver disease 
and history of gastrectomy 
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4.1.4 Clinical Presentation 
Table 4.6 displays the clinical presentations in TB/HIV co-infected patients. Sign and 
symptoms assessed were based on TBIS 10A form which included cough more than two 
weeks, cough with sputum, hemoptysis, loss of weight, fever, night sweat and loss of 
appetite. The frequency distribution of symptoms presented among TB/HIV co-infected 
patients in study sites are shown in Table 4.6. At diagnosis, most of the patients 
presented with fever (74.9%), followed by loss of weight (69.2%), cough more than two 
weeks (67.0), loss of appetite (66.1%), cough with sputum (48.5%) and night sweats 
(43.2%). Hemoptysis was experienced by only 13.7% of the  patients.  
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Table 4.6: Distribution of clinical presentations in 227 TB/HIV co-infected patients 
Variables 
 
 N (%) 
Cough more than two weeks Yes 152 (67.0) 
 No 75 (33.0) 
   
Cough with sputum Yes 110 (48.5) 
 No 117 (51.5) 
   
Hemoptysis Yes 31 (13.7) 
 No 196 (86.3) 
   
Loss of weight Yes 157 (69.2) 
 No 70 (30.8) 
   
Fever Yes 170 (74.9) 
 No 57 (25.1) 
   
Night sweats Yes 98 (43.2) 
 No 129 (56.8) 
   
Loss of appetite Yes 150 (66.1) 
 No 77 (33.9) 
   
Chest x-ray changes No lesion 52 (22.9) 
 Minimal lesion 109 (48.0) 
 Advanced lesion  66 (29.1) 
   
Lymph node enlargement No lymphadenopathy 120 (52.9) 
 Lymphadenopathy 107 (47.1) 
   
 
4.1.5 HIV-related Characteristics 
Table 4.7 showed the distribution of characteristics of HIV in TB/HIV co-infected 
patients. The majority of the patients (67.3%) was diagnosed to have HIV before TB 
diagnosis. There were 140 (61.7%) patients on anti-retroviral therapy, whereas 87 
(38.3%) were not on any anti-retroviral therapy. Among them, antiretroviral therapy 
was initiated before TB diagnosis in 39 (17.2%)  patients and another 101 (44.5%) 
patients were started on antiretroviral therapy after they were diagnosed with TB. For 
these patients, the median time from TB diagnosis to initiating ART was 51.5 (SD 62.2) 
days. In terms of ART regimen for 140 (61.7%) who were on ART during TB 
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treatment, 127 (56.2%) were on two NRTI and an NNRTI, ten patients (4.4%) on NtRTI 
+ NNRTI, two patients (0.9%) on  two NRTI + PI and only one patient (0.4%) received 
NtRTI + PI. 
 
Table 4.7:Distribution of HIV-related characteristics in 227  in TB/HIV co-infected 
patients 
Variables 
 
 N (%) 
Timing of HIV diagnosis Same year (2010) 74 (32.6) 
in relation to TB diagnosis Before 2010 153 (67.4) 
   
Opportunistic infection Yes 108 (47.6) 
 No 119 (52.4) 
   
Anti-retroviral therapy Yes 140 (61.7) 
 No 87 (38.3) 
   
Anti-retroviral regime  No ART 87 (38.3) 
 2NRTI + NNRTI 127 (56.2) 
 NtRTI + NNRTI 10 (4.4) 
 2NRTI + PI 2 (0.9) 
 NtRTI + PI 1 (0.4) 
   
Timing of antiretroviral therapy No ART 87 (38.3) 
 Before TB diagnosis 39 (17.2) 
 During TB treatment 101 (44.5) 
   
Median time starting 
antiretroviral during TB 
treatmenta  
51.5 (IQR 62.2) days 
   
an= 101 
IQR:Interquartile range;NRTI = Nucleoside Reverse Transcriptase Inhibitor, NNRTI = Non-Nucleoside Reverse Transcriptase 
Inhibitor, PI = Protease Inhibitor 
 
4.1.6 Laboratory Investigations 
Table 4.8 describes the frequency distribution of laboratory characteristics among 
TB/HIV co-infected patients in the study sites. A total of 178 (78.4%) of the patients 
had a low hemoglobin level (<12 g/DL). CD4 counts were available for only 208 
patients (91.6%). The mean CD4 count was 109.8 (SD 131.3) cells/µl with a median of 
59 (IQR 133.5) cells/µl. Among the 95 patients with  available HIV RNA viral load 
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result, the median HIV RNA viral load was 204,638.0 copies/ml (IQR 828,620.0). CD4 
count and HIV RNA viral load test were not available for all patients because those tests 
are expensive and were done on a case by case basis. 
From a total of 227 patients, 167 isolates (73.6%) were tested for anti-TB drug 
sensitivity. One isolate was resistant to pyrazinamide, one was resistant to streptomycin 
and another one was resistant to rifampicin. None of the isolates had multidrug resistant 
tuberculosis (MDR-TB). Co-infection with Hepatitis B were reported in 15 patients 
(6.6%), Hepatitis C in 127 patients (55.9%), Toxoplasmosis in 51 patients (22.5%) and 
syphilis in 11 patients (4.8%). 
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Table 4.8: Distribution of laboratory profiles in 227 TB/HIV co-infected patients 
Variables 
 
 N (%) 
Hemoglobin level < 12 g/dL 178 (78.4) 
 ≥ 12 g/dL 49 (21.6) 
(Mean (SD)) 10.5(±1.9)g/dL 
   
Total White Blood Cell  
(Mean (SD)) 
6.3 (±3.3) 103/µl 
   
Platelet (Mean (SD)) 268.8 (±112.4) 103 /µl 
   
Urea (Mean (SD)) 3.8 (±1.6) mmol/L 
   
Natrium (Mean (SD)) 133.1 (±4.3) mmol/L 
   
Potassium(Mean (SD)) 5.6 (±21.4) mmol/L 
   
Creatinine (Mean (SD)) 69.0 (±36.8) mmol/L 
   
Total Protein (Mean (SD)) 76.7 (±10.7) g/L 
   
Serum albumin 
(Mean (SD)) 
26.5 (±7.5)g/L 
   
Total bilirubin (Mean (SD)) 13.7 (±17.3)µmol/L 
   
Alkaline Phosphatase  
(Mean (SD)) 
162.0 (±121.4)U/L 
   
Alanine Transaminase  
(Mean (SD)) 
45.0 (±87.0)U/L 
   
CD4 T-lymphocytes counta < 200 cells/µl 168 (74.0) 
 ≥ 200 cells/µl 39 (17.2) 
 Not available 20 (8.8) 
(Median (IQR)) 59 (IQR 133.5)cells/µl  
   
aHIV RNA viral load  
(Median (IQR)) 
204638.0 (IQR 828620.0) copies/ml 
   
HbsAg Reactive 15 (6.6) 
 Non-reactive 212 (93.4) 
   
Anti-HCV Reactive 127 (55.9) 
 Non-reactive 89 (39.2) 
 Not available 11 (4.8) 
   
Toxoplasma IgG Reactive 51 (22.5) 
 Non-reactive 62 (27.3) 
 Not available 114 (50.2) 
   
Rapid Plasma Reagen (RPR) Reactive 11 (4.8) 
 Non-reactive 125 (55.1) 
 Not available 91(40.1) 
a Available for 95 patients only. 
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4.2 Tuberculosis treatment outcomes in TB/HIV co-infected patients 
4.2.1 Tuberculosis treatment outcomes 
During this study, a total 227 patients were found to have TB-HIV co-infection in four 
centres from 1st January 2010 till 30th September 2010. At the end of TB treatment, 
patients were classified into five groups according to outcomes. They were classified as 
‘cured’ if they were smear-negative at, or one month prior to the completion of 
treatment and on  at least one previous occasion; as ‘treatment completed’ if patients 
completed treatment but did not have proof of cure;as ‘treatment failure’ if patients 
remained or became again smear positive at five months or later during treatment; as 
‘treatment defaulted ’ if the treatment was interrupted for two months or more and as 
‘death’ if a patient died for any reason during the course of treatment.  
 
Among 227 patients analysed, successful outcomes were achieved in 117 patients 
(53.4%) with 18.1% of patients cured and another 33.5% completed treatment. The 
unsuccessful outcomes were those patients who ‘defaulted’ (24.7%, n=56) and ‘died’ 
(20.3%). There was no cases of treatment failure identified.  
 
However, 8 (3.4%) were still on treatment and did not meet any other outcome at the 
end of the study period (30thSeptember 2011). Patients who were categorized as still on 
treatment at the end of 12 months included patients whose treatment was prolonged 
because of side effects or complications or whose treatment was re-started several times 
because of multiple episodes of defaulting treatment.  
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Figure 4.2: Flowchart of TB treatment outcomes in 227 TB/HIV co-infected 
patients. 
 
4.2.2 Factors associated with tuberculosis treatment default 
For this analysis, treatment outcomes were divided into two groups; defaulters and non-
defaulters.  Four variables  (cure, completed treatment, still on treatment, died) were 
combined into one variable named ‘non-defaulters’ and were compared with 
‘defaulters’ to identify factors associated with treatment default.  
Table 4.9 below displays the socio-demographic and lifestyle characteristics of 227 
TB/HIV co-infected patients stratified by TB treatment outcomes (non-defaulters and 
defaulters).   
Successful outcomes 
n = 117 
 
 
 
 
Unsuccessful outcome  
n = 102 
Cure 
n=41 
 
 
Still on treatment 
n=8 
Completed 
treatment 
n=76 
Treatment 
failure, 
n=0 
Defaulted 
treatment,  
n=56 
Died 
n=46 
 
TB treatment outcomes 
n = 227 
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Table 4.9: Socio-demographic and lifestyle characteristics of 227 TB/HIV co-infected 
patients in Klang Valley stratified by non-defaulters and defaulters.  
Characteristics 
  Non-defaulters* 
 
Defaulters 
  n (%)    n (%) 
Age group     
< 34  56 (32.7)  17 (30.4) 
35-54 
 
105 (61.5) 
 
36(64.2) 
≥ 55 
 
10 (5.8) 
 
3 (5.4) 
  
   
Gender 
 
   
Male 
 
146 (85.4)  54 (96.4) 
Female 
 
25 (14.6) 
 
2 (3.6) 
    
Ethnicity 
 
   
Malay 
 
86 (50.3)  24 (42.9) 
Chinese  
 
31 (18.1)  6 (10.7) 
Indian 22 (12.9)  15 (26.8) 
Others 
 
32 (18.7) 
 
11 (19.6) 
    
Nationality     
Malaysian  140 (81.9)  45 (80.4) 
Non-Malaysian  31 (18.1)  11 (19.6) 
     
Employment  
 
   
Employed 
 
96 (56.1) 
 
34 (60.7) 
Unemployed 
 
75 (43.9) 
 
22 (39.3) 
    
Incarceration# 
 
   
Yes 
 
154 (90.1)  52 (92.9) 
No 
 
17 (9.9) 
 
4 (7.1) 
    
Marital status 
 
   
Single/Divorced 
 
113 (66.1)  39 (69.6) 
Married 
 
58 (33.9)  17 (30.4) 
    
Religion 
 
   
Islam 
 
92 (53.8)  29 (51.8) 
Buddhism 
 
32 (18.7)  6 (10.7) 
Hindu 
 
19 (11.1)  11 (19.6) 
Others 
 
28 (16.4) 
 
10 (17.9) 
    
Smoking 
 
   
Ever smoked 
 
124 (72.5)  44 (78.6) 
Never smoked 
 
47 (27.5) 
 
12 (21.4) 
    
Alcohol intake 
 
   
Ever take alcohol 
 
35 (20.5)  19 (33.9) 
Never take alcohol 
 
136 (79.5) 
 
37 (66.1) 
    
Mode of HIV 
transmission 
 
   
Intravenous drug users 
 
90 (52.6)  37 (66.1) 
Sexual 
 
73 (42.7)  17 (30.4) 
Other/unknown 8 (4.7)  2 (3.6) 
#Incarceration: Prisoners/Drug Rehabilitation Centre  inmates at the time of TB diagnosis. 
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Table 4.10 to Table 4.13 below displays the TB-related, HIV-related characteristics and 
laboratory profiles of 227 TB/HIV co-infected patients stratified by TB treatment 
outcomes (non-defaulters and defaulters).  
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Table 4.10: TB-related characteristics of TB/HIV co-infected patients in Klang 
Valley stratified by non-defaulters and defaulters. 
Characteristics 
 
Non-defaulters Defaulters 
 n (%) n (%) 
Types of  TB 
 
  
Pulmonary TB 
 
83 (48.5) 27 (48.2) 
Extrapulmonary TB 
 
48 (28.1) 17 (30.4) 
Both 
 
40 (23.4) 12 (21.4) 
   
Status of TB diagnosis    
Newly diagnosed TB  125 (73.1) 36 (64.3) 
Ever had TB before  46 (26.9) 20 (35.7) 
    
Case detection    
Passive  161(94.2) 55 (98.2) 
Active  10 (5.8) 1 (1.8) 
    
Intensive phase regime 
 
  
aHRZ 
 
145 (84.8) 50(89.3) 
HZ 
 
6 (3.5) 2 (3.6) 
Others 
 
20 (11.7) 4 (7.1) 
   
bChanged in treatment    
Yes  141 (82.5) 49 (87.5) 
No  30 (17.5) 7 (12.5) 
    
Lymph node enlargement    
Yes  72 (42.1) 35 (62.5) 
No  99 (57.9) 21 (37.5) 
    
Cough more than two weeks 
 
  
Yes 
 
59 (34.5) 16 (28.6) 
No 
 
112 (65.5) 40 (71.4) 
   
Cough with sputum 
 
  
Yes 
 
86 (50.3) 31 (55.4) 
No 
 
85 (49.7) 25 (44.6) 
   
Haemoptysis 
 
  
Yes 
 
24 (14.0) 7 (12.5) 
No 
 
147 (86.0) 49 (87.5) 
   
Loss of weight 
 
  
Yes 
 
120 (70.2) 37 (66.1) 
No 
 
51 (29.8) 19 (33.9) 
   
Fever 
 
  
Yes 
 
126 (73.7) 44 (78.6) 
No 
 
45 (26.3) 12 (21.4) 
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Table 4.10, continued. 
Characteristics  Non-defaulters Defaulters 
  n (%) n (%) 
Night sweats 
 
  
Yes 
 
73 (42.7) 25 (44.6) 
No 
 
98 (57.3) 31 (55.4) 
   
Loss of appetite 
 
  
Yes 
 
109 (63.7) 41 (73.2) 
No 
 
62 (36.3) 15 (26.8) 
   
BCG scar    
Scar present  149 (87.1) 48 (85.7) 
No scar/ NR  22 (12.9) 8 (14.3) 
    
Diabetes Mellitus    
Yes  4 (2.3) 2 (3.4) 
No  167 (97.7) 54 (96.6) 
    
cCo-morbidities    
Yes  32 (18.7) 9 (16.1) 
No  139 (81.3) 47 (83.9) 
    
Chest x-ray changes    
No lesion  39 (22.8) 13 (23.2) 
Minimal lesion  81 (47.4) 28 (50.0) 
Advanced lesion  51 (29.8) 15 (26.8) 
    
Note:-aHRZ: Isoniazid, Ryfampycin & Pyrazinamide; HZ: Isoniazid & Pyrazinamide only; HR: Isoniazid &Ryfampycin 
bChange in diagnosis: change from the initial TB regime (HRZ) to another due to side effects of treatment or adverse reaction. 
cCo-morbidities: Include diabetes mellitus, congenital heart disease, malabsorption syndrome, malignancies, chronic liver disease 
and history of gastrectomy 
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Table 4.11: HIV-related characteristics of TB/HIV co-infected patients in 
Klang Valley stratified by non-defaulters and defaulters. 
Variables 
 
Non-defaulters 
n (%) 
Defaulters 
n (%) 
Timing of HIV diagnosis   
in relation to TB diagnosis   
Same year (2010) 60 (35.1) 14 (25.0) 
Before 2010 111 (64.9) 42 (75.0) 
   
Opportunistic infection   
Yes 89 (52.0) 19 (33.9) 
No 82 (48.0) 37 (66.1) 
   
Anti-retroviral therapy   
Yes 55 (32.2) 32 (57.1) 
No 116 (67.8) 24 (42.9) 
   
Anti-retroviral regime    
No ART 55 (32.2) 32 (57.1) 
2NRTI + NNRTI 105 (61.4) 22 (39.3) 
Others 11 (6.4) 2 (3.6) 
   
Timing of antiretroviral 
therapy 
  
No ART 55 (32.2) 32 (57.1) 
Before TB diagnosis 29 (17.0) 10 (17.9) 
During TB treatment 87 (50.8) 14 (25.0) 
   
NRTI = Nucleoside Reverse Transcriptase Inhibitor, NNRTI = Non- Nucleoside Reverse Transcriptase Inhibitor 
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Table 4.12:Laboratory profiles (categorical variables) of TB/HIV co-infected 
patients (N=227) in the Klang Valley stratified by non-defaulters and defaulters. 
Variables 
 
Non-defaulters 
n (%) 
Defaulters 
n (%) 
Hemoglobin level   
< 12 g/dL 131 (76.6) 47 (83.9) 
≥ 12 g/dL 40 (23.4) 9 (16.1) 
   
Serum albumin   
< 35 g/L 137 (80.1) 50 (89.3) 
≥ 35 g/L 34 (19.9) 6 (10.7) 
   
HbsAg   
Reactive 12 (7.0) 3 (5.4) 
Non-reactive 159 (93.0) 53 (94.6) 
   
CD4 count   
< 200cells/µl 128 (74.9) 40 (71.4) 
≥ 200cells/µl 29 (17.0) 10 (17.9) 
Not available 14 (8.2) 6 (10.7) 
   
Anti-HCV   
Reactive 91 (53.2) 36 (64.3) 
Non-reactive/NA 80 (46.8) 20 (35.7) 
   
Toxoplasma IgG   
Reactive 38 (22.2) 13 (23.2) 
Non-reactive/NA 133 (77.8) 43 (76.8) 
   
Rapid Plasma Reagen (RPR)  
Reactive 10 (5.8) 1 (1.8) 
Non-reactive/NA 161 (94.2) 55 (98.2) 
   
NA: Not available 
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Table 4.13:Laboratory profiles (continuous variables) of TB/HIV co-infected 
patients (N=227) in the Klang Valley stratified by non-defaulters and defaulters. 
Variables Non-defaulters 
(n=171)   
  Mean (SD) 
    
Defaulters 
(n=56) 
             Mean (SD) 
 
   
Hemoglobin, g/dL 10.63 (1.84) 10.11 (1.84) 
   
Total White Blood Cell, 103/µl 6.44 (3.30) 5.96 (3.12) 
   
Platelet, 103/µl 275.70 (114.74) 248.02 ( 103.07) 
   
Urea, mmol/L 3.74 (1.56) 4.03 (1.60) 
   
Natrium, mmol/L 133.68 (3.73) 131.34 (5.22) 
   
Potassium, mmol/L 6.13 (24.61) 3.81 (0.45) 
   
Creatinine,mmol/L 68.82 (40.91) 69.72 (19.51) 
   
Total Protein, g/L 76.26 (11.25) 77.10 (8.78) 
   
Serum albumin, g/L 26.80 (7.55) 25.72 (7.20) 
   
Total bilirubin, µmol/L 14.00 (19.20) 12.75 (9.15) 
   
Alkaline Phosphatase, U/L 156.95 (123.28) 177.16 (115.28) 
  
Alanine Transaminase, U/L 48.83 (99.01) 33.36 (24.27) 
  
 
4.2.3 Time to tuberculosis treatment default. 
Time analysis of default from treatment was performed using the Kaplan-Meier survival 
method. Survival time was measured from the date of starting TB treatment until the 
date of defaulting TB treatment. Among the 227 TB/HIV co-infected patients on TB 
treatment, 56 (24. 7%)  defaulted. The mean survival time was 390.8 (95% CI: 363.1, 
418.6) days or 13.0 (95%CI: 12.1, 14.0) months. The median survival time was not 
calculated because the cumulative proportion of survival was still more than 50%. The 
KM survival curve for patients who defaulted from TB treatment is displayed in Figure 
4.3. 
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Figure 4.3: Kaplan-Meier curve for TB/HIV co-infected patients who defaulted TB 
treatment (n=227). 
 
4.2.4 Univariate analysis 
Univariate Cox proportional hazards analysis was performed on each independent 
variable to determine the crude estimate of the predictor of tuberculosis treatment 
outcome. It was  also to determine which of the characteristics were significantly 
associated with TB treatment default and which should be selected for the multivariate 
analyses if the p-value was less than 0.25. 
4.2.5 Socio-demographic and lifestyle characteristics of defaulters of  TB 
treatment. 
The association between the socio-demographic characteristics and lifestyle 
characteristics with TB treatment default in TB-HIV co-infected patients are displayed 
in Table 4.14. There was a significant association between TB treatment defaulters and 
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alcohol intake. Patients who had history of alcohol intake had a higher risk of defaulting 
from TB treatment than patients who gave no history of alcohol intake (HR: 1.79; 
95%CI: 1.03-3.11). The other socio-demographic and lifestyle characteristics variables 
were not statistically significant. 
 Table 4.14: Univariate analysis of sociodemographic and lifestyle predictors for 
defaulting tuberculosis treatment in 227 TB/HIV co-infected patients. 
Characteristics 
  
 
N  
Crude 
HR 
  95% CI 
         
  
 
   Age group < 34 73  1.00 
 
- 
 
35-54 141  1.15 
 
0.65-2.05 
 
≥55 13  1.19 
 
0.35-4.06 
  
 
   Gender Male 200 3.97 
 
0.97-16.27 
 
Female 27 1.00 
 
- 
  
 
   Nationality Malaysian 185 0.96 
 
0.50-1.86 
 
Non-Malaysian 42 1.00 
 
- 
  
 
   
  
 
   Ethnicity Malay 110  0.89 
 
0.43-1.81 
 
Chinese  37  0.62 
 
0.23-1.67 
 
Indian 37  1.81 
 
0.83-3.94 
 
Others 43 1.00 
 
- 
  
 
   Employment status Employed 97 0.74 
 
0.43-1.27 
 
Unemployed 130 1.00 
 
- 
  
 
   Incarceration Yes 21 0.87 
 
0.31-2.39 
 
No 206 1.00 
 
- 
  
 
   Marital status Single/Divorced 152 1.22 
 
0.69-2.15 
 
Married 75 1.00 
 
- 
  
 
   Smoking Yes 168 1.44 
 
0.76-2.72 
 
No 59 1.00 
 
- 
  
 
   Alcohol Yes 173 1.79 
 
1.03-3.11* 
 
No 54 1.00 
 
- 
  
 
   Mode of HIV Sexual 89 1.00 - 
Transmission IDU 127 1.73  0.42-7.19 
 Others 11 0.96  0.22-4.13 
      
 Body weight < 50kg 133 0.86  0.51-1.44 
 ≥ 51kg 94 1.00  - 
      
 *p<0.05; HR: hazards ratio; CI: Confidence Interval, IDU: Intravenous drug user 
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4.2.6 Clinical characteristics and laboratory profile; and default from TB 
treatment. 
Table 4.15 to Table 4.18 displays the association of patient’s clinical characteristics and 
laboratory profiles with TB treatment default. In univariate analysis, only lymph node 
enlargement and ART were significantly associated with default from TB treatment 
(p<0.05). TB/HIV co-infected patients who had lymphadenopathy  had two times risk of 
default from TB treatment than patients who do not have lymphadenopathy (HR:2.01; 
95%CI:1.17-3.46). Patients who were not on ART had more than three times risk of 
default from TB treatment than those who were on ART (OR: 3.47; 95%CI: 2.04- 5.90). 
The other clinical characteristics and laboratory variables were not found to be 
statistically significant.   
Results 
 
 150 
 
Table 4.15: Univariate analysis of TB-related characteristics as predictors for 
defaulting tuberculosis treatment in 227 TB/HIV co-infected patients 
Characteristics N Crude HR 95% CI 
    
Types of TB    
Pulmonary TB  111 1.21 0.61-2.39 
Extra-pulmonary TB 64 1.26 0.60-2.65 
Both 52 1.00 - 
    
Status of TB diagnosis    
Newly diagnosed TB 161 0.69 0.40-1.18 
Ever had TB before 66 1.00 - 
    
CXR Changes    
No lesion 52 1.00 - 
Minimal lesion 109 1.01 0.52-1.94 
Advanced lesion 56 0.99 0.47-2.08 
    
Intensive Phase Regime    
HRZ 195 1.86 0.67-5.15 
HZ 8 1.58 0.29-8.62 
Others 24 1.00 - 
    
Changed Treatment    
Yes 37 1.69 0.76-3.73 
No 190 1.00 - 
    
BCG Scar    
Yes 197 1.00 - 
No 30 1.18 0.56-2.47 
    
Co-morbidities    
Yes 41 0.92 0.45-1.87 
No 186 1.00 - 
    
Diabetes mellitus    
Yes 6 1.30 0.32-5.32 
No 221 1.00 - 
    
*p<0.05; HR: Hazards ratio; CI: Confidence Interval; CXR: Chest x-ray 
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Table 4.16: Univariate analysis of initial clinical presentations as predictors 
for defaulting tuberculosis treatment in 227 TB/HIV co-infected patients. 
Characteristics N Crude HR 95% CI 
    
Cough more than two 
weeks 
   
Yes 152 1.20 0.67-2.14 
No 75 1.00 - 
    
Cough with sputum    
Yes 110 0.94 0.56-1.60 
No 117 1.00 - 
    
Hemoptysis    
Yes 31 1.01 0.60-1.72 
No 196 1.00 - 
    
Loss of weight    
Yes 157 1.25 0.72-2.17 
No 70 1.00 - 
    
Fever    
Yes 170 1.27 0.67-2.41 
No 57 1.00 - 
    
Night sweats    
Yes 98 1.01 0.60-1.72 
No 129 1.00 - 
    
Loss of appetite    
Yes 150 1.46 0.81-2.64 
No 77 1.00 - 
    
Lymphadenopathy    
Yes 107 2.01 1.17-3.46* 
No 120 1.00  
    
*p<0.05; HR: Hazards ratio; CI: Confidence Interval ;NA: Not available; RPR: Rapid Plasma Reagin 
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Table 4.17: Univariate analysis of HIV-related characteristics as predictors 
for defaulting tuberculosis treatment in 227 TB/HIV co-infected patients. 
Characteristics N Crude HR 95% CI 
    
Timing of HIV 
diagnosis in relation to 
TB diagnosis 
   
Same year (2010) 74 0.70 0.38-1.28 
Before 2010 153 1.00 - 
    
Anti-retroviral 
therapy 
   
Yes 140 1.00 - 
No 87 3.47 2.04-5.90* 
    
Opportunistic 
Infection 
   
Yes 108 0.56 0.32-0.97 
No 119 1.00 - 
    
Number of OI    
No OI 119 1.00 - 
One OI 79 0.56 0.30-1.03 
Two OIs 23 0.54 0.19-1.52 
Three or more OIs 6 0.60 0.08-4.40 
    
*p<0.05; HR: Hazards ratio; CI: Confidence Interval 
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Table 4.18: Univariate analysis of baseline laboratory profile as predictors for 
defaulting tuberculosis treatment in 227 TB/HIV co-infected patients. 
Characteristics N Crude HR 95% CI 
    
Hemoglobin level    
< 12 g/dL 178 1.71 0.84-3.49 
≥ 12 g/dL 49 1.00 - 
    
Serum albumin    
< 35 g/L 187 2.07 0.89-4.82 
≥ 35 g/L 40 1.00 - 
    
CD4 count    
Not available 168 1.13 0.56-2.26 
< 200 cells/µl 39 1.76 0.64-4.86 
≥ 200 cells/µl 20 1.00 - 
    
HbsAg    
Positive 15 0.90 0.28-2.88 
Negative 212 1.00 - 
    
Anti-HCV    
Reactive 127 1.60 0.92-2.76 
Non-reactive/NA 89 1.00 - 
    
Toxoplasma IgG    
Reactive 51 1.11 0.60-2.06 
Non-reactive/NA 176 1.00 - 
    
Rapid Plasma Reagen     
Reactive 11 0.26 0.04-2.08 
Non-reactive/NA 216 1.00 - 
    
*p<0.05; HR: Hazards ratio; CI: Confidence Interval; NA: Not available. 
 
4.2.7 Multivariate analysis 
In the multivariate analysis, all covariates with cut-off p-value of less than 0.25 in the 
univariate analysis and any others that were thought to be of clinical importance, were 
included. The final model was selected based on the principle of parsimony and best fit 
using the Hosmer-Lemeshow approach of using -2 log likelihood ratios. The variable 
with the largest p-value was deleted from the model. This step was continued  until no 
covariates could be deleted from the model. At this point, each of the deleted covariates 
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were added back into the model one at a time to ensure that none of them were 
significant or showed evidence of being a confounder. 
The significant independent factors associated with TB treatment default after 
multivariate analysis are presented in Table 4.20.  The outcome variable is classified 
into ‘defaulter’ and ‘non-defaulter’. In the unadjusted (univariate analysis), we 
identified nineteen possible predictive factors for default from TB treatment (univariate 
p<0.25 to avoid missing out possible predictors) including employment status, alcohol 
intake, body weight, mode of HIV transmission, status of TB diagnosis, intensive phase 
regime, changed in TB treatment regime, loss of appetite, lympadenopathy, presence of 
opportunistic infection, number of opportunistic infection, status of antiretroviral 
therapy, haemoglobin level, platelet count, serum albumin, alkaline phosphatase (ALP), 
urea, Rapid Plasma Reagin and anti-HCV serology. 
After adjusting for other predictors in multiple Cox regression analysis, the significant 
predictors of default from TB treatment in HIV-infected patients were alcohol intake, 
presence of  lymphadenopathy, status of antiretroviral therapy and serum albumin level. 
All possible two way interactions between the variables in the main effect model were 
checked and no significant interaction term was identified. The proportional hazard 
assumption was checked by two methods. First, the proportional hazards assumption 
was tested univariately using log minus log plot (LML) and hazard plot for all 
significant variables. All variables showed parallel lines which indicated the 
proportional hazard assumption were fulfilled. Second, the proportional hazard 
assumption was checked by the correlation test between partial residuals and survival 
time rank. The correlation test showed correlation was very small (less than 0.3) and p-
value more than 0.05 which indicated that the proportional hazard assumption was met. 
All these are summarized in Table 4.19. 
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Table 4.19: Pearson’s correlation between variables and survival time rank of 
TB/HIV patients defaulting TB treatment. 
Variables Pearson’s r-value P-value 
Alcohol intake   
Ever drink 0.076 0.579 
   
Lymphadenopathy   
Yes 0.045 0.690 
   
Antiretroviral therapy   
No ART -0.018 0.315 
   
Serum albumin   
< 35 g/L -0.032 0.815 
   
    Note: n=56 
 
The strongest predictor of default from TB treatment was not being put on anti-
retroviral therapy, with a hazard ratio of 3.75 (95%CI:2.19-6.42). This indicated that 
patients who were not on antiretroviral therapy were almost four times more likely to 
default from TB treatment than those who were on anti-retroviral therapy. A TB/HIV 
co-infected patient who had an albumin level less than 35 g/L were about three times 
more likely to default from TB treatment (HR: 2.89; 95%CI: 1.22-6.84).   
Patients with lymphadenopathy were twice more likely to default TB treatment (HR: 
2.03; 95%CI: 1.18-3.49). Alcohol intake was also an independent predictor of default 
from TB treatment in TB/HIV co-infected patients (HR: 1.93, 95%CI:1.10-3.38). The 
employment status,  body weight, mode of HIV transmission, status of TB diagnosis, 
intensive phase regime, change in TB treatment regime, loss of appetite,  presence of 
opportunistic infections, number of opportunistic infections, haemoglobin level, platelet 
count, alkaline phosphatase (ALP), urea, Rapid Plasma Reagin and anti-HCV serology 
showed no significant association with default from TB treatment in the multivariate 
analysis. 
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Table 4.20: Significant independent predictors of default from TB treatment in 227 
TB/HIV co-infected patients in the Klang Valley. 
Characteristics  
Crude  
HR 95% CI   
aAdjusted 
HR 95% CI 
 
          
Alcohol intake 
      Ever drink 
 
1.79 1.03-3.11 
 
1.93 1.10-3.38* 
Never drink 
 
1.00 - 
 
1.00  - 
       Lymphadenopathy 
      Yes 
 
2.01 1.17-3.46 
 
2.03 1.18-3.49* 
No 
 
1.00 - 
 
1.00 - 
       Antiretroviral 
therapy 
      Yes 
 
1.00 - 
 
1.00 - 
No 
 
3.47 2.04-5.90 
 
3.75 2.19-6.42* 
       Serum albumin 
      < 35 g/L 
 
2.07 0.89-4.82 
 
2.89 1.22-6.84* 
≥35 g/L 
 
1.00 - 
 
1.00 - 
       HR: Hazards Ratio, CI: Confidence Interval, * p < 0.05 
aAdjusted for employment status,  body weight, mode of HIV transmission, status of TB diagnosis, intensive phase regime, 
changed in TB treatment regime, loss of appetite,  presence of opportunistic infections, number of opportunistic infections, 
hemoglobin, platelet, alkaline phosphatase (ALP), urea, Rapid Plasma Reagin and anti-HCV serology 
 
4.3   Survival of TB/HIV co-infected patients during TB treatment 
4.3.1 Mortality rate 
To determine the survival of TB/HIV co-infected patients during TB treatment, the 
survival status of all patients (n = 227), including those who were still on TB treatment 
were assessed at the end of the study period.  To verify the patient's status, patient data 
was linked to the National Registration Department database. Patients who died during 
treatment default were reclassified as having died instead of having defaulted treatment. 
In total, seven (7) patients who were originally classified as defaulters were later 
reclassified as having died, meaning the total number of deaths during TB treatment was 
53 (23.3%). 
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4.3.2 Cause of death 
Information on the cause of death was available for 45 patients (84.9% of all deceased). 
The cause of death is summarized in the Table 4.21 below. 
 
Table 4.21:  Cause of death in 53 TB/HIV co-infected patients 
Causes of death   n % 
Opportunistic infections associated with HIV 8 15.1 
Pneumonia 8 15.1 
Hospital acquired pneumonia 6 11.3 
Acute coronary syndrome 1 1.9 
Fungal septicaemia 
 
2 3.8 
Septicaemia 7 13.2 
Hospital acquired pneumonia 6 11.3 
TB meningitis 5 9.4 
Nosocomial infection 2 3.8 
Hepatic encephalopathy 2 3.8 
Hypoglycaemia 1 1.9 
Neuroglycopaenic shock 1 1.9 
Neuroleptic malignant syndrome 1 1.9 
Opium overdose 1 1.9 
Not available   8 15.1 
TOTAL  53 100.0 
 
4.4 Predictors of Mortality in TB/HIV co-infected patients 
4.4.1 Mean survival time of TB/HIV co-infected patients. 
Survival time was measured from the date of starting TB treatment until the date of the 
patient’s death or the end of the study. There were 53  (23.3%) deaths  among the 227 
TB/HIV co-infected patients. The overall mean survival time from TB diagnosis to 
death was 11.07 months (95% CI: 10.35, 11.78) as shown in Figure 4.4 below. Median 
survival time was not calculated because the cumulative proportion of survival was still 
more than 50%.  
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Figure 4.4: Kaplan-Meier curve for overall survival estimate among TB/HIV co-
infected patients (n=227) 
 
4.4.2 Survival Time 
Survival at 2, 6 and 12 months after initiating TB treatment were 90.7% (95%CI: 90.3-
91.1), 82.8% (95%CI: 82.6-83.1) and 78.8% (95%CI: 78.3-79.3) respectively (Table 
4.22). The range of survival time was 1.3 months to 21.6 months. 
Table 4.22: Summary of KM estimates for 227 TB/HIV co-infected patients 
Time Number of deaths % Survival 
95% 
Confidence 
Interval 
2 months 21 90.7 90.3-91.1 
6 months 40 82.8 82.6-83.1 
12 months 48 78.8 78.3-79.3 
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4.4.3 Kaplan Meier Estimates 
The Kaplan Meier (KM) estimates and log rank for the estimation of the univariate 
association between socio-demographic and lifestyle characteristics with survival time 
is shown in Table 4.23. As shown in Table 4.23, there were statistically significant 
differences in the mean survival time for  ethnicity (p=0.036),  employment status 
(p=0.002), imprisonment (p=0.006) and mode of HIV transmission (p=0.031). Other 
variables were not statistically significant. The mean survival time for Malay patients 
was 16.30 months (95%CI 14.79,17.81) which was the shortest duration compared to 
other ethnic groups. Those who were employed had significantly longer mean survival 
time (19.12 months, 95%CI: 17.96,20.29) compared to those who were unemployed 
(19.12 months; 95%CI: 17.96,20.29). Those infected via the homosexual route had 
significantly longer mean survival time (15.06 months; 95%CI: 9.53, 20.60) compared 
to infections via injecting drugs,  heterosexual and other routes.  
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Table 4.23: K-M estimate and log rank test between socio-demographic and lifestyle 
characteristics. 
Variables N 
N of 
event 
Censored, 
n 
Mean survival time, 
months (95% CI) 
Log-
rank p 
value 
Age group 
(years) 
     
< 34 73 12 61 18.13 (16.64,19.61) 0.267 
35-54 141 38 103 17.02 (15.73,18.30)  
≥ 55 13 3 10 15.54 (12.17,20.91 )  
      
Gender      
Male 200 47 153 17.53 (16.48,18.57) 0.992 
Female 27 6 21 17.13 (14.40,19.86)  
      
Nationality     
Malaysian 185 48 137 17.14 (16.03, 18.26) 0.074 
Non-Malaysian 42 5 37 19.30 (17.43,21.16)  
      
Ethnicity      
Malay 110 35 75 16.30 (14.79,17.81) 0.036* 
Chinese  37 5 32 18.28 (16.12,20.45)  
Indian 37 8 29 17.37 (15.14, 19.60)  
Others 43 5 38 19.35 (17.52, 21.17)  
      
Employment      
Employed 97 13 84 19.12 (17.96,20.29) 0.002* 
Unemployed 130 40 90 16.19 (14.77, 17.62)  
      
Imprisonment     
Yes 21 10 11 13.40 (10.01, 16.80) 0.006* 
No 206 43 163 17.90 (16.90, 18.90)  
      
Marital status     
Single/divorced 152 41 111 16.97 (15.73, 18.21) 0.075 
Married 75 12 63 18.64 (17.09, 20.19)  
      
Smoking      
Yes 168 42 126 17.23 (16.06,18.40) 0.323 
No 59 11 48 18.38 (16.64,20.12)  
      
Alcohol intake     
Yes 54 12 42 17.67 (15.78, 19.56) 0.777 
No 173 41 132 17.44 (16.30, 18.58)  
      
Mode of HIV transmission    
IDU 127 40 87 16.24 (14.83, 17.66) 0.012* 
Heterosexual 81 9 72 19.39 (18.04, 20.73  
Homosexual 8 1 7 19.18 (17.06, 21.30)  
Others 11 3 8 16.43 (11.94,20.92)  
      
Body weight     
< 50kg 133 36 97 16.71 (15.32, 18.11) 0.08 
≥50kg 94 17 77 18.66 (17.38, 19.94)  
            
* The median survival was not calculated because the cumulative proportion surviving was still high (> 50%) 
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Table 4.24 displays the univariate association between TB-related and HIV-related 
characteristics with survival time. There were statistically significant differences in the 
survival time of patients who had maintenance therapy, opportunistic infection and 
antiretroviral therapy. 
The mean survival time for patients who received maintenance regime for TB treatment 
was much longer than those who were not on any maintenance therapy. The mean 
survival time for patients who received isoniazid and rifampicin was 19.77 months 
(95%CI: 19.00,20.54).  Patients who were on maintenance therapy had improved the 
mean survival time by almost 43%.  
The mean survival time among patients who did not have opportunistic infection was 
longer (18.72 months, 95%CI: 17.54, 19.89) compared to  patients with opportunistic 
infection (16.23months; 95%CI: 14.67,17.79). TB/HIV co-infected patients  who 
received concurrent antiretroviral therapy were also having longer mean survival time 
(19.03 months; 95%CI: 18.05, 20.02) compared to those who were not receiving ART 
(15.12 months; 95%CI: 13.22, 17.02). 
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Table 4.24: K-M estimate and log rank test to determine the univariate 
association between clinical characteristics and survival time. 
Variables N 
N of 
event 
Censored, 
n 
Mean survival 
time, months  
(95% CI) 
Log-
rank p 
value 
Types of  TB      
Pulmonary 110 24 86 17.55 (16.18, 18.93) 0.851 
Extrapulmonary 65 15 50 17.37 (15.47, 19.26)  
Both 52 14 38 17.32 (15.32,19.31)  
      
Status of TB diagnosis     
Newly 
diagnosed TB 
161 36 125 17.68 (16.54, 18.83) 0.574 
Ever had TB 
before 
66 17 49 17.13 (15.25, 19.01) 
 
      
Intensive phase regime     
HRZ 195 44 151 17.54 (16.48,18.62) 0.863 
HZ 8 2 6 16.08 (10.69,21.47)  
Others 24 7 17 17.11 (14.61,19.62)  
      
Maintenance phase regime    
No 
maintenance 
64 
35 29 11.32 (8.97, 13.68) 
< 0.001* 
HR 137 15 122 19.77 (19.00,20.54)  
Others 26 2 24 19.37 (17.61,21.12)  
      
Changed in TB 
treatment 
   
 
Yes 37 9 28 17.58 (15.54, 19.61) 0.982 
No 189 44 145 17.42 (16.32, 18.52)  
      
Case detection      
Passive 216 48 168 17.70 (16.70, 18.69) 0.008 
Active 11 5 6 13.95 (9.26, 18.65)  
      
Cough more than two weeks    
Yes 152 33 119 17.65 (16.50,18.80) 0.41 
No 75 20 55 16.95 (15.16, 18.74)  
      
Cough with sputum     
Yes 110 31 79 16.53 (16.56,18.52) 0.889 
No 117 22 95 18.46 (17.24, 19.67)  
      
Haemoptysis      
Yes 31 7 24 17.05 (14.48, 19.63) 0.078 
No 196 46 150 17.53 (16.48, 18.59)  
      
Loss of weight      
Yes 157 37 120 17.56 (16.40, 18.72) 0.96 
No 70 16 54 17.45 (15.63, 19.27)  
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Table 4.24,  continued. 
Variables N 
N of 
event 
Censored, 
n 
Mean survival 
time, months  
(95% CI) 
Log-
rank p 
value 
Fever      
Yes 170 40 130 17.53 (16.40,18.66) 0.904 
No 57 13 44 17.09 (15.21,18.97)  
      
Night sweats      
Yes 98 18 80 18.53 (17.21, 19.84) 0.122 
No 129 35 94 16.76 (15.37, 18.15)  
      
Loss of 
appetite 
     
Yes 150 36 114 17.52 (16.32,18.72) 0.75 
No 77 17 60 17.08 (15.44,18.71)  
      
Co-morbidities      
Yes 41 13 28 16.07 (13.54, 18.61) 0.158 
No 186 40 146 17.69 (16.65, 18.72)  
      
Diabetes mellitus     
Yes 6 3 3 13.29 (7.94, 18.64) 0.152 
No 221 50 171 17.63 (16.64, 18.61)  
      
Presence of BCG scar    
Yes 197 48 149 17.44 (16.39, 18.49) 0.436 
No 30 5 25 17.66 (15.04, 20.28)  
      
Opportunistic infections     
Yes 108 33 75 16.23 (14.67,17.79) 0.014* 
No 119 20 99 18.72 (17.54, 19.89)  
      
Timing of HIV diagnosis     
Same year  74 16 58 16.60 (14.88,18.32) 0.857 
Before 2010 
153 
37 116 
 17.60 (16.45, 
18.76) 
 
      
Antiretroviral 
therapy 
 
    
Yes 140 23 117 19.03 (18.05, 20.02) < 0.001* 
No 87 30 57 15.12 (13.22, 17.02)  
* The median survival was not calculated because the cumulative proportion surviving was still high (> 
50%) 
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Table 4.25 displays the univariate association between laboratory profiles with survival 
time. Only CD4 count (p=0.047) and Toxoplasma serology (p=0.049) showed 
statistically significant difference in the survival time.  
Patients who had CD4 count  more than 200 cells/µl had better mean survival time 
(19.90 months; 95%CI: 18.69, 21.14) compared to those with CD4 count less than 200 
cells/µl (16.97 months; 95%CI: 15.78, 18.16) and  those whose CD4 count were not 
available (16.13 months; 95%CI: 12.46, 19.79). Patients with non-reactive Toxoplasma 
test or whose Toxoplasma test was not available had better survival than patients who 
had reactive (positive) Toxoplasma serology test (18.07 vs. 15.69 months). 
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* The median survival was not calculated because the cumulative proportion surviving was still high (> 50%) 
 
4.4.4 Kaplan Meier Survival Curve 
In general, there were significant differences in survival rates in terms of ethnicity, 
employment status, imprisonment, mode of HIV transmission, the maintenance phase of 
tuberculosis treatment, concurrent opportunistic infection, anti-retroviral therapy, CD4 
T-lymphocytes and Toxoplasma serology. Survival curves for these significant variables 
are shown in Figure 4.5. 
Table 4.25: K-M estimate and log rank test to determine the univariate association 
between laboratory independent variables and survival time 
Variables N N of 
event 
Censored
, n  
Mean survival time 
(months)              
(95% CI) 
Log 
rank p-
value 
 Hemoglobin level 
     < 12 g/dL 178 45 133 17.26 (16.13,18.39) 0.216
≥ 12 g/dL 49 8 41 18.04 (16.18,19.91) 
 
      Serum albumin 
level 
     < 35g/dL 187 46 141 17.37 (16.29, 18.46) 0.369
≥ 35g/dL 40 7 33 17.79 (15.60, 19.98) 
 
      CD4 T-lymphocytes count 
    < 200 cells/µl 168 45 123 16.97 (15.78, 18.16) 0.047*
≥ 200 cells/µl 39 3 36 19.90 (18.69, 21.14) 
 Not available 20 5 15 16.13 (12.46, 19.79) 
      HbsAg 
     Reactive 15 3 12 17.39 (14.19, 20.59) 0.736
Non-reactive 212 50 162 17.48 (16.46, 18.50) 
 
      Hepatitis C serology 
     Reactive 127 36 91 16.75 (15.37, 18.13) 0.059
Non-reactive/NA 100 17 83 18.53 (17.19, 19.87) 
 
      Toxoplasma IgG 
     Reactive 51 17 34 15.69 (13.35, 18.04) 0.049*
Non-reactive/NA 176 36 140 18.07 (17.02, 19.12) 
 
      RPR 
     Reactive 11 1 10 19.69 (17.80, 21.58) 0.240
Non-reactive/NA 216 52 164 17.39 (16.36,18.41) 
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a) Ethnicity (p=0.036) 
 
   
 
b) Employment (p=0.002) 
 
 
(c) Imprisonment (p=0.006) 
 
   
 
(d) Mode of HIV transmission 
(p=0.012) 
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(e) Maintenance phase (p< 0.001) 
   
 
(f) Opportunistic infection (p=0.014) 
 
(g) Anti-retroviral therapy (p< 0.001) 
   
 
(h) CD4 counts (p=0.047) 
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(i) Toxoplasma serology (p=0.049) 
 
    
Figure 4.5: The survival plot of significant variables using Kaplan Meier Survival 
Curves 
 
There were no significant difference  in the survival distributions according to age 
group, gender, nationality,  marital status, smoking status, alcohol intake, types of TB, 
status of TB diagnosis, case detection, TB symptoms at diagnosis (cough more than two 
weeks, cough with sputum, hemoptysis, night sweats, loss of weight,loss of appetite), 
co-morbidities, lymphadenopathy, chest x-ray changes, haemoglobin level, serum 
albumin level, HbsAg, anti-HCV serology or Rapid Plasma Reagin (RPR) serology test 
(Figure 4.6). 
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(a) Age group (p=0.267) 
 
b) Gender (p=0.992) 
 
 
c) Nationality (p=0.074) 
 
 
d) Marital status (p=0.075) 
 
(e) Smoking status (p=0.323) 
 
(f) Alcohol intake (p=0.777) 
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(g) Types of TB (p=0.851) 
 
(h) Status of TB diagnosis (p=0.574) 
(i) Change in TB treatment (p=0.982) (j) Intensive phase regime (p=0.863) 
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(k) Case detection (p=0.088) (l) Cough more than two weeks 
(p=0.410) 
 
(m) Cough with sputum (p=0.078) (n) Hemoptysis (p=0.889) 
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(o) Loss of weight (p=0.889) 
 
(p) Loss of appetite (p=0.750) 
 
q) Fever 
 
 
r) Night sweats (p=0.122) 
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s) Co-morbidities (p=0.158) 
 
 
t) Lymphadenopathy (p=0.728) 
 
 
u) Chest x-ray changes (p=0. 285) 
 
v) Hemoglobin level (p=0.216) 
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w) Serum albumin (p=0.369) 
 
x) HbsAg (p=0.736) 
 
y) Anti-HCV serology (p=0.059) 
 
z) Rapid Plasma Reagin (p=0.240) 
 
Figure 4.6: The survival plot of non-significant variables using Kaplan Meier 
Survival Curves 
 
4.4.5 Univariate analysis  
The univariate Cox Proportional Hazard (CPH) Regression analysis was performed to 
assess the effect of multiple co-variates on survival. The association between the socio-
demographic and lifestyle characteristics with the survival status of TB-HIV co-infected 
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patients are displayed in Table 4.26. Only ethnicity shows a significant association with 
survival status.  The Malays had a higher risk of dying (HR: 2.90; 95%CI: 1.14,7.41) 
compared to other ethnic  groups. The other background characteristics were not 
statistically significant. 
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Table 4.26: Univariate socio-demographics and lifestyle predictors of death in 
TB/HIV co-infected patients.  
Variables   Crude HR (95% CI) 
Age group < 34 1 
 
35-54 1.70 (0.89, 3.26) 
 
≥55 1.48 (0.42, 5.24) 
   Gender Male 1.01 (0.43, 2.35) 
 
Female 1 
   Nationality Malaysian 1.75 (0.40, 7.76) 
 
Non-Malaysian 1 
   Ethnicity Malay 2.90 (1.14,7.41)* 
 
Chinese  1.17 (0.34,4.03) 
 
Indian 1.89 (0.62,5.77) 
 
Others 1 
   Employment  Employed 1 
 
Unemployed 0.39 (0.21, 0.73) 
   Incarceration Yes 0.39 (0.20, 0.78) 
 
No 1 
   Marital status Single/divorced 1.78 (0.94, 3.39) 
 
Married 1 
   Smoking Ever smoking 0.72 (0.37,1.39) 
 
Never smoking 1 
   Alcohol intake Ever take alcohol 0.91 (0.46,1.86) 
 
Never take 
alcohol 1 
   
Mode of HIV transmission 
Intravenous drug 
users 1.08 (0.33, 3.48) 
 
Sexual 0.35 (0.10,1.27) 
 
Others 1 
   Body weight < 50 kg 1.67 (0.94,2.97) 
 
≥ 51 kg 1 
  
*Incarceration: Prisoners/Drug Rehabilitation Centre  inmates at the time of TB diagnosis. 
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Table 4.27 displays the association of patient’s clinical characteristics and laboratory 
profiles with their survival status. Maintenance therapy regime, opportunistic infection, 
number of opportunistic infections and antiretroviral therapy were significantly 
associated with survival status. 
 
Table 4.27: Univariate clinical predictors of death in TB/HIV co-infected patients. 
Variables   
Crude HR 
(95% CI) 
   Types of  TB Pulmonary 1.06 (0.56, 2.02) 
 
Extrapulmonary 1.21 (0.63, 2.34) 
 
Both 1 
   Status of TB diagnosis Newly diagnosed TB 0.85 (0.48,1.51) 
 
Ever had TB before 1 
   Intensive Phase Regime HRZa 0.80 (0.36, 1.79) 
 
HZ 0.88 (0.18, 4.25) 
 
Others 1 
   Maintenance Phase Regime No maintenance 7.11(2.18, 23.15)* 
 
HR 0.95 ( 0.27, 3.27) 
 
Others 1 
   Changed in treatmentb Yes 0.99 (0.48, 2.03) 
 No  
   
Case detection Passive 0.97 (0.29, 3.28) 
 
Active 1 
   Cough more than two weeks Yes 0.79 (0.46, 1.38) 
 
No 1 
   Cough with sputum Yes 1.63 (0.94, 2.81) 
 
No 1 
   Hemoptysis Yes 0.94 (0.43, 2.09) 
 
No 1 
   Loss of weight Yes 1.02 (0.57, 1.83) 
 
No 1 
   Fever Yes 1.04 (0.56, 1.94) 
 
No 1 
   Night sweats Yes 0.64 (0.36, 1.13) 
 
No 1 
   Loss of appetite Yes 1.10 (0.62, 1.96) 
 
No 1 
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Table 4.27, continued. 
Variables   
Crude HR 
(95% CI) 
Co-morbiditiesc Yes 1.13 (0.15, 8.77) 
 
No 
 
   Diabetes mellitus Yes 0.44 (0.14, 1.40) 
 
No 1 
   Presence of BCG scar Yes 0.70 (0.28,1.75) 
 
No scar/ NR 1 
   Lymphadenopathy Yes 0.91 (0.53,1.56) 
 
No 1 
   Opportunistic infection Yes 1.98 (1.14,3.46) 
 
No 1 
   Chest x-ray changes No lesion 1 
 
Minimal lesion 0.96 (0.47, 1.98) 
 
Advanced lesion 1.52 (0.73, 3.17) 
   Number of Opportunistic 
Infection (OI) No OI 1 
 One OI 1.86 (1.02, 3.39) 
 Two OIs 2.02 (0.85, 4.78) 
 More than two OI 3.72 (1.10,, 12.52) 
   
Antiretroviral Therapy Yes 1 
 
No 2.50 (1.45, 4.31) 
  
aHRZ: Isoniazid, Ryfampycin & Pyrazinamide; HZ: Isoniazid & Pyrazinamide only; HR: Isoniazid &Ryfampycin 
bChange in diagnosis: Change from the initial TB regime (HRZ) to another due to side effects of treatment or adverse reaction. 
cCo-morbidities: Include diabetes mellitus, congenital heart disease, malabsorption syndrome, malignancies, chronic liver disease 
and history of gastrectomy 
 
 
There were statistically significant associations between serum albumin level and CD4 
T-lymphocytes count with survival status of TB/HIV co-infected patients. 
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Table 4.28: Univariate laboratory predictors of death in TB/HIV co-infected patients. 
Variables 
Crude HR 
(95% CI) 
 Haemoglobin level 
 < 12 g/dL 1.60 (0.75,3.40) 
≥ 12 g/dL 1 
  Total White Blood Cell, 103 /µl 1.12 (1.05, 1.18) 
  Platelet, 103 /µl 0.10 (0.99,1.00) 
  Urea, mmol/L 1.05 (0.89, 1.25) 
  Natrium, mmol/L 1.06 (0.99, 1.15) 
  Potassium, mmol/L 1.00 (0.99, 1.02) 
  Creatinine, mmol/L 1.00 (0.99, 1.01) 
  Total Protein, g/L 0.99 (0.96, 1.02) 
  Serum albumin level 
 < 35 g/L 1.44 (0.65, 3.18) 
≥ 35 g/L 1 
  Total bilirubin, µmol/L 0.98 (0.98, 1.02) 
  Alkaline Phosphatase (ALP), U/L 1.00 (0.995, 1.001) 
  Alanine Transaminase (ALT), U/L 1.00 (0.998, 1.004) 
  CD4 T-lymphocytes count 
 Not available 3.95 (0.94, 16.53) 
< 200 cells/µl 3.90 (1.21,12.54) 
≥ 200cells/µl 1 
  HbsAg 
 Reactive 1.22 (0.38, 3.92) 
Non-reactive 1 
  Hepatitis C serology 
 Reactive 1.73 (0.97, 3.08) 
Non-reactive/unknown 1 
  Toxoplasma IgG 
 Reactive 1.77 (0.99, 3.15) 
Non-reactive/unknown 1 
  Rapid Plasma Reagin (RPR) 
 Reactive 0.33 (0.05, 2.35) 
Non-reactive/unknown 1 
  
*Ref: Reference value 
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4.4.6 Multivariate analysis 
The log rank p-value less than 0.25 was set as cut off value to choose variables for 
multiple Cox proportional hazards regression analysis.The outcome is a single outcome 
variable with two categories (alive or dead). Eighteen variables that had a log rank p-
value of less than 0.25 including age group, marital status, ethnicity, employment status, 
incarceration,body weight, cough with sputum at diagnosis, night sweats, co-morbidity 
with diabetes mellitus, presence of opportunistic infections, number of opportunistic 
infections, ART, haemoglobin level, serum albumin level, total white blood cell count, 
Toxoplasma serology test, anti-HCV serology and CD4 T-lymphocytes counts were all 
associated with survival in the univariate analyses. 
During the multivariate analysis using Cox proportional hazards regression model; 
ethnicity, number of opportunistic infections, anti-retroviral therapy, total white blood 
cell count (WBC) and CD4 T-lymphocytes were found to be associated with death in 
TB/HIV co-infected patients. Ethnicity is the strongest risk factor for death in this study. 
The risk of dying among Malay patients was almost five times higher than ethnic group 
classified as ‘Others’ (HR: 4.48; 95%CI: 1.73-11.64). 
Low CD4 T-lymphocytes count is the strongest clinical predictors of death in TB/HIV 
co-infected patients. Patients with CD4 T-lymphocytes count less than 200 cells/µl had 
almost four times higher risk of death compared to CD4 T-lymphocytes count more 
than 200 cells/µl (HR 3.89; 95% CI:1.20-12.63). Patients with three or more 
opportunistic infections had 3.61 times higher risk of death than patients who did not 
have any opportunistic infection (HR: 3.61; 95%CI:1.04-12.55). However, this group 
has a wide confidence interval because of  the small number (n=6). The risk of death in 
patients who were not on antiretroviral therapy was 3.21 times compared to patients on 
antiretroviral therapy (HR: 3.21; 95%CI: 1.76-5.85). For every 1000 cells per microliter 
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unit increase in total white blood cell (WBC), the risk of death increased by 12% (HR: 
1.12; 95%CI: 1.05-1.20). Based on the Pearson's correlation, WBC has an inverse 
relationship with number of opportunistic infections, but it was not significant and the r-
value was low (r-value = 0.06; p-value=0.366). The crude and adjusted hazard ratios are 
displayed in Table 4.29. 
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Table 4.29: Significant predictors of death in TB/HIV co-infected in the Klang 
Valley. 
Characteristics  
Crude  
HR 95% CI   
aAdjusted 
HR 95% CI 
 
          
Race 
      Malay 
 
2.90 1.14-7.41 
 
4.48 1.73-11.64* 
Chinese 
 
1.17 0.34-4.03 
 
1.78 0.51-6.25 
Indian 
 
1.89 0.62-5.77 
 
2.40 0.76-7.56 
Others 1.00 - 1.00 - 
       Number of 
Opportunistic 
infections (OI) 
      No OI 
 
1.00 - 
 
1.00 - 
One OI 
 
1.86 1.02-3.39 
 
2.68 1.40-5.13 
Two OIs 2.02 0.85-4.78 3.32 1.33-8.29 
More than two OIs  3.72 1.10-12.52  3.61 1.04-12.55* 
       Anti-retroviral 
therapy 
      Yes 
 
1.00 - 
 
1.00 - 
No 
 
2.50 1.45- 4.31 
 
3.21 1.76-5.85* 
       Total White Blood 
Cells (TWBC) 
 
1.12 1.05-1.18 
 
1.12 1.05-1.20* 
     
CD4 T-
lymphocytes count 
      Not available 3.95 0.94-16.53 2.21 0.50-9.81 
< 200 cells/µl  3.90 1.21-12.54  3.89 1.20-12.63* 
≥ 200cells/µl  1.00 -  1.00 - 
       
HR: Hazards Ratio, CI: Confidence Interval, * p < 0.05 
aAdjusted for age group, marital status, employment status, incarceration, body weight, cough with sputum at diagnosis, night 
sweats, co-morbidity with diabetes mellitus,  haemoglobin level, serum albumin level,  toxoplasma serology test and anti-
HCV serology.  
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The final model was checked for model assumptions to ensure that it is fit enough to 
predict death. 
Proportional hazards assumption 
The assumption of the proportional hazards was checked by examining the hazard 
function and the Log-Minus-Log (LML) plots for all the statistically significant 
predictors of death in TB/HIV co-infected patients. The log minus log hazard curves 
plotted against survival time in all categorical variables that were included in the final 
model were parallel (Figure 4.7). For these four categorical predictors, all the plots 
showed  parallel lines and were not crossing with each other. Hence it can be concluded 
that the proportional hazards assumption is met. Hazard plot against survival time also 
showed the parallel pattern, which indicated the proportional hazard assumption was 
fulfilled (Figure 4.8).  
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a) Ethnicity 
 
 
 
 
 
 
b) Opportunistic Infection 
 
 
 
  
c) Antiretroviral therapy     d) CD4 count 
Figure 4.7:  The Log-minus-log cumulative hazard curve plotted against survival 
time in all categorical variables in the final model 
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a) Ethnicity 
 
 
         (b) Opportunistic Infection 
 
 
 
 
b) Antiretroviral therapy 
 
 
 
        d) CD4 counts 
 
 
Figure 4.8: The hazard function curve plotted against survival time in all 
         categorical variables in the final model 
 
The second way was by correlation of the partial residuals for all the statistically 
significant predictors with the survival time rank of TB/HIV co-infected patients to 
death. If the p-values were more than 0.05, it indicated that proportional hazards 
assumption was met. The correlation is summarized in Table 4.30. 
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Table 4.30: Pearson’s correlation between variables and survival time of TB/HIV 
co-infected patients to death 
Variables  Pearson’s r-value  P-value 
     
Race 
    Malay 
 
0.087
 
0.237
Chinese 
 
0.034 
 
0.292 
Indian 
 
0.094 
 
0.501 
     Number of Opportunistic 
infections (OIs) 
    One OI 
 
0.097
 
0.489
Two OIs -0.051 0.717 
More than two OIs  -0.013  0.927 
     Anti-retroviral therapy 
    No ART 
 
-0.012
 
0.341
     Total White Blood Cells 
(TWBC) 
 
-0.070 
 
0.617 
   
CD4 T-lymphocytes count 
    Not available -0.028 0.301
< 200 cells/µl  0.116  0.219 
     
Note: N=53     
 
4.5 Summary 
This chapter presents the results from the study of TB/HIV co-infected patients in Klang 
Valley. The socio-demographic, lifestyle, clinical characteristics and laboratory profiles 
of TB/HIV co-infected patients were presented in detail. Among the 227 patients 
eligible for analysis, 51.6% (117) achieved successful outcomes (cure, completed 
treatment), while 24.7% (56) of patients defaulted treatment and 20.3% (46) died. 
Another 3.4% (8) were still on treatment. After adjusting for other factors, default TB 
treatment in TB/HIV co-infected patients was associated with ever take alcohol (AHR 
1.93; 95% CI 1.10-3.38), not receiving antiretroviral therapy (AHR 3.75; 95% CI 2.19-
6.42), lymphadenopathy (AHR 2.03; 95% CI 1.18-3.49) and low serum albumin (AHR 
2.89; 95% CI 1.22-6.84).  
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At the end of the study period, the total number of deaths  was 53 (23.3%) out of 227 
patients with 40% of deaths occurring within two months of TB diagnosis. Survival at 2, 
6 and 12 months after initiating TB treatment were 90.7%, 82.8% and 78.8% 
respectively. After adjusting for other factors, poor  survival was associated with being 
Malay (AHR: 4.48; 95%CI: 1.73-11.64), number of opportunistic infections more than 
two (AHR: 3.61; 95%CI:1.04-12.55), not receiving antiretroviral therapy (AHR: 3.21; 
95%CI: 1.76-5.85), increase per 1000 total white blood cell count per microliter (AHR: 
1.12; 95%CI: 1.05-1.20) and CD4 T-lymphocytes count < 200 cells/µl (AHR 3.89; 95% 
CI:1.20-12.63). 
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CHAPTER 5: DISCUSSION 
About this chapter 
This chapter synthesises the results of the research in comparison with other studies and 
finally discusses the strengths and limitations of the research. The aim of this study was 
to describe and determine HIV infection among active TB cases, TB treatment 
outcomes, survival probabilities and prognostic factors affecting survival among a 
cohort of HIV-infected TB patients in Malaysia which is  an intermediate TB burden 
country with a TB incidence of 65 per 100, 000 populations per year during the study 
period (WHO, 2012). Identifying the prognostic factors will help us in the management 
of patients and provide vital information for clinical and public health  intervention 
programs. 
5.1 Characteristics of TB/HIV co-infected patients 
5.1.1 Socio-demographic 
TB is a common opportunistic infection and cause of death in HIV-infected patients in 
many parts of the world, particularly in developing countries. The results of  our study 
estimated that the proportion of TB-HIV in the Klang Valley to be 11.0%, which was 
slightly higher than the national prevalence of HIV-infected patients among tested TB 
patients in Malaysia (7.2%) in 2010 (WHO, 2012). HIV prevalence in TB patients in 
Asia ranged from 0.9% to 38% in 2010 (WHO, 2012). TB-HIV co-infection is still 
relatively low in Malaysia compared to other countries in Asia. 
The majority of the patients were males. The male to female ratio was 7:1. The finding 
that males were at risk for TB/HIV co-infection is in agreement with other studies. In 
Malaysia, the proportion of TB among males was higher compared to females. In a 
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recent report, the proportion of TB among males in Malaysia was 67.7% compared to 
females, which was 32.3% (WHO, 2012). 
In this study, the age groups with most frequent HIV infection were 35-54 years with 
the mean age of 39.1 (SD 8.6) years; which is the age range in which most cases of  
intravenous drug users were reported and sexually active age group. This is consistent 
with the report from the Malaysian Ministry of Health that documented an increasing 
trend of HIV cases among older adult in this country. In year 2011, about 60% of new 
HIV infection were reported among people aged 30-49 years (MOH, 2012b).  The age 
distributions among the TB/HIV co-infected cases were consistent with findings in 
other studies. Most of the studies found that TB/HIV co-infection was significantly 
more common among young and middle aged adults (Korzeniewska-Kosela et al., 1992; 
Van Der Werf, Sebhatu, Weldegergis, Tesfazion, & Borgdorff, 2007; Weis, Foresman, 
Cook, & Matty, 1999). A study in An Giang province, Vietnam reported that the 
TB/HIV co-infected TB patients in this study were among younger age groups, in which 
74% of cases were between 25 to 44 years of age (Thuy et al., 2007). 
The race distribution was Malays (48.5%), Chinese (16.3%) and Indians (16.3%).  The 
rest (18.9%) consisted of  indigenous ethnic groups born in Sabah and Sarawak; those 
who were born from interracial marriages and non-citizens. Surprisingly, the proportion 
of TB/HIV patients among Indians was higher than expected as Indians form only 7-8% 
of the population. However the reason for this was unclear. A previous study conducted 
in Kota Bharu, Kelantan, Malaysia had shown a higher proportion of Malays (94%)  
with  TB/HIV co-infection (Mohammad & Naing, 2004). This is to be expected because 
Kelantan has the highest percentage of Malays (93%) with the Chinese making up only 
5% and Indians only 1% of its total population. Therefore, it would not be a good 
representation of Malaysia. 
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The most common mode of HIV infection was through IDU (55.9%), followed by 
sexual transmission: 35.7% heterosexual and 3.5% homosexual. In the earlier phase of 
HIV pandemic in Malaysia until the year 2010, IDU was the main mode of HIV 
transmission. However, with intensive implementation of harm reduction programmes 
including Methadone Maintenance Therapy (MMT) and Needle Syringe Exchanged 
Programme (NSEP) since 2005, the number of HIV infections transmitted through 
sharing needles was successfully reduced. In 2011, the percentages of sexual 
transmission had superseded IDU as the main driving factor of  the HIV epidemic in 
Malaysia. Overall, the number of new HIV infections reported to the Ministry of Health 
in 2011 had decreased to 3,479 cases; which is approximately half of what was reported 
in 2002 (MOH, 2012b).  
Previous studies demonstrated that IDUs were associated with both risks of 
unsuccessful TB treatment outcomes and mortality in HIV-infected TB patients. Girardi 
et al. found that IDUs was associated with four times higher risk of unsuccessful 
outcomes (AOR:4, 95%CI: 1.35-12.5) compared to other modes of HIV infection 
(Enrico Girardi et al., 2012). In this study, IDUs remain an independent factor for 
unsatisfactory outcome of TB treatment despite adjustment for other socio-economic 
factors including years of education, place of origin (born in Italy or foreign born), age 
at TB diagnosis, history of imprisonment and type of housing. The researchers related 
this to the high proportion of intravenous drug users (48%) in their study population. 
Another study that was conducted in Spain (Ruiz-Navarro et al., 2005) found that the 
odds of potentially unsatisfactory outcomes (treatment failure and transferred out) were 
increased in intravenous drug users (AOR: 1.71, 95%CI: 1.06-2.75) after adjusting for 
age, gender and alcohol abuse. However the researchers did not provide possible 
explanations for this result. Two other studies (Alpert et al., 1997; Catala et al., 2011) 
have revealed that a history of intravenous drug use resulted in poor survival in HIV-
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infected TB patients. Drug users are exposed to the risk of contracting TB because this 
group is usually associated with poor nutrition, sanitation and hygiene; social 
displacement and high risk sexual behaviour. They also live in seclusion to avoid being 
caught by the police or anti-drugs authority. Therefore, they do not seek treatment 
unless they are seriously ill or institutionalized. Furthermore, TB treatment involves a 
number of medications which require a longer duration to complete the treatment. Their 
homeless condition and nomadic lifestyle make it difficult for health authorities to 
conduct contact tracing, to monitor their treatment and to track them if they do not come 
for further follow-up. 
A study in New York that assessed the socio-demographic characteristics and TB 
treatment outcomes of HIV-infected TB patients found that previous incarceration was 
more common among HIV- infected patients compared to HIV-negative individuals in 
this study with 41.6% of 92 HIV-infected TB patients having a history of incarceration 
(Alpert et al., 1997). Another study by Kittikraisak et al. (2009) also found that 
incarceration history was an independent factor for TB treatment default among HIV-
infected patients in Thailand (AOR: 2.0; 95% CI: 1.1-3.7). The researchers were unsure 
of the reasons for default but expected that some patients may have been re-incarcerated 
without informing  the TB clinic in which they were treated (Kittikraisak et al., 2009).  
In our study, only 21 (18.5%) patients were living in prisons or drug rehabilitation 
centres at the time of their TB diagnosis. A systematic review and meta-analysis that 
assessed population at highest risk for recent TB transmission (Nava-Aguilera et al., 
2009) found that a history of incarceration was an independent predictor of recent TB 
transmission with a combined estimated risk of 2.21 (95% CI 1.71–2.86) perhaps due to 
overcrowding and poor hygiene conditions in most detention centres. 
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Existing guidelines of the Ministry of Health Malaysia require that all persons with 
active TB should be screened for HIV infection and vice versa. This policy had 
benefited at least 10 patients (4.4%) in this study in which they were diagnosed via TB 
screening in prisons or drug rehabilitation centres where they were detained. TB 
screening not only give them an opportunity for earlier access to TB treatment but also 
hinder the TB transmission to other inmates in such closed settings.  
5.1.2 TB-related characteristics 
This study included all types of TB including smear positive PTB; smear negative PTB 
and extra-pulmonary TB.  The majority of TB in HIV-infected patients is still 
pulmonary TB but extra-pulmonary TB is now becoming more common particularly in 
those with advanced immune suppression. Patients with HIV infection were more likely 
to have smear positive PTB, alone or in combination with extrapulmonary TB. The total 
number of smear positive pulmonary TB was 40.5%. Smear negative pulmonary TB 
was diagnosed in 31.3% and extrapulmonary TB in 28.2% of patients.  This finding in 
this study was different from other studies that reported extra-pulmonary TB as the most 
common type of TB among the TB/HIV co-infected patients (Alpert et al., 1997; K P 
Cain et al., 2007; Kung et al., 2009). Extrapulmonary TB becomes more common in 
HIV-infected patients because as the immunity declines, the body is unable to prevent 
the growth and spread of  Mycobacterium tuberculosis, thus changing the clinical 
presentation of TB. However, a study in Vietnam reported a higher proportion of smear-
positive TB in HIV-infected TB patients with 83% from a total of 637 patients being 
diagnosed with smear-positive pulmonary TB (Thuy et al., 2007). This is an important 
finding as smear positive TB is the most infective type and people with smear positive 
TB can trigger a chain of transmission within the community. If smear positive TB 
patients are correctly diagnosed and successfully treated, in the long term it will help to 
reduce the burden of TB in the country. 
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The most common TB symptoms presented by the patients at diagnosis were cough of 
more than two weeks duration (67.0%), fever (74.9%), loss of appetite (66.1%) and loss 
of weight (69.2%). This is consistent with the finding that most of the patients in this 
study had pulmonary TB. Therefore, physicians should pay more attention and have a 
high index of suspicion with HIV-infected patients who present with symptoms of fever 
and cough by carrying out the appropriate tests to diagnose TB. Early diagnosis and 
immediate initiation of treatment are essential for an effective TB control program. 
Delay in diagnosis will significantly affect  both disease prognoses at the individual 
level and transmission within the community because most transmissions occur between 
the onset of cough and initiation of treatment. 
Abnormal chest x-ray was reported in 77.1% of patients, with 48.0% having minimal 
lesion and another 29.1% already having an advanced lesion. In this study, minimal 
lesion is defined as slight lesions without demonstrable cavitation in both lungs. In HIV-
infected patients, the common finding of cavitation at the apex of the lung as seen in 
immunologically normal persons is less common. Although radiographic findings in 
HIV-infected patients may reflect the degree of immune suppression, but they may also 
have a normal chest radiograph. The finding in this study is consistent with a report that 
chest x-rays in TB/HIV co-infected patients may show little change or there may be 
diffuse pulmonary infiltrates without cavitation (Shafer & Edlin., 1996). Very 
frequently, presentation of atypical chest X-ray appearance makes it difficult to 
diagnose TB in this group of patients. 
The majority of TB/HIV patients in this study had no co-morbidity (81.9%). This was 
probably due to a higher proportion of patients in this study being in the young to 
middle age group. Therefore, they were less likely to have other co-morbidities seen in 
older patients. Although diabetes mellitus is also a known risk factor for TB, only 2.6% 
of the patients in this study were reported to have diabetes mellitus and their age ranged 
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between 39 to 57 years old.. This finding concurs with the prevalence of diabetes in 
Malaysia as documented in the National Health Morbidity Survey III (NHMS III) that 
was conducted in 2006.  Data from NHMS III reported that there was a sharp increase 
of diabetes for  those aged 40 years and above with the highest prevalence in the 60 to 
64 age group (25.2%) (Letchuman GR et al., 2010). 
The patients received standard therapy in accordance with the Clinical Practice 
Guidelines on the Control and Management of TB in Malaysia that recommended that 
patients with a first episode of tuberculosis be treated with a 2-month intensive 
combination-drug regimen of rifampicin (a rifamycin derivative), isoniazid, ethambutol, 
and pyrazinamide, followed by a maintenance phase for an additional four to seven 
months (based on WHO guidelines). The drug doses in every patient were determined 
according to pre-treatment weight. The mean duration of TB treatment in this study was 
6.2 (SD 3.8) months and the median was 6.6 (IQR 6.8) months. A change in therapy 
mainly due to adverse reactions to anti-TB drugs occurred in 26% of patients. The data 
from a systematic review suggested that TB patients that were co-infected with HIV 
required at least eight months duration of rifamycin therapy with an initial daily dosing 
to ensure a better outcome (Khan et al., 2010). If this report is referred to, the duration 
of TB treatment of TB/HIV co-infected patients in Malaysia is not optimal. 
Furthermore, they reported that there were trends toward higher relapse rates if 
rifamycins were used for only six months, compared with eight months. 
From a total of 227 patients, 167 isolates (73.6%) were tested for anti-TB drug 
sensitivity and only three mono-resistant cases were identified. One isolate was resistant 
to pyrazinamide, one resistant to streptomycin and another one resistant to rifampicin. 
No MDRTB case was reported in this study. National data recently reported by WHO 
documented that MDRTB in Malaysia still at a low level of 1.3% in 2011 (WHO, 
2012).  
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5.1.3 HIV-related Characteristics 
Most TB/HIV co-infected patients had concurrent opportunistic infection at the time of 
TB diagnoses. This is consistent with other findings that have been described in other 
studies (Thuy et al., 2007; Wobeser et al., 1999). The presence of opportunistic 
infection other than TB at the time of TB diagnosis in most HIV-infected TB patients 
suggests that patients in this study already had advanced HIV at the time of diagnosis. 
This condition will increase their risk of dying from either TB or HIV. Thus, we 
strongly support the administration of isoniazid prophylaxis to prevent TB in HIV-
infected patients; which has been recommended by previous studies (Moreno et al., 
1997, Akolo & Adetifa, 2010). In Malaysia, Isoniazid Preventive Therapy (IPT) started 
in September 2011. Further research should be carried out to evaluate the effect of IPT 
in HIV-infected patients in this country. 
The median CD4 count at diagnosis for TB/HIV co-infected patients in this study were 
59 cells/µl (IQR 133.5). One study of HIV-infected TB patients in Malaysia in 2005 
found similar low CD4 counts with a median of 57 cells/µl (Nissapatorn et al., 2005). 
The median CD4 counts are similar to other studies in Thailand, which was reported to 
range between 54 cells/µl to 63 cells/µl (Cain et al., 2009; Mankatittham et al., 2009; 
Manosuthi et al., 2006; Sanguanwongse et al., 2008). However, published studies in 
sub-Saharan Africa reported a higher median CD4 count. The median CD4 count in 
sub-Saharan Africa ranged between 106 cells/µl to 317 cells/µl (Komati et al., 2010; 
Lawn, Badri, & Wood, 2005; Perriëns et al., 1995). This result supported the findings 
that TB/HIV co-infected patients in Asia were more immuno-suppressed than those in 
sub-Saharan Africa. A possible explanation for this is that patients presented late to the 
health centre to seek treatment because of perceived stigma and discrimination. Stigma 
prevents them from seeking medical treatment and utilise HIV-related services 
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(Mahajan et al, 2008). Generally, people in Malaysia are still not open to accept PLWH 
and AIDS because the feeling of suspicion and prejudice is still strong in them.  
Among the 95 patients with an available HIV RNA viral load result, the median HIV 
RNA viral load was 204,638.0 copies/ml (IQR: 828,620.0). A study in Thailand 
reported a higher median HIV RNA viral load which is 308,000 copies/ml (IQR: 
707,000). Higher HIV viral loads increase the rate of disease progression and also 
increase HIV infectiousness. The predominance of low CD4 counts and a high HIV 
RNA viral load suggests that TB is a late presentation of HIV disease in Malaysia. This 
finding is also related to delay in diagnosis due to their self-stigma and health seeking 
behaviour. 
In Malaysia, ART was introduced through the national health system in 1996. The first 
line ART is given at no cost for those who need it and the second line regimen is also 
heavily subsidised by the government. This study reflected the implication of free ART 
policy by the Malaysian government. The policy for starting ART follows international 
recommendations. Despite the well documented benefit of ART in TB/HIV co-infected 
patients and the widely available ART in this country, 38.3% of cases in this study were 
not on ART. Although there are guidelines by WHO, but the decision to start  ART 
invariably depends on the attending physician. The timing of initiating the ART after 
starting anti-TB therapy has been controversial. The initiation of ART may be deferred 
until completion of tuberculosis therapy because of concerns about potential drug 
interactions between rifampicin and some classes of antiretroviral drugs, the immune 
reconstitution inflammatory syndrome (Schiffer & Sterling, 2007), overlapping side 
effects and high pill burden. However, recent observational studies (Velasco et al., 
2009) and randomised control trial (Abdool Karim et al., 2010) provided evidence that 
the initiation of antiretroviral therapy during TB therapy significantly improved survival 
in TB/HIV co-infected patients. 
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Recent international guidelines recommend that HIV-infected persons initiate treatment 
with nevirapine (NVP), zidovudine (AZT), and lamivudine (3TC) (WHO, 2011c). 
Rifampicin can alter drug levels of nevirapine, thus the guidelines recommend that in 
patients receiving rifampicin, nevirapine should be replaced with efavirenz (EFV). In 
this study, most of the patients (56.2%) received the combination of stavudine (d4T), 
lamivudine (3TC) and efavirenz (EFV). However, in this guidelines WHO had advised 
all countries to progressively reduce the use of d4T in first line regiments because of its 
well-recognised toxicities.  
Early diagnosis of both TB and HIV, will not only promise an earlier access to 
appropriate treatment, but also provide more opportunities for deciding the proper 
timing of ART initiation and then better prognosis by saving lives (WHO, 2008).   
5.2 Poor treatment outcome 
Monitoring the outcome of TB treatment is an essential part of TB disease surveillance. 
This is to ensure that the disease is successfully eliminated. The treatment success has 
been reported to differ between the HIV-positive and HIV-negative TB patients. 
Previous studies that evaluated TB treatment outcomes found that HIV co-infections 
were associated with poorer outcomes compared to HIV-negative patients (Anunnatsiri, 
Chetchotisakd, & Wanke, 2005; Ruiz-Navarro et al., 2005). The researchers in Spain 
related the high number of HIV-positive TB patients in their study being intravenous 
drug users (58.6%) with high co-morbidity as the most likely explanation for treatment 
interruption (Ruiz-Navarro et al., 2005). In Thailand,  the majority of  HIV-infected TB 
patients had advanced HIV disease and were not treated effectively for their HIV 
infection, therefore, they were also at risk of contracting other opportunistic infections 
related to death as an outcome (Anunnatsiri et al., 2005). 
 
Discussion 
 198 
 
Consistent with other findings, the results of this study indicated that HIV-infected TB 
patients in the Klang Valley have poor treatment outcomes with a treatment success rate 
only 53.4% compared to the 85% treatment success rate targeted by the WHO. The 
treatment success rate in the present study was similar to that found in other studies 
conducted in the city of Recife, Brazil (58.8%) (Magda Maruza, Arraes, & Ximenes, 
2008), in Vietnam (56.5%) (Quy et al., 2006), in Tanzania (59.0%) (Van den Broek et 
al., 1998) and in Malawi (50.9%) (Harries et al., 1998). A higher percentage was found 
in another study involving TB/HIV co-infected patients in India (Vijay et al., 2011) with 
the treatment success rate of 75.0% and in Sau Paulo, Brazil (78.0%) (Klautau & 
Kuschnaroff, 2005). 
This study reported a high default rate or non-adherence to TB treatment (25.6%) 
among the TB/HIV co-infected patients. However, this finding shows a substantial 
improvement as compared to a single centre study done in Kuala Lumpur which 
reported 40.5 % of non-adherence (defaulted and absconded) among 252 TB/HIV cases 
between January 2001 and December 2002 (Nissapatorn et al., 2005). The high default 
rate observed in our study could perhaps be due to patients stopping medication once 
they felt better; or other reasons which require further studies. A systematic review of 
qualitative studies that assessed patient adherence to TB treatment had identified 
patients' adherence to their treatment regimens as being influenced by the interaction of 
a number of factors. These included health service factors such as the organization of 
treatment and care; social context (family, community and household influences); 
personal factors (including attitudes towards treatment and illness) and the financial 
burden of treatment (SA Munro et al., 2007). 
There are variations in the rates of non-adherence to TB treatment among TB/HIV co-
infected patients as reported by previous studies. The percentage of noncompliance 
ranged from 1.0% in Vietnam (Thuy et al., 2007) to 21.7% as observed in a study in in 
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Pernambuco, Brazil (M Maruza et al., 2011). Male gender, smoking and CD4 T-cell 
count less than 200 cells/mm3 were found to be associated with treatment default in the 
study among Brazilians (M Maruza et al., 2011) whereas age older than 29  years, 
having complete or incomplete secondary or university education, and using  ART were 
identified as protective factors against TB treatment default. The association between 
DOTS and improved survival as reported by Alpert et al. proved that compliance with 
TB treatment was important an important factor (Alpert et al., 1997). 
Non-adherence not only contributed to the spread of TB, but also the emergence of drug 
resistant TB. Although the drug resistant cases in Malaysia are still considered low, the 
numbers are actually increasing each year. Based on the results of the sensitivity test for 
Mycobacterium TB isolates reported by the National Public Health Laboratory, Sungai 
Buloh; there was an average of 500 mono-resistant cases seen every year from 2004 to 
2008. The number of multidrug resistant cases was reported to be around 40 cases 
yearly and this contributes to less than 1% of total TB cases (MOH, 2010). 
5.3 Risk factors for default from TB treatment in HIV-infected 
patients 
TB treatment default is defined as an interruption of treatment for two or more months. 
It is an important public health problem because patients who default treatment may 
continue to transmit infection to others and may acquire drug-resistant TB strains. On 
the other hand, completing TB treatment is not easy for patients because TB treatment 
takes a minimum of six months and thus may require frequent clinic visits for 
medication monitoring and refills. They may also develop unpleasant side effects of the 
anti-TB drugs. 
The identification of risk factors for default from TB treatment is crucial in order to 
improve TB treatment outcomes among HIV-infected patients. In a recent study in 
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Brazil, the default rate was 21.7% among males. Smoking and CD4 T-cell count less 
than 200 cells/mm3 were identified as risk factors for default in HIV-infected 
individuals. Age over 29 years, complete or incomplete secondary or university 
education and the use of highly active antiretroviral therapy (HAART) was identified as 
associated with lower rate of TB treatment default (M Maruza et al., 2011). In an earlier 
study in Thailand, factors associated with TB treatment default among HIV-infected TB 
patients included a history of incarceration, smoking and having a symptom complaint 
(Kittikraisak et al., 2009).  
Apart from individual characteristics, health facility and patient-specific factors are also 
associated with TB treatment default in HIV-infected patients as shown by a study in 
urban Uganda (Elbireer et al., 2011). In this study, they found that the distance from 
home to clinic, long waiting time at the clinic, poor drug availability, conduct of staff, 
lack of opportunity to express feelings were all associated with treatment default. Other 
patient-related factors were lack of health education. Not being aware of the duration of 
treatment or the risk of discontinuing it, not knowing that TB can be cured, length of TB 
treatment and side effects of treatment were also associated with defaulting from TB 
treatment. 
During our study, we found that 56 (25.6%) of TB/HIV co-infected patients had 
defaulted TB treatment. After adjusting for other factors in the multivariate analysis; 
alcohol intake, presence of lymphadenopathy, status of antiretroviral therapy and serum 
albumin level were significantly associated with default from TB treatment in HIV-
infected patients. 
In this study, patients who ever consumed alcohol were two times more likely to default 
from TB treatment than those who did not give a history of alcohol intake (AHR: 1.93, 
95%CI: 1.10-3.38). The finding that alcohol consumption was associated with TB 
treatment default was consistent with other previous studies (Hasker et al., 2008; 
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Jakubowiak et al., 2007; Muture et al., 2011). In  a systematic review, alcohol was 
shown to have a pathogenic impact on the immune system making patients more 
susceptible to active TB infection as well as to the reactivation of latent disease among 
heavy drinkers with a pooled relative risk of 2.94 (95%CI: 1.89-4.59) (Rehm et al., 
2009). Alcohol abuse leads to forgetting the taking of medications and eventual default. 
The association of alcohol intake with default from TB treatment needs to be better 
understood to plan for a more appropriate intervention program to reduce default rate in 
this group of patients. 
An association between lymphadenopathy and default from TB treatment (AOR: 2.03, 
95%CI: 1.18-3.49) was observed in this study. This finding has not been reported 
elsewhere, but TB lymphadenitis is the most common form of extrapulmonary TB in 
both HIV infected and non-HIV patients and is generally associated with a higher 
degree of immune-suppression. Extrapulmonary TB has been found in the past to be 
significantly associated with death in HIV-infected patients compared to patients with 
pulmonary TB only (AHR: 5.1; 95%CI: 1.9-25.9) perhaps due to a higher bacterial load 
of Mycobacterium tuberculosis and have much more severe immunodeficiency status 
(Sungkanuparph et al., 2007). 
This study also found that TB/HIV co-infected patients who were not on antiretroviral 
therapy were 3.75 times more likely to default from TB treatment than those who 
received antiretroviral therapy (AOR: 3.75, 95% CI 2.19-6.42).  This is in line with 
findings by Maruza et al. (M Maruza et al., 2011) in Brazil. A study in India also 
reported that non initiation of ART is significantly associated with unfavourable 
outcome (AOR: 4.90, 95% CI 1.85–12.96) (Vijay et al., 2011). In a study that was 
conducted in twelve HIV centres in Greater London and Southeast England, the 
researchers reported that treatment interruption  is more likely to occur in patients with 
concomitant TB treatment and HAART due to adverse events (Gillian L. Dean et al.,  
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2003). Although patients who received HAART had shown to have significant 
decreased of viral load, AIDS-defining illness and death; but patients with concomitant 
treatment commonly experienced adverse events (gastrointestinal disturbances, seizures, 
memory loss, psychosis, and pancreatitis) which eventually lead to discontinuation or 
interruption of TB therapy. 
This study suggested that lower serum albumin (less than 35 g/L) is a predictor of TB 
treatment default (AOR: 2.89, 95% CI 1.22-6.84). However, there are no previous 
studies that reported similar findings. Poor nutritional status, which is associated with 
both TB disease and HIV can account for low levels of albumin. Their mean body 
weight, 49.7 (SD 9.0)kg is 21% lower than the mean body weight for Malaysian adult 
(Azmi et al., 2009) suggested that they probably have poor general well being and 
nutritional status. The anthropometric assessment of the Malaysian Adults Nutrition 
Survey (MANS) involving 6,775 men and 3,441 women aged 18 to 59 years showed 
that the overall mean body weight and BMI of Malaysian adult were 62.65 kg (95%CI: 
62.20-63.09) and 24.37 kg/m2 (95%CI: 24.21-24.53) respectively. Other studies have 
reported that albumin level is also a strong prognostic marker of HIV disease 
progression (Mehta et al., 2006; Shah et al., 2007) and can be used as an alternative 
marker of disease progression, particularly in resource-limited settings. 
In this study, we found that patients with lymphadenopathy, lower serum albumin level 
and not receiving antiretroviral therapy were all associated with a high rate of default 
from TB treatment in HIV-infected TB patients. These patients were probably severely 
ill due to poor immune status, as supported by low mean haemoglobin level (10.5 (SD 
1.9) g/dL) and were thus unable to tolerate their medications making it difficult for them 
to comply with their follow-up schedules at health centres. Hemoglobin and serum 
albumin levels are conventionally thought to be proxies for general nutritional status 
(Forse & Shizgal, 1980).  
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The finding that receiving antiretroviral therapy was protective against treatment default 
reinforces the need for early initiation of antiretroviral therapy in HIV-infected TB 
patients. The results also indicate that the strategy to reduce rates of TB treatment 
default should be targeted to specific high risk groups and in particular to alcohol 
drinkers. This requires further research since failure to complete TB treatment is a risk 
factor for TB transmission to others, especially those who are smear positive. Poor 
adherence to TB treatment is also associated with higher rates of TB recurrence 
(Korenromp et al., 2003) and the emergence of drug resistance TB.  
5.4 Mortality in TB/HIV co-infected patient 
TB is the leading direct cause of death among people living with HIV (PLWH) in 
Africa and a major cause of death elsewhere. A meta-analysis of fifteen cohort studies 
comparing mortality in PLWH with and without TB revealed that PLWH with TB had 
approximately two times higher risk of death from all causes compared to PLWH 
without TB (HR: 1.8; 95%CI: 1.4-2.3) which indicates that PLWH with TB die earlier 
compared to PLWH without TB (Straetemans et al., 2010). In sub-Saharan Africa, a 
region with a high prevalence of HIV, up to 30% of HIV-positive TB patients (all 
forms) die before the end of treatment. Early deaths are defined as deaths that occur 
within less than 30 days of TB treatment which often are due to TB while later deaths 
are related to complications of HIV. HIV-positive patients who are smear-negative have 
a worse prognosis than smear-positive TB patients because they are likely to get more 
severe forms of TB.  
HIV infection as a predictor of death in TB patients has been established in many 
previous studies (Elliott et al., 1995; Harries et al., 1998; Kawai et al., 2006; Mugusi et 
al., 2009; Quy et al., 2006; Van den Broek et al., 1998). In this study, death during TB 
treatment occurred in 53 (23.3%) of TB/HIV co-infected patients with 40% of deaths 
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occurring within two months of TB diagnosis. This finding is similar to case fatality 
rates during TB treatment that was reported in previous studies in Thailand, which was 
29% (Sanguanwongse et al., 2008) and Vietnam (26%) (Thuy et al., 2007). Data from 
the National TB Control Programme showed that the rate of TB death in Malaysia in 
2011 was 8.0% of the total notified TB cases in that year (MOH, 2012a). Our study 
findings indicate that HIV increases the risk of death in our cohort of patients. 
In a prospective study that was conducted in Africa, 31% from a total of 827 adult TB 
patients were dying at the end of TB treatment. It is surprising to note that almost fifty 
percent of deaths occurred in the first month of treatment. However, there is no 
information about availability of ART in the study which could be the reason for that 
scenario. 
5.5 Survival probabilities of TB/HIV co-infection 
The overall survival at 2, 6 and 12 months after initiating TB treatment in this study was 
90.7%, 82.8% and 78.8% respectively. The survival probabilities are considered good as 
they were higher compared to the overall survival at 2, 6 and 12 months in Zambia 
(Elliott et al., 1995); with their overall survival rates being 89%, 76% and 66% 
respectively. Another study done in Rome, Italy also showed lower survival 
probabilities with their 6-month survival being 78% and 1-year survival rate was 57% 
(Palmieri et al., 1999). However, both studies were done before the HAART were 
widely available and with the old regime of ART. A recent study in Southern Ethiopia 
reported that their HIV positive TB patients (n=370) had almost similar survival 
probabilities to our study; with their  survival rate of 93.7% at 2 months which 
decreased to 85.7% after seven months of treatment. In this study, 33.2% of HIV-
infected TB patients were known to have started CPT and 14.1% were known to have 
started ART (Shaweno & Worku, 2012) . 
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The mean survival time in our study was 11.07 months (95% CI: 10.35, 11.78). The 
median survival time was not calculated in this study because the cumulative proportion 
of survival was still more than 50%. In previous studies, the median survival time in 
HIV-infected TB patients ranged from 7.3 months (Vijay et al., 2011) to 22.0 months 
(Elliott et al., 1995). The median survival time  in our study is quite similar to the 
median survival time reported in Thailand (Chaisangcharoen, 2005) which was 10.9 
months (95% CI: 8.42, 13.45). This may be because conditions in Thailand, which is 
also a developing country, may be similar to that in  Malaysia. Thailand also 
implemented free access to HAART which is similar to Malaysia. In order to reduce the 
cost and to facilitate drug supply management, the Thai Ministry of Public Health used 
ﬁxed-dose combination of generic drugs generic stavudine, lamivudine, and nevirapine; 
known as “GPO-VIR”  (Sungkanuparph, Techasathit, Utaipiboon, & Chasombat, 2010). 
5.6 Prognostic factors for TB/HIV survival 
Among HIV-infected patients, age group, marital status, ethnicity, employment status, 
imprisonment, mode of HIV transmission, cough with sputum at diagnosis, night sweat, 
co-morbidity with diabetes mellitus, opportunistic infection, ART, haemoglobin and 
serum albumin level, total white blood cell count, Toxoplasma serology test and CD4 T-
lymphocytes counts were all associated with survival in univariate analyses. In the 
multivariate analysis the significant independent predictors of survival were ethnicity, 
opportunistic infections, antiretroviral therapy, total white blood cell count and CD4 T-
lymphocytes. 
In this study it was established that the only social risk factor for survival was ethnicity. 
Malays had almost five times higher risk of death than the ethnic group classified as 
‘Others’ (HR: 4.48; 95%CI: 1.73-11.64) even after adjusting for potential confounders 
which included employment status, body weight and serum albumin level in 
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multivariate analysis. Malays patients have the shortest mean survival time compared to 
other ethnic groups which was 16.30 months (95%CI 14.79,17.81). This is the first 
published study on TB/HIV survival in Malaysia; therefore comparison about survival 
status among ethnic groups with other Malaysian studies cannot be made. This warrants 
further research as reasons for this finding are not clear. Thus, future research needs to 
focus on the ethnic differences in relation to treatment adherence and access to care. 
The finding that every 103 increase in total white blood cell per microliter (HR: 1.12; 
95%CI: 1.05-1.20) is associated with higher mortality in HIV-infected TB patients 
finding is novel. We have not found any study in the literature that presents a similar 
association. Most  previous studies have focused on T lymphocyte subsets, particularly 
CD4+, and generally reported depressed CD4+ T cells in peripheral blood of TB patient. 
In this study, the total white blood cell results were that documented at the time of TB 
diagnosis (pre-TB treatment). This finding may reflect that the risk of dying is increased 
with the severity of infection at TB diagnosis.   
The immune responses against HIV-infected TB have not been fully clarified. 
Generally, infection will cause white blood cells to be elevated. The major types of 
white blood cells; neutrophils, lymphocytes, monocytes, eosinophils and basophils play 
a different role in the immune system with a different disease-fighting activity. In active 
TB disease, neutrophils and monocytes are the main components of white blood cell 
that response to mycobacterial infection (Morris, Bird, & Nell, 1989). A recent study by 
Berry et al supported that neutrophils play a role in the pathogenesis of TB which 
resulted from over-activation by IFN-gamma and type I IFNs (Berry et al., 2010). A 
study in South Africa found that patients at the time of TB diagnosis had high absolute 
neutrophil and monocyte counts, which were depleted during treatment, but low 
lymphocyte subset counts which increased with TB treatment (Veenstra et al., 2006). 
However, in TB patients who were co-infected with HIV, HIV viruses will attack 
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lymphocytes and cause further depletion of CD4+ T cells. There is conflicting evidence 
of  the effect of Mycobacterium tuberculosis (MTB) on HIV replication, but several 
studies had shown that MTB infection may increase HIV replication and worsen the 
patient’s immune status (Pawlowski et al., 2012). 
Another factor that was independently associated with decreased survival in this study 
was the number of opportunistic infections. Patients with three or more types of 
opportunistic infections had 3.61 times higher risk of death than patients who did not 
have any opportunistic infection (HR: 3.61; 95% CI:1.04-12.55). The finding that 
opportunistic infection was associated with death were consistent with other studies in 
this area  (Catala et al., 2011; Enrico Girardi et al., 2012; Palmieri et al., 1999; 
Podlekareva et al., 2009; Whalen et al., 1997). Although these studies demonstrated a 
positive association between opportunistic infections and death in TB/HIV co-infected 
patients, the investigators did not examine the relationship between the number of 
opportunistic infections and risk of death. To our knowledge, this is the first study to 
report that the number of opportunistic infections is associated with death in TB/HIV 
co-infection. TB is known to be the most common opportunistic infection in HIV 
patients. A study by Wong et al in South Africa who investigated the cause of death of 
TB/HIV patients on antiretroviral therapy by needle biopsy found that TB was the main 
cause of death regardless of antiretrovirals status (pre-ART, early-ART or late-ART); 
with disseminated TB being responsible for 87% of deaths in the first three months of 
ART (Wong et al., 2012). 
In addition to concurrent opportunistic infections, not receiving antiretrovirals (HR: 
3.21; 95% CI: 1.76-5.85) was also associated with death in TB/HIV co-infected 
patients. This study demonstrated that ART can improve both the TB treatment outcome 
and also survival. The mean survival time of patients on ART was 19.0 months (95% 
CI: 18.1-20.0) and the mean survival time of patients who were not on ART was 15.1 
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months (95% CI: 13.2-17.0). The survival probability at 12 months for patients on ART 
was 86.3% compared to 66.7% in patients who were not on ART. This finding shows 
that HIV-infected TB patients treated with ART had almost 23% better survival 
compared with those who were not treated with ART. The benefit of ART in reducing 
the death rates of TB/HIV co-infected patients have been well documented in other 
studies (Gadkowski et al., 2009; E Girardi et al., 2001; Manosuthi et al., 2006; 
Sanguanwongse et al., 2008; Varma et al., 2009). The widespread use of antiretroviral 
therapy since 1996 has markedly improved the survival of HIV-infected patients in both 
developing and developed countries by reducing the number of deaths due to many 
opportunistic infections. In TB/HIV co-infected patients, the decision to introduce 
antiretroviral therapy is not an easy decision because of concerns about treatment-
related complications. However, Dheda et al. (Dheda, Lampe, Johnson, & Lipman, 
2004) compared outcomes in patients starting TB treatment during the pre-HAART era 
(before 1996) with those in patients starting treatment during the HAART era (during or 
after 1996) and found that the risk of death during the follow-up period was reduced by 
60% for the latter (during HAART era) (HR 0.40, 95%CI: 0.19-0.84). Velasco et al. 
(Velasco et al., 2009) proved that HIV-associated TB patients will have better survival 
if HAART and TB treatment were started concurrently (HR 0.37, 95% CI 0.17 – 0.66).  
Furthermore, there were clinical trials that showed timely initiation of antiretroviral 
therapy in TB/HIV co-infected patients saved lives particularly those with low CD4 
(Abdool Karim et al., 2010; Blanc, Sok, & Laureillard, 2011; Havlir et al., 2011; 
Nanteza et al., 2011). A recent clinical trial by Abdool Karim et al. comparing the 
outcomes in early versus late ART concluded that in severely immune-compromised 
patients with CD4 counts less than 50/mm3, ART should be started as soon as possible 
after the start of TB treatment. Although earlier initiation of ART is associated with a 
higher risk of IRIS, but the finding that it is also associated with two thirds lower risk of  
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death  than later ART is far more important (incidence rate ratio, 4.7). However, for 
those with a higher CD4 count, they recommended that the initiation of ART be 
deferred until the first four weeks of continuation phase of TB treatment in order to 
reduce the risk of IRIS (Abdool Karim et al., 2011).  
This study adds to the literature that low CD4 T-lymphocytes are associated with higher 
risk of death in TB/HIV co-infected patients during TB treatment. In our study, patients 
with CD4 T-lymphocytes count lower than 200 cells/µl had almost four times higher 
risk of death compared to those with CD4 T-lymphocytes count more than 200 cells/µl 
(HR 3.89; 95% CI: 1.20-12.63). This finding has been well established in other previous 
studies (Alpert et al., 1997; Catala et al., 2011; Gadkowski et al., 2009; E Girardi et al., 
2001; Podlekareva et al., 2009; Sanguanwongse et al., 2008; Shafer et al., 1996; 
Velasco et al., 2009). The mean survival time of patients with CD4 < 200 cells/µl is 
17.0 months (95% CI: 15.8-18.2) which is lower than the mean survival time for 
patients with CD4 > 200 cells/µl (20.0 months; 95% CI: 18.7-21.1). The mean survival 
time for patients whose CD4 counts were not available was 16.1 months (95% CI: 12.5-
19.8). This finding is similar to those with CD4 < 200 cells/µl; suggesting that this 
group of patients might have had lower CD4 counts as well. The numbers of CD4 T-
lymphocytes and their activities decrease in HIV infection, but the mechanisms 
underlying this progressive reduction are still not well understood. Even though 
opportunistic infections usually occur at less than 200 CD4+ cells/µl, TB is commonly 
thought to occur at a higher concentration. 
Other variables in the literature review that was found to be predictors of mortality in 
TB/HIV infected patients like increasing age, extra-pulmonary TB and TB drug 
resistant were not reproduced in this study, probably due to the small sample size. For 
example, our sample size was not powerful enough to evaluate the association between 
Discussion 
 210 
 
drug resistant TB and death because only three cases of resistance to anti-TB drug was 
found  in our study.    
The high mortality rate in this study (23.3%) despite the use of rifampicin for two 
months of intensive phase could possibly be contributed by patients with immune-
suppression. These patients had low CD4 counts and opportunistic infection and were 
not treated with anti-retroviral therapy.  
5.7 Strengths of the study 
This study present findings of much needed research in TB/HIV co-infection. To our 
knowledge, this study is the first report in Malaysia to identify the risk factors for 
mortality during TB treatment in and determine the survival time. This study supports 
Malaysia’s target in the Millenium Development Goal, which aims to reduce the burden 
of HIV/AIDS and TB disease as a public health problem by 50% by the year 2015 
compared to the mid 1990 levels. Malaysia is currently on track to achieve this. 
We believe that this study will provide benefits to TB/HIV co-infected patients in 
Malaysia. The results of this study will help policy makers to estimate the burden of 
HIV infection among active TB cases in Malaysia thus enabling them to make informed 
decisions on treatment and program priorities. The results of this study will also help to 
engage policy makers, researchers and communities to collaborate to generate the 
knowledge that is needed for better care for TB/HIV co-infected patients in Malaysia; as 
well as to promote further research in this area. Such interventions and care may include 
access to improved tools for TB screening in people living with HIV, better linkages 
between TB and HIV clinics, careful monitoring for drug-resistant TB and prevention of 
TB occurrence in HIV infected persons. 
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5.8 Limitations of the study 
There are a few limitations to be considered in relation to the findings in our study. The 
study was only carried out in Kuala Lumpur and Selangor; which are the central parts of 
Malaysia and can be considered as the most urbanised area in Malaysia. The results 
from this study may not be generalizable to the whole of Malaysia. 
This study is limited by its observational study design. In this study, some of the 
predictors that had been related to observed survival in other studies of TB/HIV co-
infected patients, such as DOT supervision, Tuberculin skin testing (TST), co-
trimoxazole preventive therapy, and complication regarding treatment were not 
assessed. It would also be interesting to know the differential for the WBC particularly 
the absolute neutrophil count. However, these predictors were excluded from the 
analysis because data related to these predictors were incomplete or unavailable in many 
of the patients’ records. The reason was to avoid too many missing values which might 
have affected the results of the study. These variables might have affected the result of 
our study by making our estimation more complete. 
Another limitation of this study arose from dealing with secondary data. Patient 
information was retrieved from their medical records or folders available in the TB 
clinic and the medical records unit of the respective hospitals. Some reports were not 
clear and confusing since different doctors reported in different ways.  However, the 
problem of missing data was minimized by carrying out the study prospectively 
whereby the participants were ‘active’ patients who were still on follow-up. This study 
design avoided the possibility that patients’ folders were discarded because patients did 
not turn up for follow-up for a long time. Data verification was done by cross-checking 
the data in TB Clinic with patients’ records at HIV Clinic and their medical records 
during admission. 
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The transferred-out patients (n=32, 12%) who were subsequently excluded in our 
analysis may slightly bias our results. However, there was no statistically significant 
difference in the age group, gender and ethnic distribution between  the patients 
included in analyses compared  to transferred out patients.  We were unable to include 
these patients because their records were not available and their treatment outcomes 
were unknown.  
In this study, the mean follow-up duration was 14.3 months (±6.3) months and the 
median was 15.9 (IQR 5.8) months, therefore the survival rate may be underestimated. 
The follow-up time should be longer to enable accurate estimation of survival time of 
these patients.  A larger sample size may be required to further support the findings 
obtained from the present study. In many TB patients, multiple causes of death may act 
simultaneously, so the cause of death may not be determined accurately as there were 
no post-mortem reports. 
5.9 Summary 
Tuberculosis is a preventable and curable disease regardless of a patient’s HIV status. 
The characteristics of HIV-positive patients in this study may represent the actual 
situation in Malaysia, where the majority of them are males, of Malay ethnicity and 
intravenous drug users. The prognosis for TB/HIV co-infected patients during TB 
treatment was poor, which was contributed by the underlying immune-suppression 
induced by HIV infection rather than complications from active TB. The findings in this 
study may differ from reports of studies done in other countries due to differences in the 
countries’ socio-demographic profile, cultural practices and beliefs. 
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CHAPTER 6: CONCLUSIONS AND 
RECOMMENDATIONS 
 
About this chapter 
This final chapter summarizes the major findings in this thesis; propose the likely 
implications of the findings, recommendations and finally make suggestions for future 
research based on the data analyses in this thesis. As TB/HIV co-infections become 
more common across the globe, it is important to know how far one can make broad 
generalizations concerning characteristics of TB patients with HIV co-infection and 
factors that predict TB treatment success rates as well as survival. A prospective cohort 
study was used to characterize TB/HIV co-infected patients, to determine the risk 
factors for TB treatment default and to identify predictors of survival in order to 
establish generalizations and comparisons with findings from other countries.  This 
thesis explored the predictors of survival of TB/HIV co-infected patients by evaluating a 
large number of variables.  
6.1 Reviews of main findings 
6.1.1 Characteristics of TB/HIV co-infected patients 
Analysis of the socio-demographic data showed that 62.1 percent of TB/HIV co-
infected patients in the Klang Valley were 35-54 years old with a mean age of 39.1 
(standard deviation 8.6). The majority were male, Malay, single and unemployed. The 
most common mode of HIV transmission was through injecting drug use. Pulmonary 
TB occurred in 48.9 percent of patients, followed by extra-pulmonary TB (28.2 percent) 
and 22.9 percent had both pulmonary and extra-pulmonary TB. The majority of TB/HIV 
co-infected patients had haemoglobin level less than 12 g/dL and baseline CD4 less than 
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200 cells/μL. These laboratory readings indicate that these patients were in the advanced 
HIV infection stage. Patients who received antiretroviral therapy constitute 61.3 
percent. The most common antiretroviral regimens were two NRTI with one NNRTI 
(56.2 percent). 
6.1.2 TB treatment outcomes and predictors of defaulted TB treatment  
Among the 227 patients eligible for analysis, 51.6 percent (117) achieved successful 
outcomes (cure, completed treatment), while 25.6 percent (56) of patients defaulted 
treatment and 20.3 percent (46) died. 
Alcohol intake, not receiving antiretroviral therapy, presence of lymphadenopathy and 
low serum albumin were independent predictors of defaulted TB treatment in TB/HIV 
co-infected patients. These predictors are comparable to those identified in other studies 
with the exception of the presence of lymphadenopathy and low serum albumin.  
Concurrent anti-retroviral treatment and good immune status are vital to achieving 
success in the treatment of HIV-infected TB patients. The high default rate (25.6 
percent) warrants a detailed review of the implementation of Directly Observed Therapy 
(DOT) with priority to be directed to those most at risk patients in order to improve 
treatment outcomes.  
In general, HIV-infected tuberculosis patients in the Klang Valley had poor treatment 
outcomes except for those who were prescribed concurrent anti-retroviral treatment and 
had good immune status. 
6.1.3 Predictors of death 
This study identified the independent significant predictors of survival in TB/HIV co-
infected patients. These factors include being Malay, having more than two 
opportunistic infections (OI), not receiving antiretroviral therapy, increase per 1000 
Conclusions and Recommendations 
 215 
 
total white blood cell count per microliter and CD4 T-lymphocytes count less than 200 
cells/µl. 
In this study, antiretroviral therapy is one of the modifiable factors that was associated 
with survival in TB/HIV co-infected patients. This is the main finding of this study 
which supports the fact that the degree of immune-suppression influences survival in 
TB-HIV co-infected patients during TB treatment. Early initiation of antiretroviral 
therapy in these patients can improve survival by restoring immune function and 
preventing opportunistic infections. It was found that HIV-infected TB patients who 
were treated with ART had almost 23 percent better survival compared with those who 
were not treated with ART.  
In conclusion, our study highlights important issues about the factors that are associated 
with TB treatment default and survival of TB/HIV co-infected patients in the Malaysian 
population. This study contributes mainly to the building of knowledge in the 
management of TB/HIV co-infected patients. It is a significant contribution as it 
provides evidence for the formulation of public health policy. 
6.2 Implication to clinical /hospital care 
The results of this study highlight the patients’ characteristics that affect their treatment 
success rate and survival. Early recognition and management of risk factors or 
predictors of mortality will help to decrease morbidity and ultimately the TB/HIV co-
infected patients will achieve better chances for survival.  
The high degree of immune-suppression and high case fatality rates during the early 
stage of the disease among people with TB/HIV co-infection warrants that co-infected 
people should be diagnosed as early as possible. TB is more difficult to detect in HIV 
infected patients due to its unique and myriad presentations.  Therefore, a high index of 
suspicion is required to make a timely diagnosis of TB in this group of patients. 
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Clinicians should be encouraged to offer HIV testing to all TB patients and to assess 
HIV risk factors in patients who present with TB. Any intervention designed to improve 
treatment outcomes for such patients must focus on early diagnosis and treatment of 
both TB and HIV infection. This will require improvements in current levels of TB 
screening among people living with HIV and HIV testing among TB patients, along 
with improvements in the quality of TB diagnosis. 
The finding that almost 74 percent of patients had a CD4 count less than 200 suggests 
that all TB/HIV patients should have early access to appropriate opportunistic infection 
prophylaxis and ART. Furthermore, in our study, we found that increasing number of 
opportunistic infections are associated with death in TB/HIV co-infection. The timely 
implementation of these two treatment interventions is critical to decrease case fatality 
rates. Unless contraindicated, co-trimoxazole prophylactic therapy (CPT) should be 
provided to all TB/HIV patients during TB treatment because of its value in prevention 
of PCP, toxoplasmosis and bacterial infections.  CPT has been shown to reduce overall 
mortality during TB treatment (Raizada, 2009). 
The outcome of this study will guide clinicians and health care providers to have a 
better understanding of risk factors for TB treatment default and recognise the 
predictors of mortality due to TB/HIV co-infection in the local context. This is 
potentially useful in the development of Malaysian Clinical Practice Guidelines (CPG) 
for the management of TB/HIV co-infection and revision of current CPG for 
Management of Tuberculosis. Successful TB treatment and better survival in TB/HIV 
co-infected patients largely depend on an individualized approach, with emphasis on 
treatment adherence, lifestyle factors and timely monitoring of laboratory markers. 
Proper management and monitoring of the patient after initiation of the treatment are 
important to interrupt further spread of TB.  Drug interactions, drug side effects and the 
immune reconstitution inflammatory syndrome (IRIS) should be managed well. Patients 
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who present with characteristics identified as high risk for death should be closely 
monitored to ensure early recognition and management of complications.  
6.2.1 Recommendations 
Defaulting TB treatment is a complex issue with various factors impacting on treatment 
compliance behaviour. Patients who adhere poorly to TB treatment regimen should be 
traced and given intensive drug counselling to improve their survival. General TB 
health education and counselling stressing on the duration of treatment, side effects and 
the risk of discontinuing TB treatment should be given to these patients. Integration of 
TB and HIV services and counselling may allow for efficient delivery of important 
information. Collaboration with shelter homes and Non-governmental Organizations 
(NGOs) as well as community volunteers need to be enhanced to ensure that TB/HIV 
co-infected patients adhere to both TB treatment and antiretroviral therapy. 
Ideally, treatment for both TB and HIV infections should be conducted by personnel in 
the same department who will be responsible for monitoring the patient. This scenario 
will contribute towards reducing the default rate in the study population. However, due 
to inadequate space in the public hospitals, TB and HIV units are still being operated in 
separate buildings. If a proper tracking system and referral mechanism are not put in 
place, this can hamper inter-unit referrals of co-infected patients and may lead to delays 
for these patients to seek treatment and hence loss to follow up. Lack of infrastructure 
was seen as a general problem within treatment centres. HIV positive patients can be 
easily exposed to TB patients waiting in over-crowded outpatient clinics as well as in 
the wards. Improvements in the infrastructure of the health system together with 
appropriate infection control measures are required to address these challenges in order 
to prevent the spread of nosocomial TB infection to HIV positive patients who are high 
risk.  
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The findings of this study support the concomitant use of ART with anti-TB drugs to 
improve survival in TB/HIV co-infected patients. Early initiation of ART prior to the 
development of clinical markers will help to maximize a more favourable clinical 
outcome. The benefits of ART should be made available by dissemination of 
information through the electronic media such as television advertisements and 
distribution of  pamphlets, posters, to assist TB/HIV co-infected patients to have a better 
understanding of their need for treatment adherence which ultimately will improve their 
quality of life. 
6.2.2 Future research 
Future work that includes more TB-related characteristics, including Tuberculin skin 
testing (TST), bacterial culture and information on drug resistant TB  should be 
conducted. 
TB disease diagnosis in Malaysia relies on sign and symptom screening, chest 
radiography and acid fast bacilli sputum smear which have a poor sensitivity in HIV 
patients. More rapid tests for TB are needed for early and accurate diagnosis of TB in 
HIV-infected patients to provide timely specific treatment for patients in need, minimize 
TB transmission in the community and reduce mortality. Further research is needed in 
order to explore the benefits of prescribing fluconazole and cotrimoxazole, in addition 
to ART to all HIV-infected TB patients. 
Another area for future research should investigate total white blood cell count as a 
predictor of death. More information is needed on differential count of WBC in 
particular to examine the role of the absolute neutrophil count in relation to survival. 
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6.3 Implication to policy makers 
The available data have important implications for TB/HIV control in Malaysia. The 
Ministry of Health Malaysia is committed to achieve the MDG targets to reduce the TB 
incidence and the TB mortality rate. The findings of this analysis are useful to TB and 
HIV/AIDS programme managers within the Ministry of Health Malaysia as it provides 
important data on the magnitude of TB/HIV co-infection scenario in this country. The 
findings from this study can be translated into programmes or policies to improve the 
health and living status of TB/HIV co-infected patients. TB mortality ranked the highest 
among all other infectious diseases in Malaysia. Assessment of the survival rate and 
predictors of death will enable the policy makers to see the weaknesses in the system 
that need to be rectified and improved. The policy makers can identify correctly the 
patients who are at high risk. Thus future interventions will be more target-driven and 
cost-effective.  
6.3.1 Recommendations 
The results of the present study indicate a need for a coordinated TB control program 
which should include active case surveillance, effective care and treatment, and directly 
observed therapy. Strengthening the TB program will help to reduce TB/HIV co-
infection cases. The current national TB and HIV programs remain largely separated 
and fragmented; with varying levels of communication and interaction. There is a need 
for more coordination and focus on the management of patients with TB/HIV co-
infections rather than viewing  the two diseases as two separate entities. Collaborative 
efforts are necessary to implement strategies and interventions to reduce TB/HIV 
related morbidity and mortality in line with WHO’s guidelines (WHO, 2008). 
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TB/HIV case management should be optimized further. A much more comprehensive 
data collection system is required which ideally will link the TB and HIV clinics. In 
Malaysia, web-based TB case notification was implemented in 2008. This application 
should be upgraded further by including variables essential for TB/HIV monitoring such 
as CD4 counts, viral load, status of antiretroviral therapy, fluconazole and co-
trimoxazole used. There must also be a way to monitor the quality of the completeness 
and reliability of baseline and follow up data that are being collected. The 
communication between the National TB Control Program and hospitals in case-holding 
process should also be strengthened. 
Malaysia has had greater availability of antiretroviral drugs since 2005. However, a 
substantial number of HIV-infected patients are still not receiving ART treatment 
despite the WHO recommendations that all HIV-infected TB patients should be given 
ART regardless of their CD4 count (WHO,2010). It was believed that stigma and 
discrimination towards HIV-infected people, especially injecting drug users is one of 
the biggest barriers. Self-stigma prevent many patients from accessing treatment and 
care. There is a need to increase accessibility and improved utilization of ART for HIV-
infected patients; particularly those who are co-infected with TB. Creation of an 
enabling environment through public education and well-trained health care workers are 
essential in ensuring greater and sustainable access to ART.  
Developing a multi-sectoral approach has been seen to improve patients’ survival. 
Although TB treatment and antiretroviral therapy are provided free of charge by the 
Malaysian government, but some laboratory testing recommended by the WHO 
guidelines to monitor patients’ progression are chargeable and the cost has to be borne 
by the patients. Collaboration with NGOs are needed to decrease the financial burden of 
TB/HIV co-infected patients. In addition, integrating the TB and HIV care with other 
developmental organizations and community members such as religious leaders and 
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community supporters should help to remove barriers that directly or indirectly affect 
survival. 
6.3.2 Future research 
To complement this study, further qualitative study on TB treatment defaulters will be 
helpful to have a better understanding of why they default treatment which will also 
affect their survival. 
Further study in different areas and using other study designs are needed to determine 
the main reason for poor TB treatment outcome and to further assess TB/HIV mortality 
situation in Malaysia. The compilation of medication history can be made more 
comprehensive by including documented barriers to DOTS or reasons for non-
adherence and tolerance of TB treatment. There is a need to strengthen the 
documentation of the medical records system to ensure completeness of the registry 
which currently is a common problem in practice. 
Future studies should be carried out over a longer period. It will give invaluable 
information about the long term survival of TB/HIV co-infected patients including the 
recurrence rate of TB. 
6.4 Implication to patients 
The findings of this study highlight several things. TB/HIV co-infected patients had 
poor nutritional status as shown by low body weight, low serum albumin and 
haemoglobin levels. Previous studies had reported that malnutrition is a strong risk 
factor for progression from latent TB to active TB disease. On the other hand, TB itself 
is a risk factor for malnutrition; and TB patients who are malnourished (BMI less than 
18.5) had an increased risk of death even with appropriate antibiotic therapy.  
Although unemployment was not found to be significantly associated with either TB 
treatment default or death in this study, however, this factor should not be viewed 
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lightly as 57.3 percent of patients in this cohort were unemployed. It is well known that 
unemployment is strongly related to health and has socioeconomic implications for the 
patients and their family. Patients may not work because they are severely ill or do not 
want to go out to work because of the stigma of HIV and TB. Both HIV and TB are 
stigmatizing diseases that can cause them to lose self-confidence to deal with people. 
The employers may not want to keep them in the organization because of their poor 
health status or fear that the disease is contagious to others. 
6.4.1 Recommendation 
There is need for nutrition-related interventions to maintain optimal nutritional status 
that includes counselling and support to improve food intake, counselling to manage 
nutrition-related symptoms of HIV-related illnesses, counselling on management of 
treatment-related side-effects and therapeutic feeding to manage moderate and severe 
malnutrition among TB and HIV-infected adults. 
Alcohol intake is the only modifiable socioeconomic risk factor that was associated with 
TB treatment default. Patients who take alcohol should be assessed properly to 
determine the level of alcohol consumption because it can complicate the management 
of TB/HIV co-infected patients. Alcohol-dependence therapy should be given to those 
who are found in need for treatment. They may also require a longer duration of hospital 
admission; at least after completing their intensive phase of TB treatment to ensure 
treatment compliance. 
Unemployed patients should be empowered either by providing them with job-training 
or other income- generating activities. Those who are severely ill and unable to work 
should be channelled to the relevant authorities for financial assistance. 
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6.4.2 Future research 
More studies are required to understand why the risk of defaulting TB treatment is 
higher among alcohol drinkers. Further research is recommended to look into why 
Malay patients had lower survival compared to Chinese and Indian patients. There may 
be ethnic differences in relation to treatment adherence and access to care which 
requires further study. 
Quality of life in TB/HIV co-infected individuals need to be researched further, 
particularly in terms of depression and self-stigma. Further research is needed to 
determine whether reducing self-stigma and increasing TB and HIV knowledge among 
the general community and patients will reduce delay in diagnosis and hence improve 
patient outcomes. 
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Appendix F: Table 2.3 
Table 2.3 Critical appraisal of studies on TB treatment outcomes in TB/HIV co-infected patients. 
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DOES THE STUDY ADDRESS A CLEAR QUESTION 
1. Is there a clearly 
focussed question? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Consider  
 Patients Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 Disease/Condition Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 Outcome Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
ARE THE RESULT VALID 
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2. Was a defined, 
representative sample of 
patients assembled at a 
common (usually early) 
point in the course of the 
disease? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
3. Was the follow-up of 
these patients 
sufficiently long and 
complete? 
Yes Yes No 
(Only 6 
months) 
Yes Not 
clear 
Yes Yes Yes Yes Yes Not 
clear 
4. Were objective and 
unbiased outcome 
criteria used? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
5. Was there adjustments 
for important 
prognostic factors? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Consider 
 Was there 
standardisation for 
potentially important 
prognostic factors e.g. 
age? 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
No 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
No 
 Were different sub-
groups compared? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes 
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 Was there validation 
in an independent 
group of patients? 
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clear 
Not 
clear 
Not 
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Not 
clear 
Not 
clear 
Not 
clear 
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clear 
6. How likely are the 
outcome event(s) over a 
specified period of time 
Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear 
7. How precise are the 
estimates of this 
likelihood? 
Consider 
 Are the results 
presented with 
confidence intervals? 
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Yes 
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WILL THE RESULTS HELP ME WITH THIS PATIENT? 
8. Were the study patients 
similar to this patient? 
No No No No No No No No No No No 
9. Will the results lead 
directly to selecting or 
avoiding a treatment? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
10. Are the results useful 
for reassuring or 
counselling my patient? 
Yes 
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Yes 
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Consider  
 Will the evidence 
make a clinically 
important impact on 
your conclusions 
about what to offer 
or tell this patient? 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
 
Yes 
 
 
Yes 
 
Yes 
11. Scores 15 15 14 15 13 15 15 15 15 14 13 
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Appendix G: Table 2.5 
Table 2.5:  Independent factors for TB treatment default. 
Author Country Study 
Design 
Study 
period 
N TB/ 
TBHIV 
Default Rate 
(%) 
 
Outcome 
Vijay S et al., 
2003 
India Case-control 1999-
2000 
483 TB New (25%), 
Retreatment 
(45%) 
 
Male (AOR: 2.49; 95%CI: 1.10-6.18), 
alcoholism (AOR: 6.38 95%CI: 3.25-12.5) 
K.C Chang et 
al., 2004 
Hong Kong Case Control 1999 408 TB Not calculated Current smoking (OR 3.00, 95%CI 1.41–
6.39), past TB with default (OR 6.23, 95%CI 
1.95–19.91), poor  initial adherence (OR 
117.21, 95%CI 13.52–1015.92), fair initial 
adherence (OR 11.02, 95%CI 2.15–56.43), 
unknown initial adherence (OR 6.59, 95%CI 
3.47–12.49), treatment side effects (OR 
13.30, 95%CI 3.23–54.79), and subsequent 
hospitalisation (OR 0.27, 95%CI 0.11–0.67). 
 
P.C Hill et al., 
2005 
Gambia Prospective 2002-
2003 
301 TB 25.2 Uncertain that treatment would work (HR 
3.64; 95%CI: 1.42–9.31), those who 
incurred significant time or  money costs 
travelling to receive treatment (HR 2.67; 
95%CI: 1.05–6.81) 
 
P.Mishra et al., 
2005 
Nepal Case-control  150 TB  Unemployment (AOR: 9.2; 95%CI: 2.8–
29.8), low status occupation (AOR 4.4;  
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95%CI:1.5-12.5 ), low annual income (AOR 
5.4, 95%CI: 1.0-30.0), and cost of travel to 
the TB treatment facility (AOR: 3.0; 95%CI 
1.2–7.3) 
 
O.J Daniel et 
al., 2006 
Nigeria Case-control 1997-
2003 
774 TB 23 Male (AOR: 1.64; 95%CI: 1.15-2.34) 
 
 
W.M 
Jakubowiak et 
al., 2007 
Russia Case-control 2003 1805 TB 4.6 Unemployment (AOR: 4.44; 95%CI 2.23-
8.86), alcohol abuse (AOR: 1.99; 95%CI 
1.04-3.81), homelessness (AOR: 3.49; 95%CI 
1.25-9.77) 
 
De 
Albuquerque 
et al., 2007 
Brazil Prospective 2001-
2003 
1555 TB 14.8 Age (AOR: 1.89; 95% CI: 1.07-3.34), prior 
TB treatment (AOR: 2.16;  95% CI: 1.51-
3.12), illiteracy (AOR: 1.72; 95% CI:1.17-
2.53) 
 
Shargie et al., 
2007 
Southern 
Ethiopia 
Prospective 2002-
2004 
404 TB 20.0 Distance from home to treatment 
centre (AHR: 2.97; ), age > 25 years (AHR: 
1.71; ), necessity to use public transport to get 
to a treatment centre (AHR: 1.59; ) 
 
Epco Hasker 
et al., 2008 
Uzbekistan Case-control 2005 258 TB Not applicable Unemployment (AOR: 2.73; 95%CI: 1.28-
5.86), pensioner (AOR: 4.07;95%CI: 1.57-
10.52), alcoholism (AOR: 6.01; 95%CI: 1.68-
19.47) 
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Kittikraisak et 
al., 2009 
Thailand Cohort 2005-
2006 
554 TB/HIV 11.0 Incarceration history (AOR: 2.0, 95%CI: 1.1-
3.7), smoking (AOR 2.3, 1.3-4.1), symptom 
complaint score > 15 (AOR 3.4, 1.4-8.0) 
 
Amuha et al., 
2009 
Uganda Cross-
sectional 
2008 140 TB/HIV 25.0 On continuing phase of anti TB treatment 
(AOR = 6.24, 95% CI = 2.41 – 16.15),  
alcohol consumption (AOR = 3.87, 95% CI = 
1.02 – 14.67) 
 
Weiguo Xu et 
al., 2009 
China Cross-
sectional 
2006 670 TB 12.2 Illiteracy (AOR:2.42; 95% CI: 1.25-4.67), 
direct observation by village doctors  (AOR: 
0.23; 95% CI: 0.11-0.45) 
 
Bernard N 
Muture et al., 
2011 
Kenya Case-control 2006-
2008 
274 TB Not applicable Inadequate knowledge on TB (AOR 8.67; 
95% CI 1.47-51.3), herbal medication use 
(AOR 5.7; 95% CI 1.37-23.7), low income 
(AOR 5.57, CI 1.07-30.0), alcohol abuse 
(AOR 4.97; 95% CI 1.56- 15.9), previous 
default (AOR 2.33; 95% CI 1.16-4.68), co-
infection with HIV (AOR 1.56; 95% CI 1.25-
1.94) and male gender (AOR 1.43; 95% CI 
1.15-1.78)  
 
Elbireer S et 
al., 2011 
Uganda Case-control 2009 344 TB/HIV Not applicable Distance from home to clinic (AOR 2.22; 
1.21-4.06), long waiting time at the clinic 
(AOR 4.18; 2.18-8.02), poor drug availability 
(AOR 4.75; 2.29-9.84), conduct of staff 
(AOR 2.72; 1.02-7.25), lack of opportunity to 
express feeling (AOR 3.47; 1.67-7.21), lack 
of health education (AOR 5.31; 1.94–14.57); 
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not knowing that TB can be cured (AOR 
44.11; 13.66–142.41); length of TB treatment 
(AOR 10.77; 5.18–22.41), side effects of 
treatment (AOR 5.53; 2.25–13.61) 
 
Maruza M et 
al., 2011 
Brazil Prospective 2007-
2009 
273 TB/HIV 21.7 Male (AOR: 2.28; 95%CI: 1.06-4.94), 
smoking (AOR: 2.62; 95%CI: 1.31-5.26), 
CD4<200 cells/mm (AOR: 2.93; 95%CI: 
1.56-5.23), age over 29 (AOR: 0.50; 95%CI: 
0.25-0.99), complete or incomplete secondary 
or university education (AOR: 0.33; 95%CI: 
0.15-0.71), HAART use (AOR: 0.12; 95%CI: 
0.05-0.33) 
 
M da silva 
Garrido, et al. 
2012 
Brazil Case-control 2005-
2010 
11,312 TB Not applicable Previous default (AOR 3.20; p<0.001), HIV 
positivity (AOR 1.62; p<0.001), alcoholism 
(AOR 1.51; p<0.001), low education level 
(AOR 1.35; p<0.001) and other co-morbidities 
(AOR 1.31; p = 0.05). Older patients (AOR 
0.98; p = 0.001), DOT (AOR 0.72; p<0.01).  
 
Naidoo et al., 
2013 
South Africa Cross-
sectional 
NA 3107 TB 26.1 Poverty, one or more co-morbidity, high risk 
for alcohol mis-use, partner who is HIV-
positive, tobacco use. 
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Appendix H: WHO Clinical Staging 
Source: (WHO, 2007) 
 
 
Primary HIV Infection  
Asymptomatic  
Acute retroviral syndrome  
 
Clinical Stage 1  
Asymptomatic  
Persistent generalized lymphadenopathy  
 
Clinical Stage 2  
Moderate unexplained weight loss (<10% of presumed or measured body weight)  
Recurrent respiratory infections (sinusitis, tonsillitis, otitis media, and pharyngitis)  
Herpes zoster  
Angular cheilitis  
Recurrent oral ulceration  
Papular pruritic eruptions  
Seborrheic dermatitis  
Fungal nail infections  
 
Clinical Stage 3  
Unexplained severe weight loss (>10% of presumed or measured body weight)  
Unexplained chronic diarrhea for >1 month  
Unexplained persistent fever for >1 month (>37.6°C, intermittent or constant)  
Persistent oral candidiasis (thrush)  
Oral hairy leukoplakia  
Pulmonary tuberculosis (current)  
Severe presumed bacterial infections (eg, pneumonia, empyema, pyomyositis, bone or 
joint infection, meningitis, bacteremia)  
Acute necrotizing ulcerative stomatitis, gingivitis, or periodontitis  
Unexplained anemia (hemoglobin <8 g/dL)  
Neutropenia (neutrophils <500 cells/μL)  
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Chronic thrombocytopenia (platelets <50,000 cells/μL)  
 
Clinical Stage 4  
HIV wasting syndrome, as defined by the CDC (see Table 3, above)  
Pneumocystis pneumonia  
Recurrent severe bacterial pneumonia  
Chronic herpes simplex infection (orolabial, genital, or anorectal site for >1 month or 
visceral herpes at any site)  
Esophageal candidiasis (or candidiasis of trachea, bronchi, or lungs)  
Extrapulmonary tuberculosis 
Kaposi sarcoma  
Cytomegalovirus infection (retinitis or infection of other organs)  
Central nervous system toxoplasmosis  
HIV encephalopathy  
Cryptococcosis, extrapulmonary (including meningitis)  
Disseminated nontuberculosis Mycobacteria infection  
Progressive multifocal leukoencephalopathy  
Candida of the trachea, bronchi, or lungs  
Chronic cryptosporidiosis (with diarrhea)  
Chronic isosporiasis  
Disseminated mycosis (eg, histoplasmosis, coccidioidomycosis, penicilliosis)  
Recurrent nontyphoidal Salmonella bacteremia  
Lymphoma (cerebral or B-cell non-Hodgkin)  
Invasive cervical carcinoma  
Atypical disseminated leishmaniasis  
Symptomatic HIV-associated nephropathy  
Symptomatic HIV-associated cardiomyopathy  
Reactivation of American trypanosomiasis (meningoencephalitis or myocarditis 
